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Abstract
In cystic fibrosis (CF), bacteria of the Burkholderia cepacia complex (Bcc) can 
induce a fulminant inflammation with pneumonitis and sepsis. Lipopolysaccharide 
(LPS) may be an important virulence factor associated with the increased morbidity 
and mortality seen in Bcc infection but little is known about the molecular 
pathogenesis of Bcc LPS.
In this study, the inflammatory response to highly purified LPS from different Bcc 
clinical isolates and the cellular signalling pathways employed was investigated.
It has been suggested that the large inflammatory response from BcLPS may be due to 
contaminants in the LPS preparation. Phenol-chloroform petroleum ether (PCP) 
purified BcLPS preparations were compared to more highly purified, enzyme treated 
preparations of BcLPS. There were no significant differences in the levels of IL-6 and 
TNF-a induced from monocytes (MM6) and in levels of IL-8 from epithelial cells 
(A549), which indicates that there were no contaminants present that could cause an 
inflammatory response from these cells.
The inflammatory response elicited by LPS from different Bcc species that were 
tested was seen to be varied. LPS from different clinical isolates of the same clonal 
ET12 strain of Burkholderia cenocepacia were found to induce a varied inflammatory 
response. Some isolate’s LPS produced as much cytokine as prototypical Escherichia 
coli LPS and all Bcc isolates tested with the exception of environmental samples 
produced higher levels of inflammatory cytokine than LPS from the CF pathogen 
Pseudomonas aeruginosa. It was shown that passaging over time under laboratory 
conditions was not responsible for this variation. Bcc LPS samples were tested in their 
ability to prime MM6 cells for respiratory burst, samples that had previously 
produced high levels of cytokine from direct stimulation of MM6 cells were found to 
not be the most efficient primers of respiratory burst. It was found that the 
inflammatory response from Bcc LPS stimulated monocytes was separate and in some 
cases opposite to the ability to prime for respiratory burst.
Iinhibition experiments were used to investigate the Toll-like receptors and associated 
adaptor molecules and pathways utilized when monocytes were stimulated by Bcc 
LPS. The use of anti-CD 14, anti-TLR4 and anti-TLR2 antibodies in Bcc LPS 
stimulated monocytes showed that all Bcc LPS samples tested signalled via CD 14 and 
TLR4 and not via TLR2. Inhibition of MyD88 using an inhibitor peptide proved that 
all but one sample required MyD88 to signal. LPS from clinical isolate of 
Burkholderia multivorans was found to activate the inflammatory response via 
MyD88-independent pathways.
Using MAP kinase inhibitors to test for reduction of cytokine response from 
stimulated MM6 cells and direct analysis of activation through western blotting, LPS 
from all clinical Bcc isolates were seen to activate all three major MAPKs; p42/44, 
p38 and JNK. Degradation of the NF-kB inhibitory protein IkB-o, was tested using 
anti-IxB-a antibodies and activation of the transcription factor NFkB was tested using 
an electrophoretic mobility shift assay (EMSA). IxB-a was degraded and NF-kB was 
activated in all the BcLPS samples tested.
This study suggests that LPS alone from clinical isolates of Bcc is major virulence 
factor in CF that it can cause a massive inflammatory response from cells, and that the 
LPS induced signalling cascade is via classical TLR4-mediated signalling pathways 
similar to highly inflammatory LPS purified from E.coli.
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Introduction
1.1. Cystic fibrosis
1.1.1. Incidence and diagnosis
Cystic fibrosis (CF) remains the most common life shortening genetic disorder in the 
Caucasian population with an estimated survival age in the USA of 36.8 in 2006 
according to the Cystic fibrosis foundation (http://www.cff.org/AboutCF ). However 
survival ages do vary from country to country, the median estimated life expectancy 
of children with cystic fibrosis (CF) bom in 1990 in the UK is 40 years which 
represents a doubling in the last 20 years (Jaffe & Bush 2001).
The incidence of CF is approximately 1 in 2500 live births with a carrier frequency of 
1 in 25 people in European populations (Gazvani & Lewis-Jones 2004; Welsh et al 
1995). This equates to approximately 1 in 10,000 people in the UK (450 babies bom 
with CF annually).
Diagnosis of CF is usually straight forward with a child showing suggestive clinical 
symptoms or a family history, and a sweat test (collection of sweat and analysis of 
chloride concentration) confirms the diagnosis. Suggestive clinical features include 
recurrent chest infections, pancreatic insufficiency and a failure to thrive. Presently 
most CF patients are diagnosed in early childhood due to testing for the presence of 
the most common mutation (AF508) in babies in Northern Ireland, Wales and
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Scotland from the heel-prick blood test. This screening procedure was extended to all 
babies in England from April 2007 (CF screening program (NHS), 
www.gosh.nhs.uk/newbom/cfrscreening)
1.1.2. Genetic and molecular basis of CF
CF is an autosomal recessive disorder which is caused by mutations in a single gene 
on chromosome 7 that encodes for the Cystic fibrosis trans-conductance regulator 
(CFTR) (Riordan et al 1989).
CFTR is a cAMP-dependant chloride channel that influences the electrolyte and water 
balance of secretions from sweat glands, airways, pancreatic ducts, hepatobiliary 
ducts and intestinal glands. These organs are affected by the accumulation of viscous 
secretions with a progressive obstruction, scarring and destruction. Because of the 
effective management and treatment of most of the effects on these organs, especially 
in nutritional care, 84% of patients with CF die from respiratory disease rather than 
any other effect of the disease. (Liou et al 2001).
In the lung, the CFTR channel is found in surface airway epithelial cells and the cells 
of the submucosal glands. The CFTR mutation causes airway mucus to be poorly 
hydrated and together with changes in airway surface tension, hinders mucociliary 
clearance. This causes obstruction of small airways and promotes airway infection. 
Because of the respiratory systems’ interaction with the outside world and constant re­
exposure to infective bacteria the treatment of lung disease is very difficult. (Moran et 
a l 1999)
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CFTR is a member of the ATP-binding cassette transporter family of membrane 
proteins (Baldursson et al 2001). The CF gene is large (250 kb) and is comprised of 
27 exons (Zielenski 1991), the gene is transcribed into a 6.5 kb messenger RNA that 
encodes a 1480 amino acid protein (Riordan et al 1989). Since the identification of 
the gene, over 800 disease associated mutations in the CF gene have been reported 
and a further 70 DNA sequence variants have been identified (Gazvani & Lewis- 
Jones 2004) with the most common being a three base pair deletion that codes for 
phenylalanine at position 508, A508 accounts for 70% of CF alleles in the white 
population (Gibson et al 2003).
The amino acids of CFTR form five domains: two membrane spanning domains each 
composed of six subunits, two nucleotide binding domains and a cytoplasmic 
regulatory domain. The membrane spanning domains seem to contribute to the 
formation of a chloride channel pore because mutation of specific residues in the first 
membrane spanning domain changes the anion selectivity of the channel (Welsh & 
Smith 1993). The nucleotide binding domain of CFTR is responsible for the binding 
and hydrolysis of ATP which provides energy necessary for channel function (Tsui 
1995). The regulatory domain modulates the channel activity of CFTR (Rich et al 
1993)
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1.1.3. Pathological symptoms
CF manifests itself in a variety of organs and systems and leads to lung and sinus 
disease, gastrointestinal, liver and pancreatic disease, endocrine disease and growth 
problems, and infertility. In the past CF patients died from meconium ileus (failure to 
pass meconium), pancreatic insufficiency and hence nutritional deficiencies or lung 
infection as an infant or young child. The majority of CF patients presently die from 
pulmonary infection as adults.
Vulnerability to infection in CF occurs only in the airways and not at other sites such 
as the urinary tact or the skin, so there is no systemic immune defect in CF. However, 
excess inflammation occurs at several sites, for instance the presence of inflammatory 
bowel disease and pancreatitis are significantly higher amongst people with CF. 
(Lloyd-still 1994; Taylor CJ 2002)
As well as a pancreatic insufficiency and increased concentrations of chloride and 
sodium in sweat, CF causes chronic pulmonary disease which manifests itself in the 
airways and submucosal glands and then later the interstitium and alveolar spaces. 
(Gibson et al, 2003).
1.1.4. Abnormality in epithelial mucins
CF affects several organs of the body, the airways of the lung, the pancreas, small 
intestine, skin, and the vas deferens in males and cervical mucus in females. Defective 
chloride ion channel transport results in salty sweat and a build up of dehydrated and
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concentrated secretions which block epithelial ducts at many sites, most notably in the 
pancreas and the lungs.
Symptoms are varied in CF and may or may not present antenatally, however the 
lungs of the foetus show no pathology prior to birth in CF. An accumulation of viscid 
mucous in the gut can lead to an intestinal obstruction in the newborn and 
consequently 10-15% of infants will present with meconium ileus. (Chaudry et al 
2006).
Half a century ago postmortem studies on the lungs from infants that have died of 
meconium ileus have identified mucus plugging in terminal bronchioles, with 
emphysema secondary to obstruction of mucus filled bronchioles, but without signs of 
infection or inflammation (Zuelzer & Newton 1949). This suggested that mucus 
plugging was an early event (pre-infection) in the CF lung, in addition to this several 
other early observations indicated that abnormal airway surface liquid (ASL) volume 
regulation and failure to transport mucus plays a role in CF pathogenesis (Matthews et 
al 1963). There are currently two theories that explain why the CF lung is more prone 
to bacterial infection that the lungs of healthy individuals. The ’fluid' model states that 
hyper-absorption of fluid by the airway surface epithelium leads to a lower than 
normal airway-surface liquid (ASL) volume. The reduced volume and the defective 
fluid production by the submucosal glands leads to under-hydrated mucous and 
impaired mucociliary clearance. Impaired mucociliary clearance and thick airway 
secretions contribute to the establishment of an environment in the airway that 
promotes colonization of the lungs by bacteria (Matsui et al 1998). The 'salt' model, 
states that the salt content of airway fluid in CF is too high and prevents salt-sensitive
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defensin molecules in the ASL from killing bacteria, leading to increased 
susceptibility to lung infections (Moskwa et al., 2007; Smith et al 1996). Defensins 
are small (15-20 residues) cysteine-rich cationic proteins They are active against 
bacteria, fungi and enveloped viruses. Most defensins function by penetrating the 
microbe’s cell membrane by way of electrical attraction, and once embedded, forming 
a pore in the membrane which allows efflux. An increase in salt concentration inhibits 
the activity of individual factors and attenuates synergy between defensins and this is 
the theory behind the ‘salt’ model.
1.1.5. Pancreatic insufficiency
After birth, obstruction of the pancreatic ducts due to concentrated secretions causes 
mal-absorption of nutrients due to the absence of pancreatic enzymes in the small 
intestine. This loss of pancreatic enzymes causes weight loss, fatigue and delayed 
growth if not managed properly. Over a longer time period, obstruction of the 
pancreatic ducts causes fibrosis of exocrine secretory tissue due to inflammation and 
tissue damage caused by proteolytic enzymes. This eventually impairs the ability of 
the pancreas to produce insulin which leads to diabetes mellitus. Development of 
pancreatic enzyme treatments, antibiotics and better diagnosis and management 
means that survival ages of CF patients are on the increase. Because of this successful 
management, the majority of patients suffering from CF now die due to pulmonary 
complications and not any other effect of the disease.
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1.1.6. Underlying inflammatory response
At birth, the CF lung appears free from inflammation but typically within the first few 
months of life a heightened inflammatory state can be detected even in the absence of 
positive bacterial cultures (Nichols et al 2008). This has led to speculation that the 
inflammatory process in CF is autonomous and begins with a response to the 
misfolded CFTR protein within epithelial cells (DiMango et al 1998; Rao & Grigg
2006). However the majority of studies suggest that the inflammation is initiated in 
response to infection, which early in the disease can be transiently eradicated (Berger 
2002; Bonfield et al 1999).
It is thought that when CF patients acquire an endobronchial infection a strong 
inflammatory response is elicited, this response is characterized by a marked influx of 
neutrophils into the lung, and elevations in inflammatory mediators such as TNF-a, 
IL-lP, IL-6, leukotriene B4 (LTB4), and IL-8 (Konstan et al 1993). Neutrophils are the 
predominant inflammatory cell in the lungs of patients with CF, even in individuals 
with mild pulmonary involvement (Konstan 1994).
Airway epithelial cells, macrophages, and neutrophils are all capable of producing 
cytokines. Several studies have found elevated concentrations of pro-inflammatory 
cytokines in the sputum and bronchoalveolar lavage fluid (BALF) of patients with CF 
(Richman-Eisenstat 1996).
The inflammatory response in patients with CF is excessive, and current management 
of pulmonary disease in CF is directed at the consequences of infection and 
inflammation (Ramsey 1996). Moreover, some infants with CF appear to have an
7
inflammatory response in the airways, even if infection is not detected (Khan et al 
1995)
When compared to normal individuals the airway fluids of CF patients show an 
increased number of neutrophils, and increased levels of proinflammatory cytokines, 
TNF-a and IL-6, IL-8 and leukotriene B4, but decreased levels of anti-inflammatory 
IL-10. (Greally et al 1993; Bonfield et al 1995)
IL-8 is a powerful chemoattractant for neutrophils, its overproduction is the likely 
cause of excessive neutrophil infiltration in the CF lung. (Strieter 2002) Following 
this infiltration, live and dead neutrophils then release compounds such as oxidants, 
proteinases and DNA causing airway damage and inflammation. This combined with 
any bacterial infection and the reduced mucous clearance associated with CF leads to 
mucopurulent plugging bronchiectasis (Devaney et al 2003). TNF-a increases 
chemotaxis of neutrophils to the site of inflammation, adhesion of neutrophils to the 
endothelium and induces synthesis of chemoattractant neutrophils. IL-6 mediates the 
acute-phase reaction, matures B-lymphocytes and activates T-lymphocytes (Courtney 
et al 2003)
CF cell lines produce higher levels of pro-inflammatory cytokines than normal cell 
lines in response to Pseudomonas aeruginosa infection (DiMango et al 1995; Kube et 
al 2001). The absolute amounts of cytokines and chemokines produced are increased, 
and in cftr -/- mice they persist longer than in controls when challenged (Muir et al 
2003). However it has been shown that cell origin and obviously cell species origin, 
and culture conditions can impact significantly on any observed responses in vitro, 
primary culture cells from the airway epithelium of CF patients have shown variable
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production of IL-8 under different conditions when they are exposed to pro- 
inflammatory cytokines. (Aldallal et al 2002)
1.1.7. Microbiology
In individuals with CF, antenatally the lungs appear to be normal. Around the time of 
birth marked changes in fluid flux across the airway occur, the air-liquid interface at 
the epithelial surface is established and the pattern of ion transport is altered. When 
the lungs of neonates that have died of meconium ileus are examined, little 
histopathology and no inflammation can be seen. (Chmiel 2003)
In healthy individuals, mucus secreted by mucus gland and goblet cells of the large 
airways entraps particles that are then propelled by movement of cilia upwards. This 
mucociliary clearance provides an efficient system to clear pathogenic particles and is 
assisted by aerodynamic filtering and airway reflexes such as coughing and sneezing. 
In CF, after birth the airway is challenged repeatedly with various organisms which 
are normally dealt with by non-specific responses such as nitric oxide (NO) and 
antimicrobial peptides and proteins. In the airways of infants with CF these non­
specific defences may be compromised, and the thick viscid mucus is not cleared as it 
is in healthy individuals.
In CF, chronic bacterial infections of the lungs are associated with a limited spectrum 
of pathogens including Haemophilus influenzae, Staphylococcus aureus, 
Pseudomonas aeruginosa, Burkholderia cepacia complex, Stenotrophomonas
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maltophilia and Alcaligenes xylosoxidans (Bauemfeind et al, 1987; Gilligan 1991).
H. influenzae and S. aureus predominate early in life, and until the age of antibiotics 
most infants would die early on from Staphylococcal infection. At the age of three 
30% of patients are infected with P.aeruginosa, in young adults this rises to 80% 
(Bauemfeind et al 1987; Gilligan 1991).
Data collected in a 1998 multi-centre study of CF patients showed that P. aeruginosa, 
S. aureus, and H. influenzae could be cultured from the sputum or respiratory tract 
secretions of 61%, 47%, and 16% of tested CF patients, respectively (Lyczak et al 
2002).
It is estimated that up to 50% of patients have fungus in their sputum, usually 
Aspergillus fumigatus (Nunley et al 1998)and it is of particular problem in lung 
transplant where it causes tissue invasive disease. CF patients are predisposed to this 
kind of fungal infection due to lung damage and long-term antibiotic therapy.
The role of viral infections in CF has not been firmly established. However several 
studies suggested that 40% of acute pulmonary exacerbations in cystic fibrosis are 
associated with respiratory viruses; these viruses also lead to pulmonary function 
abnormalities and disease progression. Armstrong et al showed that 52% of the infants 
with cystic fibrosis admitted to the hospital with respiratory symptoms were caused by 
respiratory viruses (Armstrong et al 1998). Thirty five percent of these hospitalised 
infants acquired P aeruginosa at follow up compared with 6% of those who were not 
hospitalised for respiratory symptoms. They concluded that respiratory viral infections
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were associated with airway inflammatory changes, and admission to hospital was 
associated with early acquisition of P aeruginosa.
1.1.8. Psuedomonas aeruginosa infection in CF
Pseudomonas aeruginosa is Gram negative, aerobic bacillus with unipolar motility; it 
is an opportunistic pathogen in humans and does not normally cause a problem in 
immuno-competent individuals. An opportunistic pathogen, P. aeruginosa typically 
infects the pulmonary tract, urinary tract, bums, and wounds and also causes sepsis. It 
colonises over 80% of CF adults (Kosorok et al 2001; Nixon et al 2001).
P. aeruginosa is intrinsically resistant to a range of antibiotics due to the concerted 
action of multi-dmg efflux pumps with chromosomally encoded antibiotic resistance 
genes and the low permeability of the bacterial cellular envelope.
P. aeruginosa has the ability to develop resistance to multiple antibiotics either by 
horizontal gene transfer or by mutation in chromosomally encoded genes, some 
strains of P. aeruginosa have the ability to mutate rapidly in the lungs of patients with 
CF. These hypermutable strains demonstrate an increased ability to develop resistance 
to antibiotics (Oliver et al 2000).
During the initial infection of the airways of people with CF, P. aeruginosa continues 
its normal non-mucoid phenotype, but ultimately produces mucoid exopolysaccharide 
(MEP) or alginate. A steep oxygen concentration gradient exists between the airway
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lumen and the interior of the mucus. The hypoxic environment created causes 
P. aeruginosa to produce even more MEP which contributes to the persistence of the 
bacteria in the airway by interfering with the host defences and delivery of antibiotics 
to the bacterial cell. (Pier et al 1993; Marshall & Caroll 1991; Worlitzch et al 2002)
P. aeruginosa produces a number of toxins and virulence factors such as toxin A 
(Hollsing et al, 1987), elastase, alkaline proteinase (Sorensen et al 1983), alginate 
(Pedersen et al, 1992) and lipopolysaccharide (LPS).
Colonisation of the mucosal surface of the upper respiratory tract is the initial step 
leading to chronic lung infection and biofilm formation with microcolonies in the 
airways of the lung (Hoiby et al 1994). Chronic lung infection with mucoid 
P.aeruginosa is associated with a decline in pulmonary function and a much poorer 
prognosis in CF patients when compared to non-colonised patients (Pamukcu et al 
1995). The LPS of P. aeruginosa is considered to be a major virulence factor (Pier
2007) and due to the relevance of P. aeruginosa infection in CF this organism has 
been used as comparison during this study.
1.1.9. Management of the CF lung
Management of the CF lung includes daily physiotherapy to drain the mucus from the 
airways. Topically nebulised amiloride is used in the lung to reduce the absorption of 
sodium and water and to increase mucociliary clearance (Kohler et al 1996)
Antibiotics are used to help with acute bacterial exacerbations in the lungs, these are 
delivered either intravenously, orally or in aerosol form. When lung infection
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progresses past the point where other treatments are effective, bilateral lung 
transplantation is a clinical therapeutic option for selected patients that are suffering 
from advanced lung disease because of CF. (Egan et al 2002)
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1.2.Burkholderia cepacia complex in CF
1.2.1. History
During the mid 1940's, vegetable growers in the USA became infected by an 
organism which had been previously known to cause onion bulbs to rot. Following 
this outbreak, three bacterial isolates were identified in the autumn of 1947 and a 
fourth in the autumn of 1948. These were given the latin name, "cepacia" meaning "of 
or like onion" by Walter H. Burkholder in his paper (Burkholder 1949).
The B. cepacia species have been isolated from a variety of natural habitats such as 
plant rhizosphere, soil and river water and from several urban environments such as 
playgrounds and athletic fields (Vermis et al 2003; Miller et al 2002; Fiore et al 
2001). They have been found to have useful properties as plant pest antagonists, 
plant-growth-promoting (PGP) rhizobacteria and degradative agents of toxic 
substances (Chiarini et al 2006).
Since the 1950s the B. cepacia species have been reported as the cause of numerous 
catheter-associated urinary tract infections, wound infections, and intravenous 
catheter associated bacteraemia. In 1971, it was reported as the causative organism of 
"foot rot" in U.S. troops on swamp training exercises in northern Florida. (Taplin et al 
1971)
Prior to the 1980s, reports of infections in humans caused by B. cepacia were 
infrequent and limited to small hospital outbreaks involving non-CF patients have and 
have been due to a contaminated common source, such as disinfectant preparations or 
intravenous solutions (Anderson et al 1991; Pegues et al 1993).
14
In the early 1980s, rising incidences in CF of B. cepacia complex infections were 
reported and in 1984, Isles and associates published their seminal paper describing B. 
cepacia as an emerging pathogen in CF (Isles et al 1984).
Since the 1980s, B. cepacia species have emerged as serious respiratory pathogens in 
CF patients (Govan et al 1996). It has been isolated from up to 40% of CF patients in 
some CF clinics and there have been several outbreaks of transmissible strains of 
B.cepacia species in CF centres in North America and the United Kingdom (Johnson 
et al 1994; Pitt et al 1996). Fifty years on from the Burkholder paper, this organism is 
now recognised as an important bacterial invader and coloniser of the lungs of 
patients with cystic fibrosis (CF).
1.2.2. Members of complex
The nomenclature for the cepacia group of organisms has changed over the years. 
They were formerly known as, amongst others, Pseudomonas cepacia or 
Pseudomonas multivorans (Stanier et al 1966) the species was moved to the new 
genus, Burkholderia, in 1992.
Since the creation of the Burkholderia genus 18 years ago, the number of species in it 
has risen to over 40 validly named species and candidate species (those which cannot 
be cultured outside the host but for which there is evidence to suggest that they are 
separate species) (http://www.bacterio.cict.fr/). These species are summarised along 
with their habitat in table 1.1.
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In 1997 five sub-species were defined from within the Burkholderia cepacia species, 
known as ‘genomovars’ or ‘genomic species’. The term ‘genomovar’ is used to 
denote species which is phylogenetically distinguishable from one another but which 
are not phenotypically distinguishable. (Vandamme et al 1997) Genomovars have 
specific different genotypes but are not distinguished by the usual biochemical tests 
that are carried out in a routine diagnostic microbiology laboratory; the genomovar 
becomes a species when a biochemical test is developed that allows it to be identified.
Presently, the formerly recognised genomovars of B. cepacia have been divided into 
species that include B. cepacia genomovar I, B. multivorans (genomovar II), B. 
cenocepacia (genomovar III), B. stabilis (B. cepacia genomovar IV), B. vietnamiensis 
(B. cepacia genomovar V), B.dolosa (genomovar VI), B.ambifaria (genomovar VII), 
B anthina (genomovar VIII) and B. pyrrocinia (genomovar IX).
At present ten Burkholderia species are combined into the Burkholderia cepacia 
complex (Bcc) group of bacteria (Table 1.2.), B.cenocepacia appears twice as there 
are 2 genetically different strains and these have not been designated with different 
names yet. B.cenocepacia and B.multivorans are the most clinically relevant species 
in the lungs of patients with CF but all members of Bcc have been isolated.
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Name Habitat Reference
B.ambifaria Humans (CF), soil, rhizosphere soil
Coenye et al., 
2001
B. andropogonsis Plant material
Coenye et al., 
2001
B.anthina
Humans (CF), animals, soil, rhizosphere soil, 
river water
Vandamme et 
al., 2002
B.caledonica Soil, rhizosphere soil
Coenye et al., 
2001
B.caribensis Soil, root nodules
Achouak et 
al., 1999
B.caryophilli Plant material
Vandamme et 
al., 1997
B.cenocepacia
Human (CF and non-CF), animals, soil, 
rhizosphere soil, plant, water, industrial 
contaminant
Vandamme et 
al., 2003
B.cepacia
Human (CF and non-CF), soil, rhizosphere soil, 
plant, water
Vandamme et 
al., 1997
B.dolosa Human (CF), root nodules, rhizosphere soil
Vermis et al., 
2004
B.fungoraum
Human (CF and non-CF), animals, soil, plant, 
water, industrial contaminant
Coenye et al., 
2001
B.gladioloi (incl.
B.cocovenenans,
P.antimicrobica)
Human (CF and non-CF), animals, plant material, 
rhizosphere soil
Palleroni,
1984
B.glathei Plant material, rhizosphere soil
Zolg and 
Ottow, 1975
B.glumae Plant material
Kurita and 
Tabei, 1967
B.graminis Plant material, soil, rhizosphere soil
Viallard et al., 
1998
B.hospita Soil
Goris et al., 
2003
B.koreensis Soil
Kim et al., 
2006
B.kururiensis Water, plant material
Zhang et al., 
2000
B. mallei Horses, mules and donkeys
Palleroni,
1984
B.mimosarum Root nodules
Chen et al., 
2006
B.oklahomensis Human (non-CF), soil
Glass et al., 
2006
B.phenazinium Soil, plant material
Bell and 
Turner, 1973
B.phenoliruptrix Soil
Coenye et al., 
2005
B.phymatum Root nodules
Vandamme et 
al., 2002
B.phytofirmans Soil, plant material
Sessitsch et 
al., 2005
B.plantarii (incl. B.vandii) Plant material
Azegami et 
al., 1987
B.pseudomallei Humans, animals, soil, water
Palleroni,
1984
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B.pyrrocinia
Human (CF and non-CF), soil, rhizosphere soil, 
water
Vandamme et 
al., 2002
B.sacchari Soil
Bramer et al., 
2001
B.sordidicola Fungus
Lim et al., 
2003
B.silvatlantica Rhizosphere soil, plant material
Perin et al., 
2006
B.stabilis Human (CF and non-CF), hospital equipment
Vandamme et 
al., 2000
B.terrae Soil
Yang et al., 
2006
B.terricola Soil, rhizosphere soil, plant material
Goris et al., 
2003
B.thailandensis Soil
Brett et al., 
1998
B. tropica Plant material
Reis et al., 
2004
B.tuberum Root nodules
Vandamme et 
al., 2002
B.ubonensis Human (non-CF), soil
Yabuuchi et 
al., 2000
B.unamae Plant material, rhizosphere soil
Caballero- 
Mellado et al., 
2004
B.vietnamiensis
Human (CF and non-CF), soil, rhizosphere soil, 
plant material, animal
Gillis et al., 
1995
B.xenovorans Human (non-CF), soil, rhizosphere soil
Goris et al., 
2004
Candidatus B.kirkii Plant material
Van Oevelen 
et al., 2002
Candidatus B.calva Plant material
Van Oevelen 
et al., 2004
Candidatus
B.nigropunctata Plant material
Van Oevelen 
et al., 2004
Table 1.1.: Bacteria from the Burkholderia species and where they are most commonly isolated. 
Adapted from Burkholderia: Molecular Microbiology and Genomics, Coeyne and Vandamme, 2007.
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^ooiBurkholderia spp. LMG21262 
M l 'Burkholderia spp. R15273
Burkholderia fungorum LMG16225T 
Burkholderia spp. LMG 19510 
Burkholderia spp. R20943 
Burkholderia xenovorans LB400 
Burkholderia spp. LMG20580 
Burkholderia catedomca LMG19076T 
Burkholderia spp. R13392 
I— Burkholderia gramtnis LMG18924T 
'-Burkholderia spp. R8349 
Burkhokieha terricota LMG20594T
Burkholderia tuberum LMG21444T 
Burkholderia caribensis LMG 18531T 
Burkholderia phymatum LMG21445T 
Burkholderia phenazinrum LMG2247T 
Burkholderia spp. R701
Burkholderia kururiensis LMG19447T 
Burkholderia sacchari LMG19450T 
Burkholderia caryophyHi LMG2155T 
Burkholderia glathei LMG 14190T 
Burkholderia piantarii LMG9035T 
Burkltolderia glumae LMG2196T 
Burkholderia gladioli LMG2216T
rkholderia mallei ATCC23344 
'Burkholderia pseudomallei K96243T 
Burkholderia thaifandensis LMG20219T
Burkholderia multivorans ATCC17616T 
Burkholderia vietnamiensis LMG10929T 
Burkholderia dolosa LMG18943T 
Burkholderia ambitaria ATCC53266T 
Burkholderia cenocepada J2315T 
Burkholderia anthina C1765 
Burkholderia stabilis LMG7000 
Bur kholderia cenocepacia PC184T 
rkhdderia pyrrocinia LMG 14191T 
urkholderia cepacia ATCC25416T 
Pandoraea apista Patienl W 
rPandoraea pnomenusa “K" 
Pandoraea pulmonicola #40
Burkholderia cepacia 
complex
Rafstonia eutropha LMG 1197
■Burkholderia spp. R15821 
Bordeletla avium 35086 
Bordetella htnzU 51730 
ilelia pertussis 
"x^Bordetella parapertussis 15311
Xanthomonas axonopodis
Neisseria meningitidis MC58
Pseudomonas aeruginosa PA01
40 1
Table 1 .2 .: Phylogeny o f the Burkholderia genus using recA gene sequences. Species name and strain 
designation are indicated (T denotes type strain). The tree was constructed using 760 nucleotides o f the 
recA gene sequence and the neighbour-joining algorithm. Bootstrap values and genetic distance scale 
are shown. Bcc species (red text) are clustered in the shaded region o f the tree. Reproduced with 
permission through RightsLink from Chiarini et al 2006
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1.2.3. Biochemical and Cultural properties and Lab identification
Bcc bacteria are Gram-negative, non-spore forming, motile aerobic rods. Their 
optimal growth temperature is 25-30°C. Bcc bacteria are nutritionally versatile, they 
are able to utilise ammonium salts for energy and some can use Penicillin G as a sole 
carbon source (Beckman & Lessie 1979). Bcc bacteria are found in the environment 
in soil, water and vegetation. The majority of species are able to thrive in a wide range 
of situations from detergents to antiseptic solutions and medications. (Carson et al 
1973; Steere et al 1977)
Bcc species are used in industry and compounds produced by them such as 
pyrrolnitrins, altercidins, cepalyans and bacteriocin-like agents have been used in the 
biological control of plant infections (Govan & Harris 1985).
Identification of Bcc isolates by commercial methods such as API 20 NE and Vitek 
GNI (bioMerieux), Crystal E/NF (Becton Dickinson), Microscan GNP (Dade 
International), Rap ID NF Plus (Innovative Diagnostics Systems), Remel NF System 
(Remel) and Sherlock GLC (MIDI) are not accurate enough alone to identify specific 
Bcc species and results must be confirmed by phenotypic tests such as growth on 
Burkholderia cepacia selective agar medium (BCSA), growth on oxidative - 
fermentative base, Polymixin B, bacitracim and lactose (OFPBL) agar, biochemical 
tests for lysine and ornithine decarboxylase, oxidase activity, sucrose and adonitol 
oxidation, hemolysis, pigment production and growth at 42°C. Following this a 
molecular method for identification can be chosen, most commonly recA analysis.
The recA gene shows a sequence variability that allows Bcc to be differentiated from
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closely related bacteria and sorted into species. The recA-based identification test 
involves restriction fragment length polymorphism analysis with the HaeIII enzyme 
and species-specific PCR reactions in addition to sequencing of the entire recA gene 
(Chiarini et al, 2006).
Recently a system of identification using species-specific differences in fatty acid 
composition in cell lipidic structure and semi-automatic gas chromatography has been 
developed (Krejci & Kroppenstedtt 2006) but whether this is more accurate than 
methods already in use is still to be proven.
1.2.4. Pathogenicity
Bcc species members are recognised as opportunistic pathogens in humans. The 
majority of infections are found in patients suffering from CF but Bcc species can also 
colonise and cause infections in other patients, in particular those with chronic 
granulomatous disease (CGD) which is a rare immunodeficiency that renders patients’ 
phagocytes unable to produce reactive oxygen species (ROS). Phagocytes require an 
enzyme to produce reactive oxygen species to destroy bacteria after they ingest the 
bacteria in a process called phagocytosis. This enzyme is termed "phagocyte NADPH 
oxidase" {PHOX). Defects in one of the four essential subunits of this enzyme can all 
cause CGD of varying severity, dependent on the defect (Bylund et al 2005). In rare 
cases Bcc infection has been reported in healthy individuals with no underlying lung 
disease. (Ledson et al 1998a)
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Although they are not as common as some other pathogens in CF, organisms from the 
Bcc group have a major clinical impact. The clinical course that ensues after a patient 
has acquired a Bcc infection follows one of three patterns. First, there can be no 
discemable change in the clinical status and lung function. Second, there can be a 
chronic decline in lung function. A minority of patients show a rapid and 
uncontrollable clinical deterioration, which included necrotizing pneumonia and 
septicaemia that results in early death. The rapid decline in patient status has become 
known as 'cepacia syndrome' as the bacteraemia that is associated with this syndrome 
rarely occurs during infection with other CF pathogens (Isles et al 1984; 
Mahenthiralingam et al 2005).
The majority of patients who become infected with Bcc organisms follow the second 
pattern of infection with an accelerated decline in lung function compared to those 
infected with P. aeruginosa, so the majority of CF patients live with long term 
carriage of Bcc species. (McCloskey et al 2001)
The pathogenic mechanisms involved in severe Bcc infection are poorly understood, 
it has been shown that LPS from Bcc species elicits a much stronger inflammatory 
response from leukocytes compared with that of P. aeruginosa (Shaw et al 1995; 
Zughaier et al 1999a).
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1.2.5. Distribution of Bcc in CF
Infection with Bcc bacteria can be highly transmissible in CF patients and epidemics 
have been seen to occur in a number of CF centres, in the UK, the USA and Canada. 
(Clode et al 2000)
Studies of the distribution of Bcc species in CF patients have revealed a highly 
disproportionate distribution, with most isolates belonging to either B. multivorans or 
B. cenocepacia; in contrast, B. stabilis, B. ambifaria, and B. anthina have rarely been 
isolated (Bevivino et al 2002; Speert et al 2002; Campana et al 2005), in fact over 
85% of isolates identified from CF patients are found to be either B.cenocepacia or 
B.multivorans (Table 1.3.).
There has been compelling evidence shown by several studies that Bcc strains can 
spread between CF patients either by social contacts or via hospital admission.
(Govan et al 1993; Pegues et al 1993) Epidemic strains predominate among patients 
in some CF clinics and may have an enhanced capacity for spread (LiPuma et al 1988, 
Mahenthiralingam et al 1997). The factors contributing to this are poorly understood, 
but putative transmissibility markers have been identified. Firstly there is the 
B. cepacia epidemic strain marker (BCESM), this is a 1.4-kb sequence containing an 
open reading frame (ORF) with homology to transcriptional regulatory genes. This 
has been found in several epidemic strains but is absent from strains for which there 
was no evidence of patient-to-patient spread (Mahenthiralingam et al 1997).
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There is also the cblA gene that encodes the pilin subunit protein of cable pili that 
appears to facilitate infection by enhancing attachment to epithelial cells (Sajjan et al 
1995). Cable pili are only found to be expressed by the B. cepacia ET-12 clonal 
lineage, a B.cenocepacia strain that predominates in Ontario, Canada, and is found in 
approximately one-third of all B. cepacia-colonized patients in the United Kingdom 
(Pitt et al 1996).
The strain ET-12 lineage, the so-called "epidemic" strain, has been a particularly 
virulent clone which has spread internationally from North America to Europe and 
subsequently within European countries. The ET-12 strain appears to have infected 
patients in Toronto in the late 1980’s before spreading across Canada where it is the 
predominant B.cenocepacia lineage (Speert et al 2002), it was first introduced into the 
UK CF population in 1987 in Cardiff because of contact and transmission at a CF 
summer camp but it was not initially identified as the ET-12 strain (personal 
communication Henry Ryley), however it was first positively identified and reported 
to be in the UK CF population in 1989 (Govan et al 1993).
There is now a high incidence of B.cenocepacia ET-12 in the UK with one study 
showing that 56% of isolates were ET-12 (McDowell et al 2004).
The ET-12 lineage appears to be disproportionately associated with cepacia 
syndrome-related deaths (Ledson et al 2002), and patients infected with this strain are 
at especially high risk of poor outcome after lung transplantation (De Soyza et al., 
2001; 2004).
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Species {former genomovar designation) Approximate °/oa
B. cepacia (1) 3
B. multivorans (II) 40
B. cenocepacia (III) 45
B. stabilis (IV) <1
B. vietnamiensis (V) 6
B. dolosa (VI) 4
B. ambifaria (VII) 1
B. anthina (VIII) <1
B. pyrrocinia (IX) <1
Indeterminate 1
approximate % of infection among >1 20 0  Burkholderia cepacia 
complex -  infected cystic fibrosis patients in the United States
Table 1.3.: Distribution o f Burkholderia cepacia complex species in US cystic fibrosis patients. 
Adapted from: LiPuma: Curr Opin Pulm Med, Volume 1 l(6).November 2005.528-533
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1.2.6. Clinical management of CF patients colonised with Bcc species
Patients with CF and a chronic Bcc infection are managed with similar principals as 
those with a chronic P.aeruginosa infection, that is, with careful attention to airway 
clearance, nutrition, bronchodilator therapy and mucolytic therapy. However the 
treatment of acute episodes in patients with Bcc infection is more of a problem as Bcc 
organisms are nearly always multi-resistant to antibiotics. Antibiotic combinations 
have been shown to have a reasonable effect on acute exacerbations, especially those 
containing Menopenem. Patients with stable Bcc infections do not seem to show any 
more frequent exacerbations compared to those with P. aeruginosa infections alone 
(Moore & Elbom 2003).
Transmission of Bcc species is an ongoing problem for CF clinics, control measures 
have included segregating patients colonised with Bcc species from those who are not 
colonised. This policy has proved to be successful in minimising cross-infection of 
Bcc species between patients but has not affected initial acquisition (Thomassen 
1986; Go van et al 1993; Whiteford et al 1995; Muhdi et al 1996; Cazzola et al 1996) 
It has been suggested that in the UK, only patients colonised with transmissibility 
marker positive B.cenocepacia strains should be strictly segregated from those 
patients infected with transmissibility marker negative B.cenocepacia strains and 
other Bcc species (Ledson et al 1998b; Clode et al 2000). However data from the 
USA suggests that cblA gene and the other transmissibility marker BCESM may not 
be sufficient markers to indicate transmissibility of B.cenocepacia. (LiPuma et al 
2001; Sajjan et al 2002)
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The current UK, USA and Canadian advice to CF patients and clinics is to discourage 
Bcc positive patients from attending CF meetings and conferences because of 
potential transmission, however individual clinics make the decision as to whether to 
segregate or not. Often segregating patients brings about a whole new set of problems 
as it isolates certain patients. (Moore & Elbom 2003)
Some patients with CF may transiently acquire infections with a known transmissible 
strain of Bcc species. The CF tmst currently recommend a period of at least one year 
between negative cultures, during which at least 3 different sputum cultures have been 
taken, before a patient can be declared as having eradicated a Burkholderia species 
(Jones & Webb 2003).
1.2.7. Virulence factors in Bcc
Bcc species have many cellular and extracellular products that are considered to be 
putative virulence factors such as adhesions, extracellular polysaccharide, 
lipopolysaccharide, proteases, lipases, haemolysin and siderophores.
Bcc isolates from CF patients have been found to produce significantly more catalase, 
ornithine decarboxylase, valine, aminopeptidase, C14 lipase, alginase and protease 
than non-CF isolates and also produced complete haemolysis on bovine red blood 
cells. (Gessner & Mortensen 1990)
Intracellular invasion of Bcc species is an important factor to take into account when 
discussing virulence factors, several investigators have shown that Bcc species can 
survive in A549 human epithelial cells and macrophages (Saini et al 1999; Martin &
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Mohr 2000; Keig et al 2001). Bcc species have also been localized by 
immunohistology in patients with “cepacia syndrome” in the exudates within 
bronchial lumens and between airway epithelial cells (Sajjan et al 2001). These CF 
patients were infected by the transmissible clonal ET-12. The isolates of this clone 
carry the cblA gene, which encodes the major subunit for surface cable pili (as 
mentioned previously), which have been shown to mediate binding to respiratory 
mucins (Sajjan & Forstner 1992), and therefore may facilitate invasion. Invasion of 
cells means that eradication of the bacterium by conventional antimicrobial therapy 
more difficult.
The roles of Bcc virulence factors in CF pulmonary disease are under current 
investigation; they are incredibly complex and are slowly being elucidated. An 
understanding of these virulence factors may provide a route to a more effective 
treatment and a better prognosis.
1.3. LPS
1.3.1. Innate immunity
The innate immune system is phylogenetically conserved and is present in almost all 
multicellular organisms (Hoffman 1999). Activation of innate immunity constitutes 
the first line of defence for the host against infection and generates signals to the 
adaptive immune system that indicates the presence of infection by microbes. The 
innate or ‘non-specific’ immune system consists of soluble elements including the 
alternative and mannan binding lectin pathways of the complement system, acute 
phase proteins and cytokines. It also consists of cellular elements such as monocytes, 
macrophages, neutrophils, dendritic cells and natural killer cells.
Some elements of the innate immune system are pre-formed, such as natural 
antibodies and the alternative complement system, while others are mobilised 
following cellular activation via receptors called pathogen recognition receptors 
(PRRs) which recognise conserved molecular patterns that are found in micro­
organisms. These patterns are known as pathogen associated molecular patterns 
(PAMPs) examples of which are LPS, peptidoglycan, flagellin and bacterial DNA. 
(Beutler 2000) Cell stimulation through these receptors results in the up-regulation of 
anti-microbial killing mechanisms and pro-inflammatory mediator release. (Takeda et 
a l2003)
Innate immune responses must be tightly regulated as unbalanced inflammatory and 
immune reactions can result in either uncontrolled microbial growth or overwhelming
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inflammatory responses which result in tissue injury, vascular collapse and multi­
organ failure (Bochud & Calandra 2003).
1.3.2. LPS
LPS is a major component of the outer membrane of Gram-negative bacteria (Figure
1.1.), contributing greatly to the structural integrity of the bacteria, and protecting the 
membrane from bile salts, digestive enzymes and antibiotics, it also enables the 
bacterium to evade innate immune responses such as complement, lysozyme and 
cationic proteins (de Maagd et al 1987; Nikaido et al 1979). It is a prerequisite for 
bacterial viability.
Lipopolysaccharides are complex amphiphilic molecules with an mw of about lOkDa, 
which vary widely in chemical composition both between and among bacterial 
species. LPS is located on the outer face of the bacterial cell membrane, where it 
mediates contact with the environment. LPS is essential to the function of the outer 
membrane, and as a structural component of the cell. It is not toxic when incorporated 
into the bacterial cell wall but after release, (due to cell division or death) its toxic 
moiety, lipid A, is exposed to immune cells and induces a strong inflammatory 
response.
LPS comprises three parts an outer O-polysaccharide chain, a core polysaccharide and 
a lipid A moiety (Figure 1.2.). The Lipid A component of LPS is the main 
determinant of pro-inflammatory activity (Khan et al 1998) and the secondary
30
acylation status of the Lipid A is starting to be recognized as important as well 
(Vorachek-Warren et al 2002). All bacterial species carry a unique LPS and some of 
the variations reside in the lipid A moiety in the acylation pattern, length of fatty acid 
residues, presence of 4-amino deoxy-L-arabinose and/or phosphoethanolamine linked 
to the phospho groups on the glucosamine sugars and the number of fatty acids 
present (Dixon 2005).
Immunogenicity is associated with the polysaccharide components of LPS, the 
composition of the O-side chain varies between different bacterial species and strains. 
O-side chains are easily recognised by the host; however the chain can be modified by 
the bacteria in order to avoid detection by the host immune system. LPS with 
complete O antigen are considered as called smooth type LPS, whereas bacteria with 
LPS that lack the O antigen are considered to be rough type LPS due to their 
appearance when growing on a plate.
LPS in large doses plays a role in the pathogenesis of a variety of different clinical 
conditions, primarily sepsis but also liver disease, inflammatory bowel disease, adult 
respiratory distress syndrome and toxic shock syndrome (Morrison & Ryan 1987).
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1.3.3. Bcc LPS
LPS from Bcc has been shown to elicit a nine-fold higher release of cytokines from 
leukocytes compared to LPS from P.aeruginosa (Shaw et al 1995). The basic 
structure of Bcc LPS is similar to that of other bacteria; the O antigen consists of un­
branched polymers that are linear with di- or tri- saccharide repeating units.
Initial chemical analysis of Bcc core LPS (Maniello et al 1979; Anwar et al 1983) 
indicated the absence of any detectable 3-deoxy-D-wa««o-octulosonic acid (KDO), 
and in comparison to P. aeruginosa it was found to have a lower phosphorous content 
and more heptose. However, later on (Straus et al 1988 and 1990) isolation of KDO 
was reported from clinical Bcc strains.
It has now been verified that Bcc LPSs have between one and three molecules of 3- 
deoxy-D-maHHo-octulosonic acid (KDO) in the inner core region attached to the lipid 
A moiety. The lipid A KDO-KDO structure is well preserved among many bacterial 
species and one to three molecules of this sugar is standard. However the 
distinguishing feature of Bcc LPS is that in the inner core region, there is a unique 
sugar component named v-glycero-D-talo-l-octuXosomc acid (KO), which has been 
found in the structure of lipid A-KDO-KO. The terminal KO residue of the 
disaccharide (KO/KDO) has been found to be non-stoichiometrically substituted at 
position 8 (C-8) with 4-amino-4-deoxy-p-L-arabinopyranose (Ara4N) (Issiki et al 
2003).
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LPSs containing Ara4N have been obtained from polymyxin-resistant strains and 
mutants of enterobacterial species, such as E. coli, Salmonella enterica, and Proteus 
mirabilis, and it has been found that substitutions of Ara4N occur in the ester-linked 
phosphate group in the lipid A region and/or in the KDO in the inner core region (Boll 
et al 1994). It has been suggested that this may explain Bcc species resistance to 
polymyxin. The presence of the Ara4N residue and its positive charge reduces the 
electronegativity of LPS and decreases binding of polymyxin, causing LPS to be 
resistant to its antagonistic action (Vinion-Dubiel 2003).
1.3.4. LPS mode of action and general clinical outcome
LPS is a potent initiator of non-specific immune responses. Monocytes orchestrate the 
innate immune response to LPS by producing a variety of inflammatory cytokines that 
include TNF-a, IL-6. The over reaction to the presence of LPS can lead to sepsis, 
septic shock or systemic inflammatory response syndrome. (Guhu & Mackman, 2001) 
Sepsis occurs as a result of a systemic inflammatory response to a severe bacterial 
infection (Pinsky 2004). A cellular response to bacterial products under controlled 
conditions is necessary to protect the host from infection. When sepsis occurs then 
there is an over-activation of the immune response which leads to the production of 
pro-inflammatory cytokines. It is the receptors of the innate immune system present 
on cells which are activated by bacterial products such as LPS, which are the first step 
in the initiation of sepsis.
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1.4. Cellular pathways in response to LPS
1.4.1. LPS binding protein and CD14
Response to LPS is controlled by a range of different receptors and proteins and 
accessory molecules along a pathway that allows the host to initiate the production of 
pro-inflammatory molecules and respond to the bacteria. LPS is well recognized in 
the body and provokes a robust response from a variety of cells. LPS and LPS 
containing particles (such as intact bacteria) form complexes with a plasma protein 
called LPS binding protein (LBP). In humans LBP is present in plasma at 3-10 pg/ml 
but levels rise dramatically after an acute phase response to LPS. (Schumann et al 
1990)
LBP deficient mice showed that LBP was not required in vivo for the clearance of 
LPS from the circulation, but was essential for the rapid induction of an inflammatory 
response by small amounts of LPS or Gram-negative bacteria. (Jack et al 1997)
The role of LBP in the activation of monocytes and macrophages by LPS has been 
demonstrated, immuno-depletion of LBP from whole blood lowers the sensitivity of 
monocytes to LPS by at least two orders of magnitude (Schuann et al 1990). Studies 
with LBP deficient mice have shown that LBP is not required in vivo for the clearance 
of LPS from the circulation, but is essential for rapid induction of an inflammatory 
response by small amounts of LPS or whole bacteria (Jack et al 1997)
CD 14 is an accessory molecule that is expressed by monocytes, macrophages and 
neutrophils, it accepts the LPS molecule from LBP or can bind it directly. CD 14 is a
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myeloid marker antigen (Goyert et al 1986). The mature protein is expressed on the 
surface of myeloid cells via a glycosylphophatidylinositol (GPI) tail which anchors 
the protein to the membrane without a transmembrane segment, this membrane bound 
CD14 is known as mCD14 (Haziot et al 1988; Simmons et al 1989).
CD 14 is also found free in plasma at 2-6 pg/ml (Bazil et al 1991) and is referred to as 
soluble CD 14 (sCD14). sCD14 mediates activation of CD 14 negative cells such as 
endothelial cells and some epithelial cells when LPS is present. (Pugin et al 1993).
Over-expression of human CD 14 in transgenic mice causes a hyper-sensitivity to LPS 
and increases their susceptibility to endotoxin shock (Fererro et al 1993) .CD 14 
deficient mice are hypo-responsive to LPS and are 10 times less sensitive to LPS than 
wild type mice (Haziot et al 1995). CD 14 also promotes responses to other bacterial 
cell wall components including lipoteichoic acid from Gram positive bacteria and 
lipoarabinomannan, however much larger doses of these bacterial components are 
needed to activate cells compared to LPS (Means et al 1999).
1.4.2. Toll-like receptors
Toll-like receptors (TLRs) were named after the fruit-fly receptor Toll which was first 
discovered because it has an important role in early fly development and was later 
recognised as contributing to innate immunity in adult flies.
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The first event in an innate immune response in mammals is the activation of 
macrophages. Their role is to engulf invading pathogens and to secrete cytokines that 
activate other parts of the immune response. In Drosophila, Toll recognizes pathogens 
and provokes an innate immune response through activation of the Rel transcription 
factors Dorsal, Dif and Relish which are homologous to NF-kB in mammals. (Imler et 
al 2000) Shortly after the discovery of the role of Drosophila Toll in the host defence 
against fungal infection, a mammalian homologue of Drosophila Toll was discovered. 
(Medzhitov et al 1997)
Thirteen TLRs have been identified in mammals so far. In humans 11 members of the 
TLR family (TLR1-TLR11) have been identified all of which comprise a sub-family 
within the larger super-family of interleukin (IL) receptors (Takeda et al 2003).
TLRs are characterised by an amino-terminal extracellular domain composed of 
repeated motifs high in leucine and known as leucine rich repeats (LRRs), followed 
by a single transmembrane domain and a globular cytoplasmic domain called the 
Toll/interleukin 1 receptor (TIR) domain (Akira et al 2003). The LRR regions in the 
extracellular domain of TLRs have been implicated in the recognition of pathogens 
(Guhu & Mackman 2001).
TLRs are amongst a subset of a group of molecules called pattern recognition 
receptors (PRRs) and their main role is to mobilize the host’s defences through 
several mechanisms including opsonization of foreign antigens, induction of host 
complement, coagulation, phagocytic and pro-inflammatory signalling cascades. The 
molecular patterns recognized by these receptors are called pathogen-associated
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are essential to the integrity, function or replication of microbes and are unique to 
single celled organisms.
1.4.3. TLR2
Initial studies showed that TLR2 mediates LPS signalling, this conclusion was based 
on transfection experiments utilizing the 293 cell line and over expression of TLR2 
(Kirschning et al 1998; Yang et al 1998). However gene targeting experiments 
showed that TLR2 deficiency does not disturb any responses to LPS (Takeuchi et al 
1999) and it was found that TLR2 deficient Chinese hamster-derived cells can 
respond to LPS (Heine et al 1999). It has now been confirmed that TLR2 recognises a 
variety of microbial components including lipoproteins, peptidoglycan and 
lipoteichoic acid. TLR2 also recognises several atypical forms of LPS from 
Leptospira interrogans and Porphyromonas gingivalis (Hirschfeld et al 2001; Werts 
et al 2001).
1.4.4. TLR4
TLR4 has been identified as an essential signal transducer for LPS, it has been found 
to recognise the lipid A core of the LPS molecule (Han & Ulevitch 2005). C3H/HeJ 
and C57BL/10ScCr mice contain a mutation in the Lps gene that makes them hypo- 
responsive to LPS. Studies on these mice determined that the defective LPS signalling
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seen is due to mutations in TLR4 (Poltorak et al 1998; Qureshi et al 1999) which 
indicated that this was the signalling receptor for LPS. This was further proven when 
macrophages from mice with a targeted inactivation of he TLR4 gene did not respond 
to LPS (Hoshino et al 1999). TLR4 also functions as a signal transducer for ligands 
other than LPS, for example, gram positive bacteria derived lipoteichoic acids and the 
plant derived anti-cancer agent taxol (Ding et al 1990; Takeuchi et al 1999). Both 
TLR4 and TLR2 (along with TLRs 1 and 6) have been found to function on the cell 
surface within large receptor complexes, or ‘activation clusters’ on lipid rafts or 
microdomains (Soong et al 2004).
1.4.5. MD-2
Additional proteins are required for LPS activation of cells via TLR4. It has been 
shown that expression of the extracellular protein, MD-2, enhanced TLR4-dependant 
activation of NF-kB in transiently transfected human embryonic kidney (293) cells. 
(Shimazu et al 1999) MD-2 is required for LPS activation of the mitogen-activated 
protein kinase (MAPK) pathways P44/42, JNK and P38 (Yang et al 2000).
TLR4-MD2 complex was identified on the surface of mouse peritoneal macrophages 
which indicates that a TLR4-MD2 complex functions as the LPS signalling receptor 
on the surface of monocytes (Akashi et al 2000)
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1.4.6. MyD88 (dependant and independent pathway)
MyD88 is a cytoplasmic adaptor protein that consists of an N-terminal death domain 
and a C-terminal TIR domain. MyD88 is recruited to the TIR domain of activated 
TLRs and mediates a signalling cascade that results in the activation of various 
Mitogen activated protein (MAP) kinases and activation and nuclear translocation of 
NF-kB. Studies on MyD88 deficient mice showed that they lack the ability to respond 
to LPS (Kawai et al 1999)
MyD88 is used by all TLRs (except TLR3) to activate NF-kB MyD88-adaptor-like 
(Mai) protein is necessary to recruit MyD88 to TLR2 and TLR4. TLRs can utilise 
MyD88 dependant and independent pathways (Broad et al 2006).
Upon stimulation, MyD88 recruits a death domain-containing serine/threonine kinase, 
the IL-lR-associated kinase (IRAK). IRAK is activated by phosphorylation and then 
associated with TRAF6, leading to activation of two distinct signalling pathways. 
These two TLR-associated signaling cascades, each has a distinct adapter. A 
preliminary response is dependent upon a MyD88 adapter and a delayed response 
makes use of TRIF, or TIR-domain-containing adapter-inducing interferon-p.
TLR4 signals through four adaptor proteins which operate in functional pairs, MyD88 
with Mai (TERAP) and TRIF with TRAM. (Palsson-McDermott et al 2004)
The TRIF cascade is a MyD88-independent signaling pathway associated with TLR3 
and TLR4. A second adapter protein identified as TRAM acts as an essential bridge 
between TRIF and TLR4, acting upstream of the TRIF protein. These TIR domain-
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containing adapters are differentially recruited to TLRs upon stimulation by 
pathogenic pattems.The TRIF cascade results in the activation of IRF-3, which then 
activates interferons a and B, which are essentially for an inflammatory immune 
response. This pathway also stimulates NF-Kp, which upregulates costimulatory 
molecules CD40, CD80, and CD86 that in turn activate T-cell production and immune 
response (Boraschi et al 2006).
With very few exceptions all forms of LPS signal through TLR4 (Poltorak et al 1998) 
and through a MyD88-dependant pathway involving the adaptors MyD88 and Mai, or 
through a MyD88 independent pathway involving the adaptors TRIF and TRAM 
(Yamamoto et al 2003)
1.4.7. MAP Kinase and NF-kB activation
Mitogen activated protein kinases (MAPK) control many cellular events from 
complex programs such as embryogenesis, cell differentiation, cell proliferation and 
cell death, to short term changes required for homeostasis and acute hormonal 
responses (Chen et al 2001). MAPKs constitute more than a dozen proteins belonging 
to three families, these are extracellular signal-regulated kinases (ERKs), p38 MAPKs 
and c-Jun N-terminal kinase/stress activated protein kinases (JNK/SAPKs) (Rao 
2001).
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To date, LPS from enterobacteraceae has been shown to be a potent activator of three 
MAP kinase pathways, ERK, JNK, and p38 in macrophages. (Guhu & Mackman 
2000; Lim et al 2002).
The transcription factor, nuclear factor (NF)-kB was originally identified as a 
regulator of the expression of the kappa light-chain gene in immune B lymphocytes. 
Later NF-kB was observed to be ubiquitously expressed. NF-kB regulates the 
expression of pro-inflammatory cytokines, chemokines, enzymes that generate 
mediators of inflammation, immune receptors, and adhesion molecules, all of which 
play a key part in the initiation of inflammatory reactions. Inducers of NF-kB 
activation include proinflammatory cytokines, growth factors, microbial infections 
oxidative stress and LPS.
IkB is a protein which inhibits NF-kB by complexing with and trapping it in the 
cytoplasm. However, the unphosphorylated form which is re-synthesized after cell 
stimulation is able to bind NF-kB, allowing its transport to the nucleus and protecting 
it to further hcB-dependent inactivation. This allows NF-kB to transcribe genes that 
produce chemokines and cytokines that start the inflammatory response.
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1.4.8. Summary of LPS signalling pathway
In summary, the signalling pathway activated by prototypical LPS involves LBP 
catalysing the transfer of LPS to CD 14. This then associates with MD-2 and TLR4 on 
the cell surface. Signalling through TLR4 occurs through a MyD88-dependant 
pathway that is common to all TLRs except TLR3. Binding with TLR4 facilitates the 
recruitment of a serine/threonine kinase IL-1 receptor associated kinase (IRAK) 1 via 
MyD88. Activated IRAKI becomes highly phosphorylated and associates with TNF 
receptor associated factor (TRAF) 6, this phosphorylation activation continues 
through several kinases until JNK, ERK and p38 MAP kinases are activated. This 
ultimately leads to the translocation of transcription factors into the nucleus and 
production of cytokines. TLR4 can also signal through an MyD88 independent 
pathway via the adaptor protein TRIF/TICAM, IRF-3 and autocrine stimulation with 
IFN-J3. A summary of the receptors and pathways involved in prototypical LPS signal 
transduction can be seen in figure 1.3. The molecular pathway activated by Bcc 
species LPS has not been fully investigated until now.
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Aims of this study
Some cystic fibrosis patients colonised with Bcc bacteria suffer a rapid deterioration 
in lung function with a small percentage suffering a fatal necrotising fulminant 
pneumonia referred to as ‘cepacia syndrome’. The overall aim of this study is to 
investigate Bcc LPS as a virulence factor in the inflammatory response seen in CF 
lung disease. Briefly the aims are:
• To investigate the inflammatory response, as measured by cytokine production 
(TNF-a, IL-6, IL-8) in human cell lines (MM6, A549) when stimulated with 
highly purified LPS from different clinical and environmental Bcc isolates, 
and to compare this response to LPS from P.aeruginosa and highly potent 
LPS from E.coli.
• To investigate the intrinsic resistance of Bcc species to the antibiotic 
Polymyxin B (PMB). This will be done by testing the ability of PMB to bind 
BcLPS and inhibit cytokine production in stimulated human monocytes 
(MM6). This is of relevance as Polymyxin has a similar mode of action to host 
defensins.
• To investigate the ability of highly purified LPS from Bcc isolates to prime 
human monocytes (MM6) for respiratory burst and compare that ability to the 
inflammatory responses seen during direct stimulation with BcLPS. Over­
production of reactive oxygen species (ROS) causes host tissue damage.
• To investigate the receptors that are bound and the signalling pathways that 
are activated by BcLPS from clinical CF isolates as compared to the pathways 
stimulated by E.coli LPS.
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Materials and Methods
2.1. Cell Lines:
2.1.1. MM6 Cells: The human acute monocytic leukaemia (FAB M5)-derived cell line 
Mono Mac 6 (Ziegler-Heitbrock 1988), was obtained from the German Collection of 
Microorganisms and Cell Cultures (Braunschweig, Germany).
For culture MM6 cells were maintained in RPMI 1640, supplemented with 10% heat- 
inactivated foetal bovine serum, 5ml 200mM L-glutamine, 1% v/v non-essential 
amino acids, lOOU/ml penicillin, lOOug/ml streptomycin, and ImM sodium pyruvate. 
Cells were cultured in a humidified incubator at 37°C with 5% CO2
2.1.2. A549 Cells: Human pulmonary epithelial cells derived from a human lung 
carcinoma (Giard et al 1973). A549 cells were maintained in RPMI 1640, 
supplemented with 10% heat inactivated foetal bovine serum, 5ml 200mM L- 
glutamine and lOOU/ml penicillin, lOOug/ml streptomycin. Cells were cultured in a 
humidified incubator at 37°C with 5% CO2.
Culture medium RPMI-1640 and the supplements L-glutamine, penicillin, 
streptomycin, sodium pyruvate and non-essential amino acids were obtained from
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Cambrex, UK. Foetal bovine serum was obtained from Biosera, UK. Bovine insulin 
was obtained from Sigma, UK.
All media and supplements were tested for endotoxin contamination by Limulus 
Amoebocyte Lysate (LAL) assay in our lab and were found to contain less than 50 
pg/ml endotoxin in all cases.
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2.2. Bacterial Strains:
Table 2.2.1. Cardiff B.cepacia complex strains used in this study.
B.cepacia Strain Species Former Genomovar Source
NCTC 10743 B.cepacia I Onion
; NCTC 10661 B.cepacia I Environmental
Cardiff A1 B.multivorans II CF-Clinical
Cardiff A2 B.multivorans II CF-Clinical
Cardiff P2 B.cenocepacia ET12 
epidemic III
CF-Clinical (ET12 
lineage)
Cardiff P5 B.cenocepacia ET12 epidemic III
CF-Clinical (ET12 
lineage)
Cardiff P1
B. cenocepacia ET 12 
epidemic III CF-Clinical (ET12 lineage)
Cardiff P3 B.cenocepacia ET 12 epidemic in
CF-Clinical (ET12 
lineage)
Cardiff P4 B. cenocepacia ET12 epidemic in
CF-Clinical (ET12 
lineage)
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Table 2.2.2. Other B.cepacia complex strains used in this study.
Edinburgh B.cenocepacia ET 12 epidemic III CF-Clinical
Liverpool
London
B.cenocepacia ET12 
epidemic
B.cenocepacia ET12 
epidemic
III
III
CF-Clinical
CF-Clinical
Manchester B.cenocepacia ET 12 epidemic
B.cenocepacia ET 12 
epidemic
III CF-Clinical
New Zealand hi CF-Clinical
Table 2.2.3. All other bacterial LPS isolates that were used in this study.
Bacterial Strain Source
E.coli 0111:B4 Sigma
P.aeruginosa PA01 Sigma
S.minnesota wild-type (smooth) Sigma
S.minnesota R7 (rough) Sigma
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2.3.LPS characterisation methods
2.3.1. LPS extraction by phenol-water method
(based on the method of Galanos et al 1969 as adapted by Qureshi et al 1982)
Source of bacteria
Each bacterial isolate was stored at -80°Cin the Microbank system that involves 
porous beads in cryopreservative (Pro Lab Diagnostics, Nestor, Wirral). A bead is 
used to inoculate a Columbia agar plate which is then incubated for 24 hours at 37°C. 
The pure culture was then transferred to 1 litre of tryptone soya broth (Oxoid Ltd, 
Basingstoke, UK) in a 31 flask and incubated at 37°C for 48 hours on a rotary shaker. 
The bacteria were harvested by centrifugation at 3770 xg for 30 min using a MSE 
Mistral 3000 centrifuge, washed and centrifuged again at 12189 xg for 15 min. The 
pellet was frozen, lyophilised and stored at -20°C in an air-tight UC until used.
Method
lg of the dried bacteria were suspended in 15ml of phenol extraction reagent (90% 
Phenol- 20ml, Chloroform- 50ml, Petroleum ether- 80ml) and homogenised for a 
minimum of 10 min using a tissue grinder with PTFE pestle (Kartell) cooled in an ice 
bath. The homogenised mixture was then transferred into a 15ml polypropylene 
(organic solvent resistant) tube and centrifuged for 30 miri at 3770 xg in a Mistral 
3000 centrifuge at 4°C. The resulting supernatant was removed and filtered through a
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Whitman No 1 filter paper into a 250ml round bottom flask. Using a rotary 
evaporator, the chloroform and petroleum spirit were removed by evaporation for 15 
min. The remaining solution was transferred to another 15 polypropylene tube and 
14ml of diethyl ether/acetone (diethyl ether- 100ml, acetone- 500ml) reagent was 
added. After standing for a minimum of 1 hour at RT, the precipitated rich LPS 
fraction was collected by centrifugation at 3770 xg for 30 min in a Mistral 3000 
centrifuge. The supernatant was discarded and the pellet was washed twice more with 
14ml diethyl ether/acetone reagent followed by centrifugation. The LPS rich pellet 
was frozen and lyophilised for 30 min. It was then suspended in 3ml sterile pyrogen 
free water by heating in a 37°C water bath and by suction and displacement of the 
solution using a 5ml syringe with a 23 gauge needle. Vigorous vortexing also helped 
to disperse the pellet. The LPS suspension was centrifuged at 541745 xg for 1 hour in 
TLA-100.4 rotor using the Beckman Optima centrifuge. The pellet was then 
dispensed in 500 pi pyrogen free water and transferred into a glass bijoux, frozen and 
lyophilised. The dried LPS pellet was then referred to as BcLPS-1. It was either 
weighed and made up with pyrogen free water as a stock solution at a concentration 
of 1 mg/ml and aliquoted and saved at -20°C, or further purified.
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2.3.2. Enzymatic treatment of BccLPS-1
Method
For further purification of the LPS preparations, BcLPS-1 (suspended at 1 mg/ml in 
pyrogen free water) was treated with lpg of DNase/ml (from bovine pancreas; Sigma 
Chemical Co) and lpg RNase/ml (from bovine pancreas; BDH, Poole, UK). The 
mixture was incubated at 30°C for 90 minutes at pH 7.5, followed by the addition of 
1 pg/ml of trypsin (from bovine pancreas, Sigma Chemical Co) which was added for a 
further incubation at 30°C for 90 minutes. Finally lpg of Proteinase K/ml (from fungi; 
Sigma Chemical Co) was added and the mixture incubated at 30°C for 90 minutes. 
Following these enzymatic treatments the solution was dialysed against distilled water 
overnight and lyophilized.
A solution of pyrogen free water containing 0.2% triethylamine and 0.5% Sodium 
deoxycholate was prepared and 1ml of this solution was added to every 5 mg of dried 
LPS. An equal volume of 9:1 phenol:water solution was added and the-samples were 
then vortexed intermittently over 5 min. The phases were allowed to separate by 
gravity for 5 min. The solution was then put on ice for 10 min, followed by 
centrifugation for 2 min at 14,000 g. The phenol phase was then removed and 
submitted to re-extraction with 1 ml water containing 0.2% triethylamine and 0.5% 
Sodium deoxycholate and the first and second aqueous phases were pooled. The 
pooled aqueous phases were then subjected to re-extraction with an equal volume of 
9:1 phenohwater solution and the phenol phase was discarded.
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The aqueous phases were adjusted to make the solution 75% ethanol and 30 mM 
Sodium acetate and the LPS was allowed to precipitate at -20°C for 1 hour. The LPS 
precipitate was then collected by centrifugation for 10 min at 14,000 g and then the 
pellet was washed with cold ethanol and spun down again. The resulting pellet was 
then allowed to air-dry. This preparation was then referred to as BcLPS-2. It was 
either weighed and made up with pyrogen free water as a stock solution at a 
concentration of 1 mg/ml and aliquoted and saved at -20°C.
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2.4. Direct characterisation of B.cepacia complex LPS using whole organisms by
silver stain.
2.4.1. B.cepacia complex preparation for analysis
Bacteria were inoculated on a Columbia agar plate and incubated overnight at 37°C. 
The bacteria were harvested from the whole plate and were washed with 10 ml sterile 
PBS and re-suspended again in 10 ml DPBS. The optical density of the suspension 
was then adjusted to 1.0 at 550 nm. 1.4 ml of the suspension was transferred into an 
Eppendorf tube and centrifuged at 13,000 rpm for 5 min in a micro-centrifuge. The 
pellet was re-suspended in 50 pi lysis buffer and the mixture was boiled for 10 min in 
a water bath. 10 pi of Proteinase K digestion buffer was then added to the solution, 
this was then mixed and incubated at 60°C for 1 hour. The resulting lysate was then 
analysed by electrophoresis.
2.4.2. Electrophoresis of LPS fraction on 14% SDS-PAGE 
(This method is based on Laemmli,1970).
2.4.3. Preparation of SDS polyacrylamide discontinuous gel
18x16 cm BioRad Electrophoresis cassettes with 1.5 mm spacers were cleaned and 
fitted onto the base unit and were checked for leakage using water. 30 ml of resolving 
gel and 20 ml of stacking gel were required for the preparation of one gel.
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Firstly the resolving gel was prepared and poured immediately into the cassette using 
a 20 ml syringe avoiding production of air bubbles, the solution was then overlaid 
with 5 ml distilled water and left to polymerise for approximately 30 minutes. The 
distilled water was then removed. A stacking gel was then prepared and poured onto 
the resolving gel in the cassette again using a syringe, and the comb was inserted 
slowly to avoid trapping any air bubbles. The gel was then left to polymerise for a 
minimum of 1 hour. The gel was then stored overnight at 4°C before use.
(resolving gel buffer: 3 M Tris-HCl pH 8.8, stacking gel buffer: 0.5 M Tris-HCl pH 
6 .8)
2.4.4. SDS-PAGE
The prepared gel was allowed to stand at RT for 1 hour before being loaded. The 
comb was removed from the top of the gel cassette and the spaces were filled with 1:4 
stacking buffer (0.5 M Tris-HCl pH 6.8). Fine pipette tips were used to load 20 pi 
sample per well. The cassette was then attached to the upper reservoir and the lower 
tank filled with 3 litres reservoir buffer (stock reservoir buffer: 0.25 M Tris, 1.92 M 
glycine, 1% SDS, pH 8.3) and the upper reservoir and cassette was placed on top and 
filled with 1 litre of the same reservoir buffer. The unit was closed and the electrodes 
were fitted to a transformer with the voltage set to 100 V. When the samples had 
completely entered the stacking gel (about 30 min) the voltage was increased to 250 
V. When the bromophenol blue marker was approximately 10 mm from the bottom of 
the gel the run was ended and the cassette was removed from the buffer and carefully
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opened using a plastic spatula. The stacking gel was then removed from the top of the 
gel making it ready for silver staining.
2.4.5. Silver staining of LPS
Method based on Hitchcock and Brown (1983). (Solutions listed in appendix)
The staining steps took place in glass staining trays with continuous gentle mixing on 
a Rotastat orbital shaker. The gel was firstly immersed overnight in 250 ml of the 
fixing reagent with gentle shaking. The gel was then transferred into 250 ml oxidising 
reagent for 5 min followed by 8x30 min washes with 250 ml de-ionised water. The 
gel was then placed in 250 ml of staining solution for 10 min followed by 4 washes of 
de-ionised water for 30 min. During this washing stage, 250 ml of developing reagent 
was warmed to above 25 °C and added to the washed gel with gentle shaking. The 
development of colour was stopped when the banding was strong by adding 250 ml of 
stopping solution for 20 min. The gel was then washed briefly and then visualised 
using a UVP scanner and camera.
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2.5. Investigation of the biological activity of B.cepacia LPS
2.5.1.Neutralization of LPS induced cytokine production by polymyxin
Polymyxin B sulphate: 7730 unit/mg (Sigma-Aldrich, UK). Stock solutions of 
Polymyxin B sulphate were prepared at different concentrations, 50 mg/ml, 5 mg/ml 
and 500 pg/ml in pyrogen free water. The stock solutions were diluted 10 fold prior to 
use in the neutralisation experiments.
Mono Mac 6 cells (Human monocytes)
Mono Mac 6 cells were grown in the conditions and media stated (2.1.1.). Cell 
viability (>95%) was checked using the trypan blue exclusion method and the cell 
count was then adjusted to lxlO6 cell/ml.
LPS: LPS stock solutions (1 mg/ml) were diluted using sterile pyrogen free water and 
added to MM6 cells (lxlO6 cell/ml) to make a final concentration of 100 ng/ml and 
500 ng/ml. Stock LPS solutions were stored at -20°C until needed in pyrogen free 
glassware.
Method
MM6 cells were suspended at lxl06 and dispensed into 24 well plates in 1 ml 
aliquots. Stock LPS solutions were thawed and vigorously vortexed for 5 min. The 
LPS solution was added to each 1 ml well to make a final concentration of either 100
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ng/ml or 500 ng/ml. Then the Polymyxin solution was added to each well to make 
final concentrations of 5 pg/ml and 50 pg/ml, each experiment was setup in triplicate. 
Controls containing Polymyxin alone, LPS only and unstimulated control cells were 
also included. The cells were then incubated at 37°C, 5% CO2 in a humidified 
incubator overnight. Positive controls of cells stimulated with LPS alone were 
included and negative controls with Polymyxin only and cells with no stimulus were 
included. The cells were then centrifuged at 2500 rpm for 5 min and the supernatants 
were collected. The supernatants were placed in sterile Eppendorf tubes and then 
either stored at -80°C or immediately tested for levels of TNF-a by ELISA.
2.5.2. TNF-a ELISA
A 96 well microtitre plate (Nunc) was coated with 100 pl/well of the anti-human 
TNF-a monoclonal antibody (diluted 1/125, 80 pi from a stock of 500 pg/ml was 
diluted in 10 ml PBS to coat 1 plate). The plate was covered with an adhesive seal and 
left to incubate at RT overnight. The plate was then washed 4 times using 300 pl/well 
of 0.05% Tween 20 in PBS and blocked with 300 pl/well PBS containing 1% BSA 
and 5% sucrose for 1 hour at RT then washed 4 times. A starting standard (human 
recombinant TBF-a) containing 1000 pg/ml was diluted from a stock standard 
containing 10 pg/ml. Subsequent standard points were prepared by doubling dilutions 
down to 15.6 pg/ml.
A 100 pi of sample or standard (diluted in 0.1% BSA, 0.05% Tween 20 in Tris- 
buffered saline, pH 7.3) was added per well, mixed by gentle taping of the plate frame
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for 1 min, samples were always added in duplicate. The plate was then covered with 
an adhesive seal and left to incubate for 2 hours at RT.
A detection antibody (biotin conjugated goat polyclonal secondary antibody) was 
diluted 1/250 (50 pg/ml stock diluted to 200 ng/ml, 40 pi of stock diluted in 10 ml 
diluent). The plate was washed 4 times and 100 pi of the diluted biotinylated TNF-a 
was added to each well. The plate was then covered again and left for 2 hours at RT. 
The plate was then washed 4 times and 100 pi of Streptavidin horseradish peroxidise 
(HRP) (1/20,000 of a 1.25 mg/ml solution) was added per well, sealed and incubated 
at RT for 20 min. The plate was washed 4 times and 100 pi of 3,3 ',5,5'- 
tetramethylbenzidine (TMB) micowell peroxidase substrate solution was added per 
well and incubated for 20-30 min in the dark at RT. The reaction was halted by the 
addition of 50 pi 0.5 M H2SO4 per well and mixing by gentle tapping. The optical 
density of each well was determined using a microtitre plate reader set to 450 nm and 
540 nm for wavelength correction.
The results were calculated by averaging the sample duplicate’s optical density and 
subtracting the zero standard reading from it. The resulting optical densities from the 
standards were plotted against the actual concentrations of the standards and 
linearised by using a log-log best fit curve. The TNF-a concentrations in the samples 
that were tested were calculated from the best fit curve.
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2.5.3. IL-6 ELISA
The IL-6 ELISA method was similar to the TNF-a ELISA except the IL-6 capture 
antibody was diluted 1/125 to give a final concentration of 4 pg/ml from a stock 
solution of 500 pg/ml.
A starting standard containing 1200 pg/ml was prepared from a stock standard 
containing 10 pg/ml. The subsequent standards points were prepared by doubling 
dilutions to 18.75 pg/ml. Biotinylated antibody was diluted 1/2000 (50 pg/ml stock 
diluted to 25 ng/ml, 5 pi of stock diluted in 10 ml diluent), all the other steps were 
performed identically to the TNF-a method.
2.5.4. IL-8 ELISA
The IL-8 method was similar to the TNF-a ELISA except the IL-8 capture antibody 
was diluted 1/125 to give a final concentration of 4 pg/ml from a stock solution of 
500 pg/ml.
A starting standard containing 2000 pg/ml was prepared from a stock standard 
containing 10 pg/ml. The subsequent standards points were prepared by doubling 
dilutions to 31.25 pg/ml. Biotinylated antibody was diluted 1/2500 (50 pg/ml stock 
diluted to 20 ng/ml, 4 pi of stock diluted in 10 ml diluent), all the other steps were 
performed identically to the TNF-a method.
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2.5.5. Comparison of BcLPS-1 andBcLPS-2 purified LPS samples
MM6 cells were grown in conditions the conditions and media stated earlier (2.1.1.). 
Cell viability (>95%) was checked using the trypan blue exclusion method and the 
cell count was then adjusted to lxlO6 cell/ml. The cells were then dispensed in 1 ml 
aliquots into 24 well culture plates. B.cepacia LPS that had either been purified to 
BcLPSl or BcLPS2 level were added to each well in duplicate to make a final 
concentration of 1 pg/ml, control wells containing 1 pg/ml E.coli LPS and non­
stimulated wells were included on each plate. The plate was then mixed by gentle 
tapping and incubated at 37°C, 5% CO2 for 16 hours. The cells were harvested and 
spun down in a centrifuge at 2500 rpm and the supernatants were collected and either 
stored at -80°C until testing or tested immediately for level TNF-a or IL-6 by ELISA.
2.5.6. Comparison of LPS from different ET12 strains
MM6 cells were grown in the conditions and media stated earlier (2.1.1.). Cell 
viability (>95%) was checked using the trypan blue exclusion method and the cell 
count was then adjusted to lxlO6 cell/ml. The cells were then dispensed in 1 ml 
aliquots into 24 well culture plates. B.cepacia LPS extracted from various ET12 
epidemic strains were added to each well in duplicate to make a final concentration of 
1 pg/ml, control wells containing 1 pg/ml E.coli LPS and non-stimulated wells were 
included on each plate. The plate was then mixed by gentle tapping and incubated at 
37°C, 5% CO2 for 16 hours. The cells were harvested and spun down in a centrifuge
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at 2500 rpm and the supernatants collected and either stored at -80°C until testing or 
tested immediately for TNF-a or IL-6 by ELISA.
2.5.7. Effect of B.cepacia LPS on the production of IL-8 in A549 cells
A549 cells were maintained in the conditions and media stated earlier (2.1.1.). Cells 
were cultured in a humidified incubator at 37°C with 5% CO2. When the cells were 
confluent they were trypsinised for ~5 min and centrifuged at 2500rpm for 5 min. The 
cells were then re-suspended in medium and dispensed in 1 ml aliquots into 24 well 
culture plates at a concentration of lxl05 cells/ml. The cells were then maintained at 
37°C, 5% CO2 in a humidified incubator until confluent, the media was refreshed 
everyday. When the cells were confluent they were washed in sterile PBS and then 
maintained for 2 days in the same media but without foetal bovine serum. To 
duplicate test wells, 1% human serum was added with 1 pg of LPS either from the 
B.cepacia isolates or E.coli to duplicate test wells. Controls were set up containing 
LPS alone for each sample, human serum alone and a negative control containing 
neither. The cells were incubated for 16 hours overnight and the supernatants 
collected and either tested immediately for IL-8 concentration by ELISA or stored 
until use at -80°C.
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2.6. Respiratory burst measured by enhanced chemiluminescence
2.6.1. B.cepacia LPS effect on MM6 cells respiratory burst
Priming:
MM6 cells were grown in the conditions and media stated earlier (2.1.1.). The cells 
were tested for viability (>95%), counted, washed and suspended in medium in 5 ml 
flasks at a concentration of lxl06 cells/ml. The cell were then stimulated with 100 ng 
B.cepacia LPS or E.coli LPS and incubated at 37°C, 5% CO2 for 24 hours. A negative 
control without LPS was always included.
The primed cells were then spun down at 2500 rpm and washed twice in DPBS in 
plastic centrifuge tubes, the cells were re-suspended in standard buffer at a 
concentration of 1.5x106 cells/ml.
Respiratory burst activation:
100 pi of 3.5 mM of luminol was added to each 1 ml of cell suspension.
150 pi aliquots of the cell solution were then dispensed in quadruplicate into a white 
96 well plate (FluoroNunc-PolySorp, Gibco, UK). The plate was then allowed to 
equilibrate in a luminometer for 5 min. Finally 50 pi of opsonised zymosan (500 
pg/ml) was added per well and the plate returned to the luminometer which was set to 
take a reading every 5 min for a total of 40 min (or until the reaction had finished). 
Chemiluminescence was measured in relative light units (RLU) which is a 
measurement of the number of photons generated by the reaction each time.
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2.7. Investigations into the signalling pathway triggered by B.cepacia LPS
2.7.1. Cell stimulation with B.cepacia LPS and protein extraction
MM6 cells were grown up in conditions and media stated earlier (2.1.1.). Cell 
viability (>95%) was checked using the trypan blue exclusion method and the cell 
count was then adjusted to lxlO6 cell/ml and dispensed in 10 ml aliquots into T25 
tissue culture flasks.
LPS stock solutions (1 mg/ml) were allowed to thaw and vigorously vortexed for at 
least 5 min, they were then diluted using sterile pyrogen free water and added to each 
flask to obtain a final concentration of 1 pg/ml LPS. A flask of non-stimulated cells 
was always included as a negative control. The cells were then incubated at 37°C for 
1 hour and then transferred to 10 ml centrifuge tubes, centrifuged at 2500 xg and 
washed in ice-cold DPBS. The cells were then transferred to 1 ml Eppendorf tubes 
and washed again in DPBS. The supernatant was entirely removed and 300 pi of ice- 
cold RIPA buffer working solution was added to lyse the cells, the cells were then left 
for 30 min on ice. After this time the cell lysates were then subjected to sonication (on 
ice) for 3x10 seconds for each sample. The samples were then centrifuged at 2500 xg 
for 5 min at 4°C to remove cell debris. 40 pi volumes of the cell fractions were then 
transferred into separate tubes and either used straight away of stored at -80°C until 
needed.
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2.7.2.Coomassie blue G dye binding method for protein estimation
After LPS stimulation and cell fractionation, samples were tested for protein 
concentration to ensure equal amounts of protein could be loaded onto the gel for 
electrophoresis. Bovine serum albumin (BSA) standards were added in triplicate to a 
96 well plate. The standards ranged from 200 pg/pl up to 1200 pg/pl and included a 
blank sample. The cell lysate samples were added to wells in triplicate. Coomassie 
Blue G working solution was made up from a stock solution on the day of use and 
200 pi of this was added to each test well, this was left for a few minutes for the 
colour to develop and then the optical density was read in a microtitre plate reader set 
to 620 nm. The protein concentration was determined for each sample using a 
standard curve derived from the BSA standards.
2.7.3. Western blotting
Electrophoresis using Novex system and NuPAGE gels.
Test samples were mixed with calculated volumes of LDS, water and reducing buffer 
to ensure equal amounts of protein in each sample. The samples were then vortexed 
and placed in a 70°C water bath for 10 min to fully denature proteins. The samples 
were then removed and kept on ice until loading. A NuPAGE pre-cast gel (Bis-Tris- 
HC1 buffered 10%) was inserted into a mini-cell unit and sealed in. The inner 
chamber was filled with ~200 ml of reducing buffer ensuring the wells were covered. 
10 pi volumes of the test samples were then loaded into the wells using a fine pipette
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tip. For each run a MagicMark (Invitrogen) protein ladder, SEE Blue visual marker 
and positive and negative control samples were included. The outer chamber was then 
filled with -600 ml running buffer, the gel was then electrophoresed at 200V for 45 
min or until the SEE Blue marker was within 10 mm of the bottom of the gel.
2.7.4. Transfer to nitrocellulose membrane
Firstly NuPAGE transfer buffer was made up and blotting pads and filter paper were 
immersed in it for an hour, the nitrocellulose membrane was cut to size and also 
immersed in the transfer buffer for 10 min. The gel was then removed from the Mini­
cell, and the plastic plate was removed carefully using a spatula, the gel forming the 
wells at the top was removed. The soaked nitrocellulose membrane was laid over the 
gel and then the gel was sandwiched in-between 2 soaked filter papers. 2 soaked 
blotting pads were placed on top and below the gel and filter paper and the entire 
‘sandwich’ was rolled with a glass pipette to remove any trapped air bubbles, it was 
then assembled in the blotting module. The blotting module was placed in a Mini-cell 
unit a small amount of transfer buffer was poured into the blotting module to ensure 
the membrane and gel were completely covered and the rest of the transfer buffer was 
poured into the outer chamber. The unit was run for 75 min at 30 V constant current at 
RT.
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2.7.5. Chemiluminescent detection using anti-rabbit Western Breeze kit 
(Invitrogen).
All steps in this procedure were carried out at RT. The nitrocellulose membrane was 
removed from the Mini-cell transfer module and placed in a dish, the membrane was 
then rinsed with 20 ml ultra-pure water for 5 min on a rotary shaker, this wash was 
repeated once. The membrane was then blocked with 10 ml of prepared blocking 
solution for 30 min, after this time the blocking solution was decanted and the 
membrane was washed in 20 ml water twice for 5 min on a rotary shaker. The 
membrane was then incubated with 10 ml of prepared primary antibody solution 
which contained 10 pi primary antibody (see below) in 10 ml blocking solution, this 
was left for 1 hour.
The antibody solution was decanted and the membrane washed with 20 ml of 
prepared antibody wash for 5 min on a rotary shaker, this was repeated 3 times. The 
membrane was then incubated with 10 ml secondary antibody solution for 30 min on 
a rotary shaker and then washed with 20 ml antibody wash 3 times as before. The 
membrane was finally washed with 20 ml water for 2 min twice and then placed on a 
sheet of transparent plastic and 2.5 ml of chemiluminescent substrate was applied for 
5 min during this time the membrane was not allowed to dry out. The excess substrate 
was removed by blotting with filter paper and another piece of transparent plastic was 
placed over the top of the membrane and any air bubbles were removed using a glass 
pipette. The membrane was then exposed to photographic film in the darkroom for 5 
min or longer if needed.
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2.7.6. Detection of phosphorylated p38 MAP Kinase in LPS treated MM6 cells.
MM6 cells were stimulated with various B.cepacia LPS as described above, non­
stimulated controls and an E.coli LPS was included with each incubation. 
Phosphorylated p38 MAPK was detected using the Novex system and Western 
Breeze detection as described above. P38 control cell extracts for phosphorylated and 
non-phosphorylated MAP kinases (Cell Signaling Technology) were included in each 
run. Detection antibodies for phosphorylated p38 MAP Kinase were included in the 
primary antibody solution at 1:500 dilution (20 pi in 10 ml). The detection antibody 
for phosphorylated p38 only binds when both threonine 180 and tyrosine 182 
(Thrl80/Tyrl82) are phosphorylated.
2.7.7. Detection of phosphorylated and total P42/44 MAP Kinases in LPS treated 
MM6 cells
MM6 cells were stimulated with various B.cepacia LPS as described above, non­
stimulated controls and an E.coli LPS was included with each incubation. The total 
and the phosphorylated p44/42 MAP kinase was detected using the Novex system and 
Western Breeze detection as described above. P44/42 control cell extracts for 
phosphorylated and non-phosphorylated MAP kinases (Cell Signaling Technology) 
were included in each run. Detection antibodies for phosphorylated p44/42 MAPK 
and total p44/42 MAPK were included in the primary antibody solution at a dilution 
of 1:1000 (10 pi in 10 ml). The detection antibody for phosphorylated p44/42 only
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binds when both threonine 202 and tyrosine 204 (Thr202/Tyr204) of p44 are 
phosphorylated.
2.7.8. Detection activated IkB  in LPS treated MM6 cells
MM6 cells were stimulated with various B.cepacia LPS as described above, non­
stimulated controls and an E.coli LPS was included with each incubation. The IkB - cx 
detection antibody (Santa Cruz Biotechnology, INC.) was included in the primary 
antibody solution at a dilution of 1:1000 (10 pi in 10 ml), the antibody only bound to 
IkB  when proteolysis and phosphorylation had not occurred.
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2.7.9.Investigation of the role of CD14 in LPS induced TNF-a production
MM6 cells were grown in the conditions and media previously stated (2.1.1.)- Cell 
viability (>95%) was checked using the trypan blue exclusion method and the cell 
count was then adjusted to lxl06 cell/ml and dispensed in 250 pi aliquots into 96 well 
culture plates. The cells were then pre-incubated with 5 pg of monoclonal anti-CD 14 
antibody (R&D systems). Test LPS was then added to each well at the concentration 
of 25 ng/ 250 pi. All experiments were conducted in duplicate each time, and a 
control with LPS alone and a non-stimulated control were included. The cells were 
incubated at 37°C, 5% CO2 for 16 hours, harvested, centrifuged at 2500 rpm for 5 min 
and the supernatants collected. The supernatants were then either stored at -80°C until 
use or tested immediately for TNF-a concentration by ELISA.
2.7.10. Investigation of the role of TLR4 in LPS induced TNF-a production
MM6 cells were grown in the conditions and media previously stated (2.1.1.). Cell 
viability (>95%) was checked using the trypan blue exclusion method and the cell 
count was then adjusted to lxlO6 cell/ml and dispensed in 250 pi aliquots into 96 well 
culture plates. The cells were then pre-incubated with 5 pg of HTA125 monoclonal 
anti-TLR4 antibody (eBioscience) or with an IGg2a isotype control antibody 
(eBioscience). Test LPS was then added to each well at the concentration of 100 
ng/ml. All experiments were conducted in duplicate each time, and a control with LPS 
alone and a non-stimulated control were included. The cells were incubated at 37°C, 
5% CO2 for 16 hours harvested, centrifuged at 2500 rpm for 5 min and the
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supernatants collected. The supernatants were then either stored at -80°C until use or 
tested immediately for TNF-a concentration by ELISA.
2.7.11. Investigation of the role of TLR2 in LPS induced TNF-a production
MM6 cells were grown in the conditions and media previously stated (2.1.1.). Cells 
were incubated at 37°C with 5% CO2. Cell viability (>95%) was checked using the 
trypan blue exclusion method and the cell count was then adjusted to lx l06 cell/ml 
and dispensed in 250 pi aliquots into 96 well culture plates. The cells were pre- 
incubated with 5 pg of monoclonal anti-TLR2 antibody (Abeam) and test LPS was 
added to each well at the concentration of 100 ng/ml. All experiments were conducted 
in duplicate each time, and a control with LPS alone and a non-stimulated control 
were included. The cells were incubated at 37°C, 5% CO2 for 16 hours, then 
harvested, centrifuged at 2500 rpm for 5 min and the supernatants collected. The 
supernatants were then either stored at -80°C until use or tested immediately for TNF- 
a concentration by ELISA.
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2.7.12. MyD88 inhibition
MM6 cells were grown in the conditions and media previously stated. Cells were 
incubated at 37°C with 5% C02. Cell viability (>95%) was checked using the trypan 
blue exclusion method and the cell count was then adjusted to lxlO6 cell/ml and 
dispensed in 250 pi aliquots into 96 well culture plates. The cells were then pre- 
incubated with 100 pM MyD88 homodimerization inhibitory peptide or a control 
peptide (Imgenex, USA) for 24 hours. Test LPS was then added to each well at the 
concentration of 25 ng/ 250 pi. All experiments were conducted in duplicate each 
time, and a control with LPS alone and a non-stimulated control were included. The 
cells were incubated at 37°C, 5% C02 for 6 hours and then harvested, centrifuged at 
2500 rpm for 5 min and the supernatants collected. The supernatants were then either 
stored at -80°C until use or tested immediately for TNF-a concentration by ELISA.
2.7.13. MAPK inhibition
MM6 cells were grown in the conditions and media previously stated (2.1.1.). Cell 
viability (>95%) was checked using the trypan blue exclusion method. Cells were 
dispensed in 1 ml aliquots at a concentration of lxl06 into 24 well culture plates.
The cells were then pre-incubated with 10 pi of either PD98059 (P42/44 inhibitor), 
SB203580 (P38 inhibitor) or SP600125 (JNK inhibitor) (Sigma-Aldrich) or 
combinations of the inhibitors all in duplicate, for 1 hour at 37°C. These inhibitors 
have been seen to be effective in other studies and in industry (Davies et al 2000;
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Ropert 2005). Control wells with no inhibitor were included. LPS was then added at a 
concentration of 1 pg/ml to all wells and to control wells, the plates were then mixed 
by gentle tapping and incubated overnight at 37°C, 5% CO2 in a humidified incubator. 
Supernatants were collected after centrifugation for 5 min at 2500 rpm and either 
assayed immediately for TNF-a concentration by ELISA or stored at -80°C until 
testing.
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2.8. Nuclear extracts and assessment of NF-kB activation by Electrophoretic 
Mobility Shift Assay (EMSA)
2.8.1. Preparation of subcellular fractions
In this procedure PMSF was added to each of the buffers A, C and D just prior to their 
use at concentrations stated in the appendix. MM6 cells were grown in RPM I1640 
supplemented with 10% heat-inactivated foetal bovine serum, 5ml 200mM L- 
glutamine, 1% v/v non-essential amino acids, lOOU/ml penicillin, lOOug/ml 
streptomycin, and ImM sodium pyruvate . Cells were incubated at 37°C with 5%
CO2. Cell viability (>95%) was checked using the trypan blue exclusion method.
Cells were dispensed in 1 ml aliquots at a concentration of lx l06 viable cells into 24 
well culture plates. Cells were stimulated with 1 pg/ml of LPS from B.cenocepacia, 
B.multivorans and E.coli at various time intervals (15, 30, 60, and 120 min). 
Stimulation was terminated by transferring cells into 5 ml ice-cold DPBS and each 
sample was centrifuged at 1040 xg for 5 min. The pellets were re-suspended in 1 ml 
buffer A, transferred to Eppendorf tubes and centrifuged at 9155 xg for 1 min. The 
pellets were then re-suspended in 20 pi buffer A containing 0.1% NP40 and allowed 
to stand on ice for 5 min to lyse. The cell fractions were then centrifuged at 9155 xg 
for 5 min at 4°C. After centrifugation the supernatant (cytosolic extract) was removed 
to a fresh tube and the remaining pellet was re-suspended in 15 pi buffer C containing 
the PMSF, this was then left on ice for 15 min. The fractions were then centrifuged at 
9155 xg for 5 min at 4°C. The supernatants (nuclear extracts) were then removed to 
fresh tubes and 75 pi of buffer D was added to each tube, extracts were then stored at
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-80°C until use. Samples of the extracts were taken before freezing and assayed for 
protein concentration using the coomassie blue G binding method.
2.8.2. Detection of NF-kB in cell extracts
18x16 cm BioRad Electrophoresis cassettes with 1.5 mm spacers were used. The 
polyacrylamide gel was prepared (see appendix) and poured slowly into the cassette, a 
10 well comb was inserted carefully to avoid trapping any air bubbles. The gel was 
left to polymerise for a minimum of 1 hour.
Nuclear fractions were kept on ice until used, samples of equal protein (1 pg) were 
incubated in an Eppendorf tube with 10,000 cpm of a P-labelled oligonucleotide 
containing the consensus sequence for NF-kB in binding buffer and 2 pg of poly (dl- 
dC) at RT for 30 min. The samples were then run on a 5% polyacrylamide gel at 180 
V for ~90 min or until the lower dye is ~20 mm from the bottom of the gel.
The gel was then removed and dried for 2 hours and finally autoradiographed 
overnight at -80°C on Kodak Biomax film.
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2.9. Statistical analysis of ELISA data
For statistical analysis of ELISA data the mean of the number of repeats and the 
standard error for the read-out of each sample was calculated using Microsoft Excel. P 
values (with a significance level of 0.05) were then obtained by non-parametric 
Mann-Whitney analysis using SPSS software. A non-parametric test was chosen as it 
makes no assumptions about the distribution of the data (normality).
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Results
3.1. Comparison of B.cepacia LPS-1 (BcLPS-1) and B.cepacia LPS-2 (BcLPS-2)
In order to optimise experiments throughout this study and to ensure that a reasonable 
comparison could be made between LPS extracted from clinical samples and LPS that 
has been bought already purified, a number of experiments were conducted to 
ascertain a dose response from LPS stimulated cells and a TNF-a output from cells 
stimulated with a commercially available LPS that had been further purified.
3.1.1. Effect of the quantity of LPS used to stimulate MM6 cells on the 
inflammatory activity observed.
A representative B.cepacia complex LPS (Cardiff A l, B.multivorans) was used to test 
the TNF-a response from MM6 cells at different doses. This was done primarily to 
ascertain what concentration of LPS would be most appropriate to use throughout this 
study. MM6 (106 cells) were stimulated with 100 ng, 500 ng, or 1 pg of purified LPS 
from E.coli (0111 :B4- Sigma), P.aeruginosa (PA01- Sigma) and from Cardiff Al 
clinical isolate for 6 hours. TNF-a levels were measured by ELISA.
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The results (Figure 3.1.1.) show that the amount of TNF-a produced is proportional to 
the LPS dose. For all the LPS samples the amount of TNF-a produced at 100 ng and 
500 ng was low. At 1 pg there is a profound increase in TNF-a production and it is 
much easier to see the differences between purified LPS samples when using 1 pg to 
stimulate cells compared to the lower concentrations, for this reason a concentration 
of 1 pg LPS/ 106 cells was used in the majority of experiments in this study.
The results from this experiment also illustrate that LPS from P.aeruginosa (PA01) 
produces much less TNF-a from MM6 cells compared to LPS from Cardiff Al 
(B.multivorans) LPS.
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Figure 3.1.1. Dose response from MM6 cells incubated with 100 ng, 500 ng and lpg 
LPS/106 cells (LPS from E.coli (0111 :B4), B.multivorans (Cardiff Al) and 
P.aeruginosa (PA01)). Cells were stimulated for 6 hours and the resulting 
supernatants were tested for TNF-a by ELISA. Values are means ±SD of three 
independent experiments.
Cardiff A1 P.aeruginosa
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3.1.2. Testing of control LPS
Commercial E.coli LPS (Sigma) which had been purified using PCP extraction was 
used as a control throughout this study as it is considered to have the most pro- 
inflammatory LPS structure. It was then subjected to the same enzyme treatments as 
the B.cepacia complex LPS (incubation with DNase, RNase, trypsin and proteinase 
K), inflammatory response tests were done on both the commercially available E.coli 
LPS and the further purified preparation (Figure 3.2.1.). LPS from a clinical Cardiff 
E.coli isolate was also purified and tested in order to gain a comparison. Levels of 
TNF-a from MM6 cells stimulated for 6 hours with both preparations of E.coli LPS, 
showed no significant difference (Figure 3.2.1.). Therefore through the rest of this 
study commercially bought PCP extracted E.coli LPS was used without further 
purification.
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Figure 3.2.1. TNF-a response from MM6 cells (at lxlO6 cells/ml) stimulated with 
lpg LPS fro 6 hours. LPS purified from a Cardiff E.coli isolate used throughout this 
study extracted to LPS-1 and further purified to LPS-2 compared against LPS from 
commercial E.coli (Ol 11 :B4) LPS (Sigma). The commercially bought LPS was used 
to stimulate cells (LPS-1) and also further purified in the same way as the Cardiff LPS 
before stimulation (LPS-2).
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3.1.3. Stimulation of MM6 cells with LPS extracted by different methods from
various B.cepacia complex strains.
LPS from B.cepacia complex organisms elicits a much stronger inflammatory 
response from leukocytes compared with that of P. aeruginosa LPS (Zughaier et al, 
1999a and Shaw et al, 1995). It has been suggested that this inflammatory potency 
may be due to protein contamination present in LPS preparations (Shimomura et al, 
2001) and not the LPS itself.
To determine whether LPS alone can stimulate an inflammatory response independent 
of any protein or nucleic acid contaminants, LPS from various clinical and 
environmental isolates of B.cepacia complex was first extracted by the conventional 
phenol-chloroform-petroleum ether (PCP) method of (Galanos et al, 1969). The LPS 
from this initial extraction was designated BcLPS-1. Half the LPS from each such 
preparation was then further purified using enzyme treatments and sodium 
deoxycholate, this second extraction was designated BcLPS-2.
Human monocytic (MM6) cells were stimulated with either lpg LPS/106 cells of 
extracted B.cepacia complex LPS or with LPS from E.coli 0111:B4 (Sigma). Levels 
of TNF-a (Figure 3.1.3.) and IL-6 (Figure 3.1.4.) were measured by an ELISA 
method. TNF-a was measured after 6 hours stimulation with LPS and IL-6 measured 
after 16 hours stimulation with LPS as these incubation times have been previously 
shown in our laboratory to yield optimal amounts of these cytokines (data not shown, 
Zughaier et al, 1999a)
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The level of cytokine production from the initial PCP extractions and the more highly 
purified preparations were found to be similar, with no significant differences shown 
between BcLPS-1 and BcLPS-2. Previous studies have shown that bacterial proteins 
such as flagellin and bacterial nucleic acids do provoke an inflammatory response 
(Wagner & Bauer 2006). The results indicate that the inflammatory response seen 
with human derived MM6 cells is due to LPS and not contamination by protein or 
nucleic acid.
The results also indicate that there is a difference in inflammatory activity between 
the LPS extracted from various clinical B.cepacia complex strains and the LPS from 
environmental strains. LPS from B.cepacia strains are much less inflammatory than 
either that of B.cenocepacia or B.multivorans. LPS from Cardiff A1 (B.multivorans) 
and Cardiff P5 (.B.cenocepacia ET-12) are both seen to produce levels of TNF-a and 
IL-6 that are comparable to levels produced by E.coli LPS (Figure 3.1.3. and Figure
3.1.4.).
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Figure 3.1.3. TNF-a production from MM6 cells stimulated with lpg/ml BcLPS-1 
and BcLPS-2 for 6 hours at 37°C and measured by ELISA. BcLPS-1 vs. BcLPS-2 
P=0.9103 showing that there is no significant difference between the PCP extracted 
BcLPS-1 and the more highly purified, enzyme treated BcLPS-2. Values are means 
±SD of three independent experiments.
Cardiff Cardiff Cardiff Cardiff NCTC NCTC E.coli Cells 
P1 P2 P5 A1 10743 10661 alone
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Figure 3.1.4. IL-6 production from MM6 cells stimulated with lpg/ml BcLPS-1 and 
BcLPS-2 for 16 hours at 37°C and measured by ELISA. BcLPS-1 vs. BcLPS-2 
P=0.9754 showing that there is no significant difference between the PCP extracted 
BcLPS-1 and the more highly purified, enzyme treated BcLPS-2. Values are means 
±SD of three independent experiments.
E.coli Cells 
alone
Cardiff Cardiff Cardiff Cardiff NCTC NCTC
P2 P5 P1 A1 10661 10743
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3.1.4. Stimulation of A549 cells with LPS extracted by different methods from
various B.cepacia complex strains.
A549 cells are derived from alveolar epithelial cells and so represent the primary 
interface between invading bacteria and the immune system. Increased viscosity of 
mucous membranes in the CF lung means that bacteria are not cleared away from 
these cells efficiently and so their reaction to BcLPS is relevant.
A549 cells have been shown to lack the LPS co-receptor, membrane bound CD 14 
(mCD14) and so require soluble CD 14 (sCD14) present in human serum for response 
to LPS, this would normally be present in vivo.
A549 cells were stimulated with lpg LPS/106 cells of either BcLPS-1 or BcLPS-2 
from various B.cepacia complex clinical and environmental strains. 1% human serum 
was included in each experiment to provide sCD14, control experiments were 
included where A549 were stimulated with LPS without the presence of human 
serum. IL-8 production was detected by ELISA after the optimal 16 hours stimulation.
Cells that were stimulated with LPS without human serum being present showed very 
little IL-8 production which indicates that the LPS tested all required a component of 
human serum, sCD14, in order to produce an inflammatory effect (Figure 3.1.5.)
The results also show that there was no significant difference between BcLPS-1 and 
BcLPS-2 samples tested. This indicates that IL-8 production is being caused by LPS 
alone and not any protein or nucleic acid contaminant (Figure 3.1.6.). Environmental 
isolates tested NCTC 10661 and NCTC 10743 do show a difference in production of
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IL-8 between BcLPS-1 and BcLPS-2 (Figure 3.1.5.) when tested without human 
serum, however the difference is exaggerated because of the small scale used due to 
the tiny amounts of IL-8 being produced without human serum.
LPS preparations from environmental B.cepacia strains were seen to produce lower 
levels of IL-8 than LPS from either B.cenocepacia or B.multivorans which are all of 
clinical origin. LPS preparations from Cardiff P5 {B.cenocepacia ET-12) and 
CardiffAl {B.multivorans) produced levels of IL-8 that were comparable to levels 
produced by E.coli LPS.
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Figure 3.1.5. IL-8 production from A549 cells stimulated with lpg/ml BcLPS-1 and 
BcLPS-2 without the presence of human serum for 16 hours at 37°C and measured by 
ELISA. The quantity of IL-8 produced under serum-free conditions is much reduced 
compared to incubation with 1% human serum. Values are means ±SD of three 
independent experiments.
Cardiff Cardiff Cardiff NCTC NCTC E.coli Cells
P5 P1 A1 10661 10743 alone
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Figure 3.1.6. IL-8 production from A549 cells incubated with 1% human serum and 
then stimulated with lpg/ml BcLPS-1 and BcLPS-2 for 16 hours at 37°C and 
measured by ELISA. BcLPS-1 vs. BcLPS-2 P= 0.9218 showing that there is no 
significant difference between the PCP extracted BcLPS-1 and the more highly 
purified, enzyme treated BcLPS-2. Values are means ±SD of three independent 
experiments.
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3.2. Biological activity of B.cepacia LPS
3.2.1. TNF-a production in MM6 cells stimulated by LPS
BcLPS-2 is used in all experiments from this point (and is referred to as LPS) 
although it has been shown that there is no significant difference between 
inflammatory activity of BcLPS-1 and BcLPS-2 in these experiments, further study 
would be required to make sure there is no contamination each time the samples are 
prepared, therefore it was logical to continue using BcLPS-2.
In order to assess the biological activity of various B.cepacia complex strains’ LPS 
and to compare it to LPS from E.coli and P.aeruginosa, MM6 cells were stimulated 
with LPS (lpg/106 cells) for 6 hours and resulting TNF-a levels were measured by 
ELISA. Five different B.cenocepacia ET-12 strains, one B.cenocepacia Type B, two 
B.multivorans and two environmental B.cepacia samples were tested in order to get a 
broad view of inflammatory activity. Figure 3.2.1. shows the vast difference in 
inflammatory activity observed not only between different B.cepacia complex species 
but between isolates with the same genotype. Cardiff PI, P2, P3, P4 and P5 are all 
B.cenocepacia ET-12 strains, though phenotypically and phylogenetically identical 
there were large differences in the amount of TNF-a produced. The LPS from 
environmental B.cepacia strains induced a lower inflammatory response as compared 
to the LPS from clinical samples. LPS from Cardiff P5 and Cardiff A1 again 
stimulated a level of TNF-a which was comparable to that from E.coli. All B.cepacia 
LPS tested induced significantly higher levels of TNF-a production as compared to 
LPS from P.aeruginosa.
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3.2.2. IL-6 production in MM6 cells stimulated by LPS
To investigate the induction of other inflammatory cytokines by LPS, MM6 cells 
were stimulated with LPS (1 jj.g/106 cells) for 16 hours and levels of IL-6 were then 
measured form the resulting supernatants by ELISA. The same panel of LPS samples 
were used as for the TNF-a experiments (Figure 3.2.1.). Of the B.cenocepacia LPS 
samples, that from Cardiff PI showed the lowest level of IL-6 production, with LPS 
from Cardiff A1 and Cardiff P5 showing levels that are comparable to that of E.coli. 
The LPS from B.cepacia environmental strains produced levels of IL-6 more than 5 
times lower than that of the highest B.cenocepacia and B.multivorans LPS samples. 
As with TNF-a production, LPS from P.aeruginosa produced a much lower level of 
IL-6 than that from any of the clinical B.cepacia complex samples (Figure 3.2.2.).
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Figure 3.2.1. TNF-a production from MM6 cells stimulated with lpg LPS/106 cells. 
BcLPS isolated from different strains compared with LPS isolated from P.aeruginosa 
and E.coli. Cells were stimulated for 6 hours at 37°C and measured by ELISA. Values 
are means ±SD of three independent experiments.
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Figure 3.2.2. IL-6 production from MM6 cells stimulated with lpg LPS/106 cells. 
BcLPS isolated from different strains compared with LPS isolated from P.aeruginosa 
and E.coli. Cells were stimulated for 16 hours at 37°C and measured by ELISA. 
Values are means ±SD of three independent experiments.
3.2.3. Difference in inflammatory response caused by environmental vs clinical 
strains.
Results from MM6 cells stimulated with lpg B.cepacia complex LPS/106 cells for 6 
hours and then tested for levels of TNF-a by ELISA, were pooled to ascertain the 
difference in biological activity between clinical and environmental isolates. LPS 
from all B.cenocepacia (Cardiff PI, P2, P3, P4, P5 and P6), B.multivorans (Cardiff 
A1 and Cardiff A2) and B.cepacia (NCTC 10661 and NCTC 10743) samples were 
used. The results indicate that LPS from clinical samples induced the production of 
higher levels of TNF-a than environmental LPS, also that the LPS from 
B.cenocepacia samples are not as biologically active as the B.multivorans strains 
(Figure 3.2.3.).
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Figure 3.2.3. TNF-a production from MM6 cells stimulated with lpg LPS/106cells 
of LPS isolated from B.cenocepacia and from B.multivorans vs. LPS isolated from 
Bcc environmental strains. Cells were stimulated for 6 hours at 37°C and measured by 
ELISA. Values are means ±SD of three independent experiments.
3.2.4. Variability in TNF-a production within B.cenocepacia ET-12 strains.
B.cenocepacia ET-12 strains are phylogenetically identical. Variability in 
inflammatory responses produced by LPS extracted from these samples has been 
observed earlier in this study (Figures 3.2.1. and 3.2.2.). To observe whether this 
variability is unique to Cardiff clinical B.cenocepacia strains or whether it can be seen 
in isolates from clinical sources elsewhere, B.cenocepacia ET-12 isolates that had 
been collected from CF clinics around the UK were examined. Each isolate was 
grown up and subjected to LPS extraction in an identical fashion to the Cardiff 
samples and MM6 cells were stimulated with lpg LPS/106 cells for 6 hours and the 
resulting supernatants were tested for levels of TNF-a by ELISA. The results (Figure
3.2.4.) show that there is pronounced variability in the level of TNF-a production 
from the ET-12 strains. The average TNF-a production from all five Cardiff strains is 
comparable to levels produced by the Liverpool and Edinburgh strains. However LPS 
from isolates from Manchester and London were both more inflammatory (Figure
3.2.4.).
3.2.5. Culturing and re-culturing of B.cenocepacia ET-12 strains to check for 
variability.
Variability in the biological activity of LPS extracted from identical B.cenocepacia 
ET-12 strains might be due to the amount of time the organism has been grown up in 
vitro. It is possible that with each re-culturing of the isolate within the laboratory
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environment, small structural changes could occur within the LPS, and this may 
account for the difference in TNF-a, IL-6 and IL-8 production from stimulated cells.
In order to ascertain whether this is the case, two Cardiff B.cenocepacia ET-12 strains 
were cultured, and then re-cultured 20 times each, both isolates were initially 
collected early in the infection of the patient and had not been re-cultured more than 
four times from their initial isolation from the patient’s sputum. Every fifth time the 
bacteria were cultured, a sample was taken and grown up on a larger scale in order to 
extract LPS thereby giving an image over time as to how (if at all) the inflammatory 
activity of LPS changes with re-culturing. The lowest (Cardiff PI) and highest 
(Cardiff P5) TNF-a producers were chosen in order to show any differences in 
biological activity. The results show that the level of TNF-a produced in MM6 cells 
stimulated with B.cenocepacia ET-12 LPS does not change with culturing over time 
(Figure 10). This suggests that re-culturing the bacteria in the laboratory does not 
affect the structure of LPS and therefore the inflammatory response from the LPS, and 
that the variability seen within the Cardiff ET-12 strains is not due to re-culturing.
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Figure 3.2.4. TNF-a production from MM6 cells stimulated with 1 jig/ml of LPS from 
5 different Cardiff B.cenocepacia ET-12 (PI, P2, P3, P4, P5) strains and from 
individual B.cenocepacia ET-12 strains from clinical sources around the UK. Cells 
were stimulated for 6 hours at 37°C and measured by ELISA. Values are means ±SD 
of three independent experiments.
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Figure 3.2.5. Representative B.cenocepacia ET-12 strains Cardiff P5 and Cardiff PI, 
were grown up and subbed (from 0-20 times) over time to ensure there were no 
differences in TNF-a production caused by growing the strains outside the body. LPS 
was extracted and MM6 cells were stimulated with 1 pg LPS for 6 hours and TNF-a 
was measured by ELISA. Values are means ±SD of four independent experiments.
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3.2.6. Silver staining of purified B.cepacia complex LPS
Purified LPS from representative B.cepacia complex isolates were characterised by 
silver staining on SDS-PAGE gels. Figure 3.2.6. shows LPS extracted to BcLPS-1 
and BcLPS-2 from three difference B.cepacia complex strains. The gel shows that 
these samples were all rough type LPS distinguished by a complete LPS core at the 
bottom of the gel. The gel also shows that the LPS extraction procedure does not have 
any effect on LPS O-antigen. Most of the clinical samples tested were rough type 
(Figure 3.2.6., lanes: 3,4,5,6,7,8 and Figure 3.2.7., lanes: 5,6). The other samples 
tested were either smooth type LPS or a mixture of rough and smooth. B.cepacia 
environmental samples were found to be smooth (Figure 3.2.7., lanes: 1,2). For 
comparison a smooth and rough type LPS from S.minnesota was included (Figure
3.2.6.).
3.2.7. TNF-a production from MM6 cells stimulated with rough and smooth type 
B.cepacia complex LPS
Purified representative B.cepacia complex LPS samples that were known to be either 
rough or smooth type, were used to stimulate MM6 cells in order to determine if there 
was any correlation between inflammatory response and whether the LPS samples is 
rough or smooth. Cells were stimulated with 1 pg/106 cells LPS for 6 hours and TNF- 
a levels were measured by ELISA (Figure 3.2.8.). The results show that the smooth 
type LPS samples produced a lower level of TNF-a than the rough samples. The
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smooth LPS samples tested were both from environmental strains. The rough samples 
were from clinical strains, and induced much higher TNF-a levels than the smooth 
type, but there was a large difference in TNF-a production between the two rough 
samples tested. It can be seen that although the smooth type LPSs tested here induce a 
smaller inflammatory response than the rough type LPSs, the variability in 
inflammatory responses between different rough samples is so large that the level of 
TNF-a produced cannot be directly linked to whether the sample is rough or smooth.
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Figure 3.2.6. Silver staining of various LPS samples from B. cepacia complex using 
S. minnesota as comparison samples. From left to right Lane 1- Rough sample, S. 
minnesota R7 (Rd), Lane 2- Smooth sample, S. minnesota wild-type, Lane 3- Cardiff 
A3 BcLPS-1, Lane 4- Cardiff A3 BcLPS-2, Lane 5- NCTC 13009 BcLPS- 1, Lane 6- 
NCTC 13009 BcLPS-2, Lane 7- Cardiff A1 BcLPS-1, Lane 8- Cardiff A1 BcLPS-2.
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Figure 3.2.7. Silver staining of various LPS samples from B. cepacia complex. From 
left to right, Lane 1- NCTC 10743, Lane 2- NCTC 10661, Lane 3-NCTC 10744, Lane 
4-NCTC 13011, Lane 5- Cardiff A2, Lane 6- Cardiff A l, Lane 7-Cardiff P4 , Lane 8- 
Cardiff P5.
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Figure 3.2.8. TNF-a production from MM6 cells suspended at lx l06/ml and 
stimulated with 1 pg/ml of LPS from representative Bcc isolates known to be either 
rough or smooth. Cells were stimulated for 16 hours at 37°C and measured by ELISA. 
Values are means ±SD of three independent experiments.
NCTC 10743 NCTC 10661 Cardiff A1 Cardiff P4
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3.2.8. B.cepacia complex LPS inactivation by Polymyxin B
Polymyxin B is an antibiotic that has been shown to bind LPS and prevent its ability 
to induce inflammation. However B.cepacia complex bacteria are naturally resistant 
to the antimicrobial action of Polymyxin B due to the presence of an Ara4N with a 
positive charge which reduces the electro negativity of the LPS and therefore should 
reduce binding by Polymyxin B. The question arises if Polymyxin B still inhibitory 
effects on the inflammatory activity of LPS from B.cepacia complex. In order to 
investigate the binding of representative B.cepacia complex LPS to Polymyxin B, 
MM6 (106/ml) cells were stimulated with different doses of LPS from Cardiff A1 
(chosen for the potency of its LPS to induce inflammatory cytokines from previous 
experiments), E.coli and P.aeruginosa in the presence of Polymyxin B at different 
concentrations. After 6 hours TNF-a level was measured by ELISA. Polymyxin B 
was found to effectively neutralize 100 ng Cardiff A1 LPS by more than 50% at 
concentrations of >5 pg/ml (Figure 3.2.9.) as shown by a reduction in TNF-a 
production. At an increased LPS dose of 500 ng/ml Polymyxin B also neutralized 
Cardiff A1 LPS in a dose dependant manner (Figure 3.2.10.). Results for E.coli and 
P.aeruginosa showed similar reduction in TNF-a production that was dependant on 
dose of LPS and concentration of Polymyxin B. This suggests that there is no 
difference in the binding of Cardiff A1 LPS to Polymyxin B as compared with E.coli 
and P.aeruginosa.
106
90
Figure 3.2.9. Effect of Polymyxin B sulphate on the production of TNF-a from LPS 
stimulated MM6 cells. Cells were suspended at lx l06/ml and LPS from E.coli, Bcc 
(Cardiff A l) and P.aeruginosa was added to make a final concentration of 100 ng, at 
the same time either 5 pg or 50 pg of Polymyxin B (PMB) was added. Control wells 
containing LPS alone, cells alone and Polymyxin B alone were also included. The 
incubation was terminated after 6 hours. Values are means ±SD of three independent 
experiments.
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Figure 3.2.10. Effect of Polymyxin B sulphate on the production of TNF-a from LPS 
stimulated MM6 cells. Cells were suspended at lx l06/ml and LPS from E.coli, Bcc 
(Cardiff A l) and P.aeruginosa was added to make a final concentration of 500 ng, at 
the same time either 5 pg or 50 pg of Polymyxin B (PMB) was added. Control wells 
containing LPS alone, cells alone and Polymyxin B alone were also included. The 
incubation was terminated after 6 hours. Values are means ±SD of three independent 
experiments.
3.3. Respiratory Burst in B.cepacia complex LPS primed MM6 cells
3.3.1. MM6 cells respiratory burst responses
Respiratory burst is a critical mechanism in the defence against invading pathogens 
and this oxidative activity is important in antimicrobial action by cells. Monocytes 
and macrophages produce superoxide anion in response to bacteria or bacterial 
products which have been engulfed (Allen et al, 1972).
Overproduction of reactive oxygen radicals can cause tissue damage during 
inflammation. LPS does not directly cause the triggering of a respiratory burst 
response, however it has been shown to up regulate the response by cells to other 
stimuli, therefore acting as a priming agent (Schopf et al, 1990, Yan et al, 2002).
It has been suggested that increased respiratory burst activity in the lungs may 
contribute to inflammation by the release of tissue damaging proteolytic enzymes and 
reactive oxygen species and that LPS from B.cepacia complex may play a 
considerable role in lung inflammation in cystic fibrosis (Hughes et al 1997).
In order to compare B.cepacia complex LPS to that of P.aeruginosa and E.coli in 
their ability to prime a respiratory burst response, MM6 cells were primed overnight 
with 100 ng LPS/106 cells with LPS from various representative clinical B.cepacia 
complex isolates which showed different abilities to induce TNF-a in previous 
experiments or with LPS from P.aeruginosa (PA01), or E.coli (0111 :B4). The
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respiratory burst response was triggered using opsonised zymozan and the production 
of superoxide anions was measured by enhanced chemiluminescence using Luminol.
The respiratory burst activation by opsonised zymozan was maximal at either 15 or 20 
minutes for each reaction, and the relative light unit (RLU) levels at the peak of each 
sample reaction is shown (Figures 3.3.2 and 3.3.4 and 3.3.6.).
B.cepacia complex LPS primed cells to produce varying levels of superoxide anion, 
with Cardiff Al (B.multivorans) (Figures 3.3.1. and 3.3.5.) and Cardiff P6 
(.B.cenocepacia) (Figure 3.3.3.) producing higher levels than LPS from E.coli, Cardiff 
P5 (B.ceocepacia ET-12) or Cardiff A2 (.B.multivorans)
Cardiff Al LPS showed the greatest ability to prime for respiratory burst activity 
(Figures 3.3.1. and 3.3.5.) this strain produced high levels of TNF-a, IL-6 and IL-8 in 
cytokine stimulation experiments (Figures3.1.5. and 3.2.1. and 3.2.2.).
LPS from Cardiff P5 {B.cenocepacia ET-12) was the most inflammatory B.cepacia 
complex LPS in stimulating cytokine production, but was not the most effective at 
priming MM6 cells for respiratory burst. LPS from Cardiff P6 {B.cenocepacia) 
(Figures 16a and 16b) also produce higher amounts of superoxide anion than LPS 
from E.coli but in cytokine stimulation experiments it produced lower levels of 
inflammatory cytokines than E.coli. These examples show that there is little 
correlation between ability to produce an inflammatory response directly though 
cytokine production and the ability to prime monocytes for respiratory burst. LPS 
from Cardiff PI {B.cenocepacia ET-12) (Figure 3.3.3.) and Cardiff P2 {B.cenocepacia
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ET-12) (Figure 3.3.5.) were the least effective samples tested with Cardiff P2 showing 
a lesser ability to prime for respiratory burst than even P.aeruginosa (Figure 3.3.6.), 
The differences seen between these ET-12 samples demonstrates the variability of 
LPS that is derived from identical B.cenocepacia ET-12 isolates in their ability to 
prime monocytes for respiratory burst.
It is suggested that induction of inflammatory response is separate and dissimilar to 
the oxidative burst response. The respiratory burst response is a direct method of 
killing pathogens by host cells, so inducing this response is not advantageous to 
B.cepacia complex organisms as they are cleared more efficiently when the response 
is induced.
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Figure 3.3.1. Typical chemiluminescence plot of MM6 cells primed overnight with 
100 ng LPS from representative Cardiff B.cepacia strains, E.coli and P.aeruginosa. 
Respiratory burst was triggered with opsonised zymozan and detected using luminol
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Figure 3.3.2. The peak of chemiluminescence at 15 min from MM6 cells primed 
overnight with 100 ng LPS from representative Cardiff B.cepacia strains, E.coli and 
P.aeruginosa. * = P values were obtained vs Cardiff Al LPS. Respiratory burst was 
triggered with opsonised zymozan and detected using luminol.
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Figure 3.3.3. Typical chemiluminescence plot of MM6 cells primed overnight with 
100 ng LPS from Cardiff B.cepacia strains and E.coli. Respiratory burst was triggered 
with opsonised zymozan and detected using luminol
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Figure 3.3.4. The peak of chemiluminescence at 15 min from MM6 cells primed 
overnight with 100 ng LPS from representative Cardiff B.cepacia strains and E.coli. 
* = P values were obtained vs Cardiff P6 LPS. Respiratory burst was triggered with 
opsonised zymozan and detected using luminol.
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Figure 3.3.5. Typical chemiluminescence plot of MM6 cells primed overnight with 
100 ng LPS from Cardiff B.cepacia strains E.coli and P.aeruginosa. Respiratory burst 
was triggered with opsonised zymozan and detected using luminol
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Figure 3.3.6. The peak of chemiluminescence at 20 min from MM6 cells primed 
overnight with 100 ng LPS from representative Cardiff B.cepacia strains, E.coli and 
P.aeruginosa * = P values were obtained vs Cardiff Al LPS. Respiratory burst was 
triggered with opsonised zymozan and detected using luminol.
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3.4. Investigating the receptor signalling by B.cepacia complex LPS
3.4.1. The role of CD14 in B.cepacia complex signalling
B.cepacia complex LPS might activate cells via different receptors and pathways than 
LPS from other bacterial species, a study has suggested that the closely related 
P.aeruginosa signal through TLR2 (Erridge et al, 2004). This work set out to 
elucidate the receptors that are bound and activated by B.cepacia complex LPS and to 
confirm which signalling pathway is activated between the cell surface receptor and 
the nucleus.
CD 14 has been shown to be the initial cell surface receptor to respond to LPS (Fenton 
& Golenbrock 1998), on the cell surface it is referred to as mCD14 (membrane bound 
CD 14) but it is also present in serum where it is referred to as sCD14 (solubleCD14).
In order to block the action of both mCD14 and sCD14, monoclonal anti-CD 14 
antibody (at an optimal 20pg/106 cells) was incubated with MM6 cells followed by 
stimulation with 100ng/106 cells of representative B.cepacia complex LPS. A lower 
dose of LPS was used to stimulate cells in all antibody blocking experiments to allow 
the use of as low a dose of blocking antibody as possible. TNF-a levels were 
measured by ELISA after 6 hours incubation.
E.coli LPS is already known to require CD 14 to mediate an inflammatory response, 
the results show that the production of TNF-a due to stimulation with E.coli LPS is 
reduced by a total of 75% following pre-treatment with anti-CD14 (Figure 3.4.1.).
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TNF-a levels produced by Cardiff Al (B.multivorans) and Cardiff P4 (B.cenocepacia 
ET-12) were both reduced to almost zero when pre-treated with anti-CD 14 before 
stimulation. This strongly indicates that both LPS samples utilize CD 14 to activate the 
signalling pathway that culminates in an inflammatory response. These results are 
further backed up by cytokine stimulation experiments using purified LPS and A549 
cells (Figure 3.1.5.) in the absence of sCD14 which showed a much reduced IL-8 
production compares to cells that had been incubated with human serum that provides 
sCD14.
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Figure 3.4.1. MM6 cells were pre-incubated with 5pg monoclonal anti-CD14 
antibody and then stimulated with 25ng/250pl cells of representative B.cepacia LPS 
and E.coli LPS, MM6 cells were also stimulated with LPS without anti-CD 14 as a 
control. Supernatants were harvested after 16 hours and were tested for levels of TNF- 
a by ELISA. Values are means ±SD of two independent experiments.
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3.4.2. Role of TLR4 receptor in B.cepacia complex LPS signalling
In E.coli when CD 14 has bound LPS, the signal is then conveyed through the trans­
membrane receptor TLR4. To investigate the role of TLR4 in the signalling of 
B.cepacia complex LPS, monoclonal anti-TLR4 blocking antibody (at an optimal 
20pg/106 cells) was incubated with MM6 cells before stimulation with 100ng/106 
cells of purified representative B.cepacia complex LPS or LPS from E.coli. TNF-a 
levels were measured by ELISA after 6 hours incubation. An IgG2a isotype antibody 
was included as a control and was found to not reduce the amount of TNF-a produced 
due to non-specific binding. The efficacy of anti-TLR4 antibodies has been shown to 
be good and they have been used for many years, in many different studies (Fan et al 
2007; Tonks et al 2007; Ahmad et al 2007).
All samples but one (Cardiff Al - B.multivorans) LPS, including the environmental 
strain NCTC 10743, showed a reduction of more than 80% in TNF-a production 
when the cells were pre-treated with anti-TLR4 compared to those that were not pre­
treated (Figures 3.4.2. and 3.4.3.).
There was a reduction of 40% in TNF-a production when Cardiff Al (.B.multivorans) 
was incubated with anti-TLR4 as compared to LPS alone. Although this is still a 
significant reduction, the anti-TLR4 did not inhibit TNF-a production as effectively 
as with the other LPS samples tested. All conditions were the same over the course of 
these experiments and only the LPS sample used was variable. The TNF-a production 
from E.coli LPS was seen to be reduced to zero when anti-TLR4 was included. The 
IgG2a isotype antibody had no effect on TNF-a production from E.coli LPS
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stimulated cells and had no effect on MM6 cells alone. Studies using cells which are 
deficient in the TLR4 receptor, for example C3h/HEJ mice, would confirm that these 
LPS samples are indeed signalling through TLR4.
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Figure 3.4.2. MM6 cells were pre-incubated with 5pg monoclonal anti-TLR4 
antibody and then stimulated with 25ng/250pl cells of representative B.cenocepacia 
LPS and E.coli LPS, an IGg2a isotype antibody was included with E.coli LPS and by 
itself to determine any effect. Supernatants were harvested after 16 hours and were 
tested for levels of TNF-a by ELISA. Values are means ±SD of two independent 
experiments
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Figure 3.4.3. MM6 cells were pre-incubated with 5pg monoclonal anti-TLR4 
antibody and then stimulated with 25ng/250jil of cells of B.cepacia LPS and E.coli 
LPS, an IGg2a isotype antibody was included with E.coli LPS and by itself to 
determine any effect. Supernatants were harvested after 16 hours and were tested for 
levels of TNF-a by ELISA. Values are means ±SD of two independent experiments.
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3.4.3. Role of TLR2 receptor in B.multivorans LPS signalling
Using a monoclonal antibody to TLR4 reduced the TNF-a production from MM6 
cells stimulated with LPS from B.cepacia complex LPS dramatically. The exception 
in the samples tested was the Cardiff Al {B.multivorans) sample which showed only a 
partial reduction in TNF-a production when pre-treated with anti-TLR4, this could be 
due to the efficacy of the blocking antibody or because Cardiff Al is partially 
signalling through another receptor. Some atypical LPS samples have been shown to 
signal through TLR2, because of this, the possible role of TLR2 in signalling was 
investigated. (Werts et al 2001; Erridge et al 2004).
Monoclonal anti-TLR2 blocking antibody (5pg/250ul) was incubated with MM6 cells 
(106/ml) before stimulation with lOOng/ml of purified Cardiff Al (.B.multivorans), 
Cardiff P2 (B.multivorans) LPS or LPS from E.coli.
TNF-a levels were measured by ELISA after 6 hours incubation. The results for 
incubation with anti-TLR2 and treatment with Cardiff Al LPS (Figure 3.4.4.) show 
that there was an insignificant reduction in the production of TNF-a, which may 
indicate that TLR2 is not required for LPS signalling from this strain. Cardiff A2 and 
E.coli LPS also show no difference in inflammatory activity when pre-incubated with 
anti-TLR2 which may indicate that this receptor is not required for signal transduction 
for LPS from these strains either.
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Figure 3.4.4. MM6 cells were pre-incubated with 5pg monoclonal anti-TLR2 
antibody and then stimulated with 25ng/250pl of cells of B.multivorans LPS and 
E.coli LPS. Supernatants were harvested after 16 hours and were tested for levels of 
TNF-a by ELISA. Values are means ±SD of two independent experiments.
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3.4.4. Role of MyD88 adaptor protein in B.cepacia complex LPS signalling
LPS has been shown to signal via MyD88 dependent (Miyake 2004) and 
independently of MyD88 (Hoebe et al, 2003) through TRIF/TRAM. In order to find 
out whether representative B.cepacia complex LPS samples require MyD88 to signal, 
MM6 cells 106/ml were incubated with either 100 pM of MyD88 inhibitor peptide 
(sequence= DRQIKIWFQNRRMKWKKRDVLPGT) or 100 pM of a control peptide 
(sequence= DRQIKIWFQNRRMKWKK) for 24 hours. The MyD88 inhibitor peptide 
is cell permeable and prevents the homodimerization of MyD88 thus preventing 
signalling through it. The cells were stimulated with 100 ng purified LPS from E.coli, 
Cardiff Al and Cardiff P5 for 6 hours and TNF-a levels were measured by ELISA. 
The amount of TNF-a produced by E.coli LPS stimulated cells was reduced 
significantly when MyD88 inhibitor peptide was present (P=<0.0001) (Figure 3.4.5.) 
and inclusion of the control peptide had no effect.
Cardiff Al LPS (Figure 3.4.6.) showed a much lower reduction in TNF-a level when 
MyD88 inhibitor peptide was included although still significant (P=0.0002). This 
result may indicate that as well as signalling through MyD88, Cardiff Al LPS may 
stimulate via the MyD88 independent pathway. This could only be confirmed with 
use of other techniques and models, for example using a MyD88'7" mouse or by using 
RNAi to inactivate the MyD88 gene. When the control peptide was included it no 
effect on TNF-a production.
Cardiff P5 LPS stimulated cells (Figure 3.4.7.) showed a significant reduction in 
TNF-a production when incubated with MyD88 inhibitor protein when compared
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with LPS alone (.P=<0.0001) which would suggest that this purified LPS signals only 
through MyD88. The control peptide again showed no effect on the level of TNF-a 
produced.
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Figure 3.4.5. MM6 cells suspended at lxlO6 cells/ml were incubated with either 100 
pM of MyD88 inhibitor peptide or 100 pM of a control peptide for 24 hours then 
stimulated with 100 ng of LPS from E.coli for 6 hours, control cells stimulated with 
LPS alone were included. The supernatants were tested for TNF-a by ELISA.
* = P values were obtained vs E.coli LPS alone. Values are means ±SD of three 
independent experiments.
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Figure 3.4.6. MM6 cells suspended at lxlO6 cells/ml were incubated with either 100 
pM of MyD88 inhibitor peptide or 100 pM of a control peptide for 24 hours then 
stimulated with 100 ng of LPS from B.multivorans (Cardiff A l) for 6 hours, control 
cells stimulated with LPS alone were included. The supernatants were tested for TNF- 
a by ELISA. * = P values were obtained vs Cardiff Al LPS alone. Values are means 
±SD of three independent experiments.
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Figure 3.4.8. MM6 cells suspended at lxlO6 cells/ml were incubated with either 100 
pM of MyD88 inhibitor peptide or 100 pM of a control peptide for 24 hours then 
stimulated with 100 ng of LPS from B.cenocepacia (Cardiff P5) for 6 hours, control 
cells stimulated with LPS alone were included. The supernatants were tested for TNF- 
a by ELISA. * = P values were obtained vs Cardiff P5 LPS alone. Values are means 
±SD of three independent experiments.
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3.5. MAP Kinase activation by B.cepacia complex LPS
3.5.1. Phosphorylation of P38 by B.cepacia complex LPS
Mitogen activated protein (MAP) kinases belong to three families, P38 MAPKs, 
extracellular signal-regulated kinases (ERKs) and c-Jun N-terminal kinase (JNK).
LPS from various bacteria has been shown to activate all three families, but primarily 
ERKs and P38 (Raingeaud et al 1995; Scherle et al 1998).
MAP kinase activation has not been investigated in B.cepacia complex bacteria in 
detail. MAP kinases activate by phosphorylation which can be detected by western 
blot. To compare whether MAPK activation pathways used by B.cepacia complex 
LPS was similar to that used by E.coli LPS, MM6 cells were stimulated with 1 pg 
LPS to induce a strong response, for 1 hour before protein extraction and Western blot 
analysis. Whole cell lysate from stimulated and control cell containing equal amounts 
of protein were loaded onto each lane of a 10% Bis-Tris gel. The antibody used only 
binds when the MAPK is phosphorylated and therefore active, it does not bind to non- 
phosphorylated P38. Both Cardiff P5 and Cardiff Al (Figure 3.5.1.) were shown to 
phosphorylate P38 MAPK in a similar manner to E.coli LPS. There are no bands 
present with the samples that were not stimulated with LPS.
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3.5.2. Phosphorylation of P44/42 by B.cepacia complex LPS
P44/42 is also known as ERK 1/2 and is a member of the ERK kinase group. In order 
to see whether P44/42 is activated when monocytic cells are stimulated with 
B.cepacia complex LPS MM6 cells were stimulated with 1 pg LPS for 1 hour before 
protein extraction and Western blot analysis. Equal amounts o f protein were loaded 
onto each lane for each blot. It was found that all B.cepacia complex LPS samples 
tested produced bands corresponding to P44/42 MAPK (Figures 3.5.2. and 3.5.3. and 
3.5.4.) similar to that of E.coli LPS. The antibody used only binds when the MAPK is 
phosphorylated and therefore active, it does not bind to non-phosphorylated P44/42. 
Unstimulated control cells showed much weaker banding, which may correspond to 
less phosphorylation, compared to the stimulated samples, this could be confirmed 
using densitometry.
3.5.3. Total vs phosphorylated P44/42
MM6 cells were stimulated with 1 pg LPS for 1 hour before protein extraction and 
Western blot analysis for phosphorylated P44/42 MAPK and total amount of P44/42 
MAPK. Equal amounts of protein were loaded onto each lane for each blot. Total 
P44/42 MAPK showed much denser and more intense bands than the bands for 
phosphorylated P44/42 alone which may indicate that not all P44/42 MAPK is 
activated when stimulated with any LPS tested including E.coli (Figure 3.5.5.) In 
order for these results to be quantitative in any way, a loading control antibody in the 
form of a house-keeping gene (e.g GAPDH) and densitometry would have to be
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performed. However the results here indicate that LPS from BCC is activating P44/42 
MAPK and indeed P38 MAPK. Signalling through these MAPKs has been further 
indicated with MAPK inhibition experiments (section 3.6.).
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Figure 3.5.1. Western blot of phosphorylated P38 MAPK stimulated by B.cepacia 
complex LPS. MM6 cells (lx l06/ml) were stimulated with 1 pg LPS for 1 hour. 
Lanes: 1- non-stimulated control, 2-E.coli, 3-Cardiff P5, 4-Cardiff Al, 5- non­
stimulated control. Bands shown correspond to 43kDa.
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Figure 3.5.2. Western blot of phosphorylated P44/42 MAPK stimulated by B.cepacia 
complex LPS. MM6 cells (lx l06/ml) were stimulated with 1 pg LPS for 1 hour. 
Lanes: 1- Cardiff Al. 2- Cardiff P5, 3- non-stimulated control, 4- positive control cell 
extract. Bands shown correspond to 44kDa and 42kDa.
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Figure 3.5.3. Western blot of phosphorylated P44/42 MAPK stimulated by B.cepacia 
complex LPS. MM6 cells (lx l06/ml) were stimulated with 1 pg LPS for 1 hour.
Lanes: 1- Cardiff PI, 2- non-stimulated control, 3- Cardiff P6, 4- Cardiff P4 
Bands shown correspond to 44kDa and 42kDa.
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Figure 3.5.4. Western blot of phosphorylated P44/42 MAPK stimulated by B.cepacia 
complex LPS. MM6 cells (lx l0 6/ml) were stimulated with 1 pg LPS for 1 hour. 
Lanes: 1- non-stimulated control, 2- Cardiff PI, 3- Cardiff P2, 4- Cardiff P3, 5- 
Cardiff P4, 6- Cardiff P5, 7- phosphorylated control sample.
Bands shown correspond to 44kDa and 42kDa.
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Figure 3.5.5. Western blot of phosphorylated and total P44/42 MAPK stimulated by 
B.cepacia complex LPS. MM6 cells (lx l06/ml) were stimulated with 1 pg LPS for 1 
hour.
Lanes: 1- phosphorylated P44/42 control extract, 2- phosphorylated E.coli, 3- 
phosphorylated Cardiff A l, 4- phosphorylated Cardiff P5, 5- total E.coli, 6- total 
Cardiff Al, 7- total Cardiff P5, 8- total P44/42 control extract.
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3.6. Effect of M APK inhibition on inflammatory response by B.cepacia  complex
LPS
3.6.1. Effect of specific MAP kinase inhibitors on TNF-a production stimulated 
by LPS
To assess the effect of inhibiting each of three MAP kinases through which LPS 
signalling is known to occur, and the effect of inhibiting more than one of these at a 
time, MM6 (106 /ml) cells were incubated with 10 pM of PD98059 (P42/44 inhibitor), 
SB203580 (P38 inhibitor) or SP600125 (JNK inhibitor) or a combination of inhibitors 
for 1 hour before 6 hours stimulation with B.cepacia complex LPS or E.coli LPS. 
Non-stimulated controls and controls with the MAPK inhibitors alone were included. 
These MAPK inhibitors are cell permeable and specific, they have been used 
successfully in many studies prior to this (Ropert 2005) and are used as therapeutic 
agents in disease, for example Crohn’s disease (van den blink et al 2002).
MAPK inhibitors alone were seen to have no effect on MM6 cells. In E.coli (Figure
3.6.1.) each inhibitor was seen to reduce the amount of TNF-a produced with 
inhibition of JNK causing a 40% reduction TNF-a production. Combinations of 
inhibitors were all more effective with the combination of P38 and P44/42 inhibitors 
being the most effective and totally inhibiting TNF-a production. The effect of 
MAPK inhibition on Cardiff P5 (Figure 3.6.2.) and Cardiff Al (Figure 3.6.3.) showed 
similar results to E.coli, with Cardiff P5 LPS showing slightly less of a reduction in 
TNF-a production with all of the individual MAPK inhibitors than E.coli. In the 
presence of JNK inhibitor TNF-a production was not as greatly reduced when 
stimulated by LPS from Cardiff Al compared to LPS from E.coli or Cardiff P5 but
140
-  800 
E
~  600
H 400
E.coli LPS E.coli + P38 E.coli + E.coli + JNK E.coli + P38 E.coli + E.coli + P38 Cells alone 
inhibitor P44/42 inhibitor and P44/42 P44/42 and and JNK
inhibitor inhibitors JNK inhibitors
inhibitors
Figure 3.6.1. MM6 cells suspended at lxlO6 cells/ml were incubated with either 10 
pM of the MAPK inhibitors PD98059 (P42/44 inhibitor), SB203580 (P38 inhibitor) 
or SP600125 (JNK inhibitor) or a combination of inhibitors, for 1 hour before 
stimulation with LPS for 6 hours. The level of TNF-a was measured by ELISA. 
Values are means ±SD of three independent experiments.
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Figure 3.6.2. MM6 cells suspended at lx l06 cells/ml were incubated with either 10 
pM of the MAPK inhibitors PD98059 (P42/44 inhibitor), SB203580 (P38 inhibitor) 
or SP600125 (JNK inhibitor) or a combination of inhibitors, for 1 hour before 
stimulation with LPS for 6 hours. The level of TNF-a was measured by ELISA. 
Values are means ±SD of three independent experiments.
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Figure 3.6.3. MM6 cells suspended at lxlO6 cells/ml were incubated with either 10 
pM of the MAPK inhibitors PD98059 (P42/44 inhibitor), SB203580 (P38 inhibitor) 
or SP600125 (JNK inhibitor) or a combination of inhibitors, for 1 hour before 
stimulation with LPS for 6 hours. The level of TNF-a was measured by ELISA. 
Values are means ±SD of three independent experiments.
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Figure 3.6.4. MM6 cells suspended at lx l06 cells/ml were incubated with either 10 
pM of the MAPK inhibitors PD98059 (P42/44 inhibitor), SB203580 (P38 inhibitor) 
or SP600125 (JNK inhibitor) or a combination of inhibitors, for 1 hour before 
stimulation with LPS for 6 hours. The level of IL-6 was measured by ELISA. Values 
are means ±SD of three independent experiments.
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Figure 3.6.5. MM6 cells suspended at lxlO6 cells/ml were incubated with either 10 
pM of the MAPK inhibitors PD98059 (P42/44 inhibitor), SB203580 (P38 inhibitor) 
or SP600125 (JNK inhibitor) or a combination of inhibitors, for 1 hour before 
stimulation with LPS for 6 hours. The level of IL-6 was measured by ELISA. Values 
are means ±SD of three independent experiments.
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Figure 3.6.6. MM6 cells suspended at lx l0 6 cells/ml were incubated with either 10 
pM of the MAPK inhibitors PD98059 (P42/44 inhibitor), SB203580 (P38 inhibitor) 
or SP600125 (JNK inhibitor) or a combination of inhibitors, for 1 hour before 
stimulation with LPS for 6 hours. The level of IL-6 was measured by ELISA. Values 
are means ±SD of three independent experiments.
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3.7. Assessment of IkB and NF-kB activation by B.cepacia complex LPS
3.7.1. IkB activation by B.cepacia complex LPS
IkB is an inhibitor protein for the transcription factor NF-kB. When IkB dissociates 
NF-kB translocates into the nucleus, therefore activation of IkB by LPS would 
suggest that NF-kB is also being activated.
In order to find out whether B.cepacia complex LPS activates IkB MM6 cells were 
stimulated with 1 pg LPS for 1 hour before protein extraction and Western blot 
analysis for IkB, the IkB antibody only bound when proteolysis and phosphorylation 
of the molecule had not occurred. Equal amounts of protein were loaded onto each 
lane for each blot. E.coli, Cardiff Al and Cardiff P5 all show less intense bands 
(Figures 3.7.1. and 3.7.2.) than the non-stimulated control cell bands, this may 
indicate that when the cells are stimulated with LPS from all the bacterial isolates 
tested, IkB undergoes proteolysis and phosphorylation and is therefore in an activated 
state. As IkB is the inhibitor protein for NF-kB it is reasonable to assume that if these 
purified LPS samples are activating IkB then they are also activating NF-kB. This 
theory was tested using electrophoretic mobility shift assay (EMSA) analysis (section
3.7.2.).
i
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Figure 3.7.1. Western blot of IkB in MM6 (lx l06/ml) cells stimulated by 1 pg 
B.cepacia complex LPS for 1 hour. Lanes: 1- E.coli. 2- non-stimulated control, 3- 
Cardiff P5. Bands correspond to 37 kDa.
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Figure 3.7.2. Western blot of IkB in MM6 (lx l06/ml) cells stimulated by 1 jig 
B.cepacia complex LPS for 1 hour. Lanes: 1- Cardiff Al, 2- non-stimulated control, 
3- E.coli. Bands correspond to 37 kDa.
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3.7.2. NF-kB by B.cepacia complex LPS
NF-kB activation by stimulation with B.cepacia complex LPS was tested using an 
electrophoretic mobility shift assay (EMSA, gel shift). MM6 cells were stimulated 
with 1 pg/ml of LPS from B.cenocepacia, B.multivorans at various time intervals (15, 
30, 60, and 120 min), subcellular (nuclear) fractions were then prepared and incubated 
with a 32P-labelled oligonucleotide containing the consensus sequence for NF-kB. The 
fractions were then run on a 5% polyacrylamide gel and autoradiographed overnight 
at -80°C. Figures 3.7.3. and 3.7.2. clearly show both the Cardiff P5 and Cardiff Al 
stimulated cell samples have NF-kB in the nucleus, and that there is a progressive 
increase in level of activation over the time period tested.
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Figure 3.7.3. MM6 cells (106/ml) stimulated with 1 pg Cardiff P5 LPS over 0-120 
minutes and tested for NF-kB activation by electrophoretic mobility shift assay 
(EMSA). Upper bands shown are NF-kB present in the nuclear extract that has 
interacted with probe, the lower bands are free DNA.
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Figure 3.7.4. MM6 cells (106/ml) stimulated with 1 pg Cardiff Al LPS over 0-120 
minutes and tested for NF-kB activation by EMS A. Upper bands shown are NF-kB 
present in the nuclear extract that has interacted with probe, the lower bands are free 
DNA.
Discussion
4.1. Extraction of LPS and optimisation of experiments.
Bcc species are recognised as opportunistic pathogens in humans, with the majority of 
infection found in CF patients. Although they are not as commonly isolated as other 
CF pathogens such as P.aeruginosa, organisms from the Be complex have a major 
clinical impact. The clinical course following Bcc infection follows a variable pattern 
which ranges from no discemable change in clinical status and lung function, to a 
rapid decline in lung function which is associated with necrotizing pneumonia, sepsis 
and death- this is known as ‘cepacia syndrome’.
Although pulmonary inflammation is a critical element of host defence, it also 
contributes significantly to the lung damage that is a hallmark of CF. Pathogens that 
are capable of inducing an intense and sustained inflammatory response are likely to 
add to the severity of lung disease in CF. Bacterial products from both P. aeruginosa 
and members of the Bcc stimulate an excessive and prolonged pro-inflammatory 
response in epithelial cells and/or monocytes; however, products, specifically LPS, 
from Bcc species are more potent inducers of this response than P. aeruginosa (Shaw 
et al\ 1995; Zughaier et al\ 1999a; Kube et al 2001).
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Little is known about the molecular mechanisms involved during Bcc infection.
This study aimed to elucidate the role of BcLPS as a virulence factor in infection by 
investigating the inflammatory response it invokes and the intracellular signalling 
pathway that it triggers.
LPS samples were purified using phenol-chloroform petroleum ether (PCP) 
extraction, these samples were then split into two groups, one of which was Purified 
further using DNase, RNase, trypsin and proteinase K. These two LPS preparations 
named BcLPS-1 and BcLPS-2 were then compared against each other in their 
capacity to elicit an inflammatory response from monocytes and airway epithelial 
cells.
A study by Shimomura et al (2001) showed that there was a significant difference 
between enzyme treated and non-enzyme treated Bcc LPs preparations ability to 
produce an inflammatory response in C3H/HeN murine macrophages and suggested 
that the large response seen from Bcc LPS was due to protein contamination, p was 
important to eliminate the possibility that inflammatory response from cells \vas due 
to contamination by bacterial components other than LPS such as DNA or proteins 
like flagellin, which have been shown to stimulate a cytokine response (Hayashi et al 
2001; Urban et al 2004).
This study did not find any significant difference in production of TNF-a or IL-6 frorn 
human monocytes or IL-8 from human epithelial cells when stimulated with BcLPS-1 
compared to BcLPS-2. This would suggest that purification using the standard pCP 
method alone is enough to remove any protein or nucleic acid contaminants that may
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cause an inflammatory response and that the subsequent enzyme treatments may not 
be necessary to obtain a pure LPS preparation.
The differences seen in the reduction in inflammatory response, when LPS is further 
purified, seen between the study by Shimomura et al (2001) and this study may be 
attributed to the species origin of the cells used. It has been shown that bacterial 
DNA, which is a probable contaminant in PCP purified LPS preparations, can 
provoke an inflammatory response and that this can be attributed to the presence of 
unmethylated CpG dinucleotides (Chuang et al 2002; Hartman & Krieg 2000). 
Responses to CpG motifs are mediated by toll-like receptor 9 (TLR9) (Coenye & 
Vandamme 2005) and differences in human and murine TLR9 specificity might 
explain why murine cells are stimulated by small amounts of Bcc DNA that is present 
in LPS preparations whereas human cells are not. Also it has been shown that human 
alveolar macrophages and several other human cell types express very little TLR9 
making them unresponsive to bacterial DNA CpG motifs (Suzuki et al 2005).
During this study, commercial preparations of E.coli Ol l l  :B4 LPS were used as a 
comparison to BcLPS because E.coli LPS has been investigated intensively as a 
“typical” LPS that has high endotoxic activity. The lyophilised commercial E.coli 
LPS is purified using the standard PCP method, in order to assure a meaningful 
comparison the LPS was also further treated with the same enzymes used to purify 
BcLPS. The original LPS preparation was then compared against the further purified 
sample and again, there were no significant difference in the ability of the two 
samples to stimulate TNF-a production from MM6 cells. This ensured that the 
commercial LPS was indeed free of protein and nucleic acid contaminants and
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therefore a suitable comparison to the highly purified BcLPS. The use of highly 
purified LPS preparations was fundamental to this study and ensured that the 
inflammatory responses being seen were the result of BcLPS alone, however in order 
to ensure purity, mass spectrometry would have to be conducted on all of the samples 
purified.
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4.2. Biological activity of BcLPS
Exposure to LPS results in an inflammatory response in vivo and involves the 
activation of macrophages and dendritic cells with release of pro-inflammatory 
cytokines such as TNF-a, IL-1, IL-6 (Broad et al 2006). Considerable evidence is 
now emerging that LPS from Bcc species is an important virulence factor that 
stimulates the inflammatory response in Bcc infections (Hughes et al 1997; Zughaier 
et al 1999a,b; Ryley 2003; Mahenthiralingam et al 2005). Some studies have shown 
that Bcc bacteria in the form of whole cell lysates, or purified LPS can elicit up to 10 
times more TNF-a from immune cells as equivalent treatments with LPS from other 
lung pathogens including P.aeruginosa (Shaw et al 1995; Hughes et al 1997; 
Zughaier et al 1999a). Although it has been argued that these high levels of cytokine 
production maybe due to contaminants present due to the LPS purification procedure, 
this study has used a highly purified LPS preparations, treated to remove nucleic acid 
and protein contaminants, and has found that BcLPS from certain strains can produce 
nearly as much TNF-a, IL-6 and IL-8 as the highly potent LPS from enteric E.coli.
Response to BcLPS in this study was carried out using well characterised human cell 
lines- MM6 (human monocytic cell line) and A549 (human airway epithelial cells) 
which have been previously been shown to be good models (Ziegler-Heitbrock 1994; 
Zughaier et al 1999a), this is discussed in more detail below. Many studies have used 
murine models and cell lines which may not be validly comparable to human cells as 
recent studies have shown that murine cells show differences in Toll-like receptor 
expression compared with human cells (Rehli 2002). In detail, the current differences 
in TLR4 and TLR2 expression are as follows: the predominant TLR4 expressing cells
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in both species are of the myeloid origin monocytes, macrophages, microglia, myeloid 
dendritic cells and granulocytes (Lehnardt et al 2002; Homung et al 2002). In human 
tissues, TLR4 is expressed most strongly in the spleen and on PBLs, weaker levels of 
expression are detected in most other tissues with the exception of liver, in which 
TLR4 mRNA levels are low to undetectable (Zarember & Godowski 2002). Murine 
TLR4 mRNA appears most strongly expressed in the lung, heart and spleen, with 
strong presence in muscle, liver and kidney (Qureshi et al 1999), indicating that the 
basal tissue expression might not be identical. In addition, human and murine TLR4 
genes acquired different exons during evolution, which are subject to alternative 
splicing. Both exons theoretically induce an early stop codon, probably leading to 
non-functional or very short peptide chains in human and murine cells, respectively. 
Expression levels of TLR4 transcripts appear to be modified differently on 
stimulation with the major TLR4 agonist LPS: in human monocytes and 
macrophages, TLR4 expression increases on activation (Muzio et al 2000), whereas 
in murine macrophages, TLR4 transcripts are down-regulated following cellular 
activation with LPS (Matsuguchi et al 2000; Poltorak et al 1998). There are also 
differences seen in TLR2 expression, for instance its presence in murine, but not in 
human, thymus and T-cells (Haehnel et al 2002). TLR2 mRNA expression is low or 
undetectable in murine blood cells and is strongly induced by pro-inflammatory 
cytokines or microbial activators (e.g LPS) (Matsuguchi et al 2000). In humans 
however the highest constitutive levels of TLR2 mRNA expression have been 
observed in peripheral blood leukocytes (PBLs) (Rock et al 1998). In human 
monocytes, TLR2 mRNA is further up-regulated after adherence to tissue culture 
plates but no additional induction is observed after short-term stimulation with 
bacterial products (Muzio et al 2000). Induction of TLR2 mRNA is weak or non-
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existant after stimulation of human macrophages or macrophage cell lines 
differentiated in vitro (Zarember & Godowski 2002). These differences in expression 
may explain the variability in inflammatory responses seen in cells of human and 
murine origin. Therefore in order to gain a relevant view on the responses seen in 
human disease it is important to utilize human cells.
The cell lines chosen in this study may have had an impact on the results seen, they 
were chosen for several reasons as explained below, but further work on other cells 
would have to be conducted to draw further conclusions from the results seen here.
MM6 cells are human peripheral blood monocytes derived from acute monocytic 
leukaemia, they were chosen for this study as they are a robust well characterised cell 
line and have been shown to be a good model for cytokine production when 
stimulated with bacterial cell wall products (Ziegler-Heitbrock et al 1992; Quentmeier 
et al 1996). They are relevant to the response seen in cepacia syndrome as the 
condition culminates in sepsis.
A549 cells are carcinomic human alveolar basal epithelial cells. In addition to its 
barrier function, the airway epithelium plays an important role for the immune 
response in the lung. The lung epithelium is a major source of cytokine, chemokines 
and other inflammatory mediators that affect the adaptive and innate immune 
response and therefore modulate inflammatory. The species origin was an important 
factor in choosing the cell line used, murine cells are often used as a model for LPS 
signalling, this may be unrepresentative of what would happen in a human cell line 
due to differential expression of TLR receptors in murine cells.
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In order to gain a greater understanding of the inflammatory responses seen in CF 
patients it would be necessary to use a CF cell line, these are available as 
immortalised cells, for example CFT43 cells which are immortalised airway epithelial 
cells.
The responses seen in these cells could be compared to ‘normal’ non-CF airway cells 
in order to observe any difference in response to BcLPS.
Limitations of cell lines are primarily that they are derived from an isolated 
subpopulation and may not always express phenotypic characteristics of the principal 
cell type of origin. Primary cell cultures may be more representative of cells in vivo 
but they have a limited life span, will not have been characterised as well as 
immortalised lines and are more difficult to obtain
During this study LPS from 5 different B.cenocepacia ET12 strains, 1 B.cenocepacia 
Type B, 2 B.multivorans and 2 environmental B. cepacia strains were initially tested in 
their ability to stimulate a cytokine response from MM6 and from A549 cells to gain a 
broad view of their inflammatory activity. The quantity of samples tested was dictated 
by the amount of time it took to purify the LPS from these species to a satisfactory 
level. LPS derived from clinical samples of Bcc were seen to elicit a much greater 
inflammatory response in both cell lines tested, than LPS derived from P.aeruginosa 
and from environmental B. cepacia strains, this is in agreement with several other 
studies (Shaw et al 1995; Zughaier et al 1999a; DeSoyza et al 2004). The same 
pattern of inflammatory activity from BcLPS was seen in TNF-a and IL-6 production 
from MM6 cells and in IL-8 production from A549 cells.
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There was seen to be a great variability in the inflammatory activity of LPS purified 
from different Bcc isolates tested in this study. LPS derived from clinical isolates of 
Bcc (B.cenocepacia and B.multivorans) induced more TNF-a and IL-6 from 
stimulated monocytes, than the environmental B. cepacia strain. Outside of B. 
cenocepacia and B. multivorans, the remaining Bcc species account for less than 10% 
of all CF infections caused by the complex (Reik et al 2005) and so study of these 
species is of particular relevance.
A study by Emst et al (1999) found structural differences in the lipid A component of 
LPS, the key determinant of pro-inflammatory activity, from P.aeruginosa isolated 
from the airways of CF patients compared with LPS from isolates from other patients 
and sites. A recent study (DeSoyza et al 2004) found different acylation patterns 
between B.cenocepacia and B.multivorans which they used to explain the differences 
in inflammatory activities between the whole cell lysates of these species, however 
only one lipid A was analysed from each strain. It has been shown that acylation 
status of lipid A can determine the inflammatory activity of P. aeruginosa LPS, human 
monocytes respond to very low levels of hexa-acylated lipid A but require much 
higher concentrations of penta-acylated lipidA (Hajjar et al 2002). The same may be 
true of Bcc lipid A and this may need further investigation by mass spectrometry of 
purified BcLPS, this would be an important next step for further study as it may shed 
light on the difference in inflammatory response seen through infection with different 
strains of Bcc bacteria.
B.cenocepacia is seen as the most virulent species of the Be complex and is more 
frequently associated with ‘cepacia syndrome’ than any other strain. Typically
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survival rates for patients infected with B.cenocepacia are lower than those infected 
with B.multivorans (LiPuma et al 2001). Mahenthiralingam et al reported a higher 
mortality among CF patients with B cenocepacia in Vancouver than patients with B 
multivorans. (Mahenthiralingam et al 2001) We found that a B.multivorans strain 
produced as high a TNF-a and IL-6 level as the most potent B.cenocepacia strain 
tested, these results are in contrast to a report by DeSoyza and coworkers (DeSoyza et 
al 2004) who found that whole cell lysates of B.cenocepacia were more potent 
cytokine stimulators than lysates of B.multivorans when used to stimulate U937 
monocytes. However the whole cell lysates used in this study may stimulate cytokine 
release in monocytes by multiple non-LPS factors, some of which have been shown to 
bind to CD 14 (Ryley 2004; Urban et al 2004)
Although pre-transplant infection with B.cenocepacia is reported to have a worse 
outcome than B.multivorans in patients undergoing pulmonary transplant (DeSoyza et 
al 2001), growing evidence shows that B.multivorans infection is also associated with 
poor clinical prognoses in CF patients (Baldwin et al 2008) in addition B.cenocepacia 
has been seen to the causative agent of ‘cepacia syndrome’ (Zahariadis et al 2003).
During this study LPS from 6 B.cenocepacia strains 5 of which were ET12 strains, 
were tested for inflammatory activity. There was variability in cytokine induction 
capability between the LPS isolated from within these identical strains. The ET12 
strain of B.cenocepacia has been associated with the transmission of Bcc infections 
between patients in different CF clinics and a poor clinical outcome (Ledson et al 
1998b; Ryley & Doull 2003). All ET12 samples produced high levels of both TNF-a 
and IL-6 as compared to P.aeruginosa, however there was seen to be 2 isolates that
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produced almost twice as much inflammatory cytokine than the others. The LPS from 
Cardiff PI was seen to be a less effective cytokine producer than the other ET12 
strains. This isolate was the index case from which the B.cenocepacia ET12 strain 
spread to nine other patients over a 10 year period. This patient acquired the infection 
following a stay in a summer camp in Ontario, Canada in 1987. Molecular typing by 
recA gene sequence variation analysis and pulsed field gel electrophoresis (PFGE) has 
confirmed that there are no genetic differences between these isolates from different 
patients and from the original environmental strain from which they have arisen 
(Mahenthiralingam et al 2005).
Variability in cytokine producing ability of BcLPS isolated from the clonal 
B.cenocepacia ET12 strains may have been due to passaging over time in the 
laboratory. Gram negative bacteria including P.aeruginosa can modulate the structure 
of their LPS on invasion of host tissues in order to avoid detection and reduce 
inflammatory response, therefore inflammatory potential of LPS may revert when the 
bacteria is cultured ex vivo over time (Ernst et al 1999).
In order to see whether this was the case 2 B.cenocepacia ET12 samples were 
cultured and re-cultured in the laboratory a total of 20 times, the cytokine producing 
ability was tested every 5 passages. No difference in the ability of the LPS to produce 
inflammatory cytokines was seen over this time. This suggests that the inflammatory 
activity of the LPS samples were not affected by laboratory culturing and that the 
variability seen between these samples may not be attributed to culturing in a 
laboratory environment.
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The variation in the pro-inflammatory activity of the LPS isolated from this strain and 
the variable clinical outcome in different patients carrying this strain may suggest that 
there are patient- or centre-derived factors and/or subtle patient-specific phenotypic 
changes in the LPS that mediate these clinical and inflammatory differences. The 
results seen in this study would also suggest that it is not possible to conclude that all 
ET12 clones will behave in the same way when tested in experimental models. The 
non ET12 strain of B.cenocepacia tested was relatively potent but did not produce as 
much TNF-a and IL-6 as the top ET12 producers. This theory would have to be tested 
by including a much larger panel of bacterial strains including more ET12 clones.
In order to assess whether the variability in the inflammatory response seen from 
purified ET12 BcLPS was isolated to Cardiff, other ET12 clones sourced from around 
the UK were investigated. The differences seen in the B.cenocepacia ET12 clones 
were not limited to isolates from the Cardiff CF clinic. ET12 isolates were collected 
from CF clinics from around the UK and LPS was purified using the same method as 
the Cardiff samples. TNF-a levels were measured from monocytes and again there 
was seen to be variability in the pro-inflammatory activity of the LPS preparations. 
The Manchester ET12 strain showed a TNF-a output almost as great as E.coli 
whereas the Liverpool ET12 showed a much lower level. The data suggests that there 
is no relation between the pro-inflammatory activity of LPS isolated and the 
proximity of the CF clinics that the samples were isolated from, a wide variation in 
inflammatory activity was seen from these samples collected from around the country.
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Presence of an intact O-antigen on LPS indicates a smooth-type LPS whereas lack of 
O-antigen indicates a rough-type LPS. Environmental BcLPS samples were tested by 
silver staining along with LPS derived from a B.cenocepacia ET12 strain and a 
B.multivorans to ascertain whether the LPS was of a rough or smooth chemotype 
BcLPS 1 and BcLPS2 preparations were both included which proved that the extra 
purification process of LPS had no effect on the O-antigen. The environmental 
samples were seen to smooth (intact O-antigen) and the clinical samples were rough 
(O-antigen lacking). These samples were then tested for their capacity to elicit a TNF- 
a response in monocytes. The smooth samples produced a much lower level of TNF-a 
than the rough samples tested. This has been seen in a study by Backhed et al (2003) 
where smooth LPS isolated from E.coli was seen to be 100-fold less potent than rough 
LPS at inducing an IL-8 response from the human epithelial cell line T24. In another 
study by Rittig et al (2003), brucellae organisms with a rough LPS type were seen to 
induce considerably higher amounts of cytokines and chemokines in stimulated 
human monocytes than brucellae with a smooth LPS type, however this effect could 
not be replicated with purified LPS. However due to the sample size in this study and 
the variability seen in the TNF-a producing ability of our rough BcLPS samples, no 
relationship is indicated between the rough and smooth samples of BcLPS and their 
ability to incite an inflammatory response. In vivo, shedding the O-antigen may be a 
response by Bcc organisms to avoid the adaptive immune response by the host, rough 
LPS may therefore been seen as an advantage. The lipid A component of LPS is 
essential to the integrity of the bacterial membrane whereas the O-antigen is not, 
another reason for shedding this component may be that it is metabolically demanding 
and non-essential for viability.
164
4.3. B.cepacia complex LPS inactivation by Polymyxin B (Pmx B)
Polymyxin is a cationic peptide protein which has similarities in its structure to 
defensins which are the host antimicrobial peptides. Resistance to PMB in Bcc could 
be an important virulence factor for these bacteria. Polymyxin is bactericidal for 
Gram-negative bacteria and the mode of action comprises two steps, binding and 
permeabilisation of the outer membrane and subsequent induction and leakage of 
cytoplasmic components across the cytoplasmic membrane. It has been well 
established that PMB has a high affinity for negatively charged cell surface 
components and that it’s binding to LPS plays an essential role in its bactericidal 
activity (Vaara 1992).
Typical LPSs have one to three molecules of 3-deoxy-Dma««o-octulosonic acid 
(KDO) in the inner core region attached to the lipid A moiety, and the lipid A-KDO- 
KDO structure is well conserved among a wide range of bacterial species. In the inner 
core region of the LPS of B. cepacia, a unique component, D-glycero-D-talo-2- 
octulosonic acid (KO), has been found in the structure of lipid A-KDO-KO, and it has 
been shown that the KO is partially replaced at the C-8 position with 4-amino-4- 
deoxy-L-arabinose (Ara4N) (Shimomura et al 2003). PMB is also known as a potent 
LPS antagonist that suppresses various biological activities of LPS, such as lethal 
toxicity and induction of cytokines, by forming PMB-LPS complexes with 
electrostatic and hydrophobic interactions. The presence of Ara4N with a positive 
charge that reduces the electronegativity of LPS is considered to be responsible for 
the decreased binding of PMB, causing LPS to be resistant to the antagonistic action 
of PMB (Coyne & Fenwick 1993).
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Binding of PMB was investigated in a bioassay system where the effect of stimulating 
TNF-a from MM6 cells was neutralized by PMB, the cells were checked for viability 
before and after the procedure to ensure that the PMB was not killing the cells and 
reducing TNF-a output. The results indicated that PMB neutralized Bcc LPS and 
inhibited TNF-a production in a dose dependant manner which was similar to that 
seen in E.coli and P.aeruginosa. This suggests that BcLPS and LPS from the PMB 
sensitive bacterial strains have a similar binding affinity to PMB and that PMB 
resistance in Bcc species may not be due to a decreased binding of the antibiotic to 
LPS. Coyne and Fenwick (1993) showed similar results which indicated that LPS 
induced TNF-a production in alveolar macrophages was inhibited by PMB. These 
results may suggest that the resistance of Bcc species to PMB is not due to the binding 
of the antibiotic to LPS, and that there is another system in place such as efflux pumps 
or enzymatic inactivation that allows the bacteria resistance to PMB.
When the LPS concentration used to stimulate MM6 cells was increased there was an 
interesting effect seen with the B.multivorans LPS, TNF-a was no longer inhibited in 
a dose dependant manner and the highest doses of PMB did not inhibit cytokine 
production as efficiently as had been expected. It may be that this B.multivorans strain 
has a more complete replacement of KO with Ara4N in the lipid A region of LPS 
rendering it less negatively charged than the LPS from other species, this may inhibit 
the binding of PMB in a more complex manner than other structures of lipid A. This 
theory could only be confirmed with mass spectrometry.
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4.4. Respiratory Burst in BcLPS primed monocytes
Macrophages and monocytes produce reactive oxygen species (ROS) in the 
respiratory burst in response to engulfed bacteria or bacterial products. The generated 
reactive oxygen radicals which help to kill phagocytosed bacteria are transformed to 
water by host detoxifying enzymes (Zughaier et al 1999b). However, excess 
production of reactive oxygen radicals can cause tissue damage, which may be 
particularly important in the lungs (Brown & Kelly 1994). LPS, while not triggering 
the respiratory burst directly, has been shown to up regulate this oxidative response to 
other stimuli and therefore to act as a priming agent. The potent priming activity of 
Bcc LPS for neutrophils has been described by Hughes et al (1997). They suggested 
that the increased neutrophil recruitment and respiratory burst responses in the lungs 
may contribute to inflammation by the release of tissue-damaging proteolytic 
enzymes and reactive oxygen species. In an attempt to further characterise the 
inflammatory activity of BcLPS, its ability to prime monocytes for respiratory burst 
was investigated. Release of ROS causes tissue damage and may account for the 
ability of BcLPS to cause the massive inflammatory reaction that distinguishes it from 
P.aeruginosa LPS.
In this study monocytes were primed with BcLPS, P.aeruginosa and E.coli LPS and 
then stimulated with opsonised zymozan, which is a yeast cell wall product, to trigger 
oxidative burst, superoxide anion is then detected. BcLPS samples which had 
previously produced very high levels of TNF-a when monocytes were directly 
stimulated did not produce the highest levels of ROS. It was found that the 
B.multivorans LPS and Cardiff P6 {B.cenocepacia non-ET12) tested produced higher
167
levels of superoxide anion than E.coli LPS, these were the only times in this study 
that BcLPS isolates were found to produce a greater response than E.coli LPS.
It is suggested that, from the samples tested in this study, the induction of the 
inflammatory response from BcLPS stimulated monocytes is separate and in some 
cases, may be opposite to the superoxide anion release seen from BcLPS primed 
monocytes. Respiratory burst is a mechanism that is aimed at directly and rapidly 
killing the invading pathogen and provoking this response may be considered 
disadvantageous to the survival of the bacteria in the host, bacteria that did not 
strongly provoke this response may have a chance to colonise whereas those that due 
are eradicated.
The interesting discrepancy between the ability of BcLPS to stimulate a cytokine 
response directly and its ability to prime for respiratory burst would benefit from 
future investigation; this would have to include a much larger sample size to allow 
statistical analyses to be conducted. There are several methods available to measure 
respiratory burst in primed cells superoxide production is usually quantified 
spectrophotometrically by measuring ferricytochrome c reduction however this 
method lacks sensitivity. The chemiluminescent detection method that was utilised in 
this study to investigate respiratory burst is much more sensitive but may lack a high 
specificity for superoxide and the sensitivity can be reduced further by redox cycling 
reactions which themselves generate superoxide. There are several other methods in 
development, that can be employed but which also have their drawbacks including the 
need for specialised machinery and cost (Filatov et al 1995; Tan & Berridge 2000).
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4.5. Signalling Pathway activated by BcLPS
Due to the inherent variation in inflammatory response produced by LPS from 
different Bcc species and strains used in this study, it was important to analyse the 
molecular mechanisms utilized by the different LPS isolates in stimulating these 
responses. The signalling pathways utilized by LPS from enteric organisms such as 
E.coli has been well documented, at the cell surface, LPS from classical 
enterobacteria first binds to CD 14, a GPI anchor or soluble protein that delivers the 
LPS to TLR4 associated with an accessory molecule MD2. Subsequent recruitment of 
the intracellular adaptor proteinMyD88 through homotypic Toll/IL-IR domains leads 
to intracellular signalling through NF-«B and MAPKs activation (Nahori et al 2005). 
The ultimate result of this LPS recognition is a pro-inflammatory cytokine and 
chemokine response.
Lipid A is the anchor moiety of LPS in the bacterial membrane and is the active 
component of LPS responsible for its toxic activity and functions. Lipid A from E. 
coli or Salmonella species stimulates the TLR4 receptor complex. However, lipid A 
structures show some variability between bacterial species; the degree of acylation, 
phosphorylation, or the length of acyl chains of lipid A can be responsible for 
modified pro inflammatory capacities of LPS (Darveau 1998). There is a growing list 
of atypical LPSs that utilize different receptors and pathways to the classical one 
stimulated by enterobacterial species, these include Helicobacter pylori, Leptospira 
interoggans, Rhizobium spp, Legionella spp, and Porphyromonas gingivalis (Nahori 
et al 2005). Little is known about the molecular pathways that underlie cell 
stimulation by LPS from Bcc strains.
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Cytokine stimulation experiments using A549 cells tested for IL-8 production when 
stimulated with BcLPS, had shown that without the presence of human serum there 
was no IL-8 produced. A549 cells lack membrane bound CD 14 (mCD14) which is the 
co-receptor needed for signal transduction when LPS is present (Antal-Szalmas 
2000). Experiments which did not have serum present (therefore no CD 14 present) 
were included as a control and to show that there was no other inflammatory reaction 
was being caused in the system. Contaminants such as flagellin, signal through TLR5 
and do not require CD 14 and as such would cause a reaction even when CD 14 was 
not present. These results may indicate that BcLPS required CD 14 to signal. In order 
to test this, CD 14 blocking experiments were performed.
Blocking mCD14 on the surface of MM6 cells before stimulation with BcLPS from 
B.multivorans and B.cenocepacia completely inhibited the production of TNF-a, this 
would suggests that the signalling pathways of these LPS isolates are similar to that of 
enteric organisms. A valuable next step would be to use cells from mice lacking 
CD 14 due to a targeted disruption of the CD 14 gene (CD14-deficient knockout 
(CD14KO), this would more definitively show that BcLPS is signalling through 
CD 14. CD 14 has been shown to bind non-LPS ligands (Kurt-Jones et al 2000; Esen & 
Kielian 2005) and so it was important to investigate the LPS signalling pathway 
further.
The TLR4 receptor has been demonstrated to be almost exclusively used by LPS in 
innate immune responses (Beutler 2000; Hajjar et al 2002). However some groups 
have suggested that LPS from certain organisms including Bacteroides fragilis, 
Chlamydia trachomatis and Pseudomonas aeruginosa, activate cells via binding to
170
TLR2 (Kirschning et al 1998; DaSilva Correia et al 2001; Werts et al 2001; Erridge et 
al 2004)
Blocking experiments using monoclonal anti-TLR4 antibodies showed that the 
inflammatory activity of all B.cenocepacia ET12 strains tested (Cardiff P4,P5 and P6) 
was almost completely reduced when TLR4 was blocked. Incubation with E.coli LPS 
and with an isotype control antibody, there seen to be no decrease in TNF-a 
production which indicated that the anti-TLR4 antibody was specific. TNF-a 
production by an environmental B.cepacia strain and a clinical B.multivorans was 
also blocked. However inflammatory activity induced by LPS from another clinical 
B.multivorans strain was seen to be reduced only by 50% which was unexpected; 
however this was still a significant reduction, the result may be due to the efficacy of 
the blocking antibody, although the antibodies used in this study have been shown to 
be effective in many studies previously (Homef et al 2002; Schaefer et al 2005; 
Lagoumintzis et al 2008). This result would have to be tested by other means, using 
this strain’s LPS, cells from TLR4 deficient mice (for instance CH3/HeJ mice) could 
be stimulated and a cytokine response measure. If there is no response in TLR4'7' mice 
then this would be a much stronger indication that TLR4 is required. Blocking of the 
TLR2 receptor showed that the LPS from this strain had the same level of TNFa 
production whether TLR2 was blocked or not, which would indicate that TLR2 is not 
being used as a receptor for this strain or for the other BcLPS tested. Including a TLR 
ligand such as lipoteichoic acid would demonstrate the efficacy of the anti-TLR2 
antibody. This work would benefit from being backed up with other techniques, as 
mentioned previously this could be done using knockout mice, the disadvantage of 
this would be differential expressions and sensitivities of TLRs between humans and
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mice, another way of investigating the role of TLR4 and TLR2 in BcLPS signalling 
would be to transiently transfect HEK293T cells with the Toll receptor that was to be 
tested and then stimulate with BcLPS. HEK293T cells lack expression of TLRs and 
they can be transfected with the TLR of interest to see whether it is required for the 
secretion of pro-inflammatory cytokines.
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4.6. MyD88 Inhibition
The next stage of the classical LPS signalling cascade is through cytosolic adaptor 
molecule myeloid differentiation protein 88 (MyD88)-dependent signaling, MyD88 is 
recruited to the TLR4 receptor through interaction with the TER domain of TLR4 
(O’Neil et al 2003). This complex in turn facilitates the recruitment of IRAKI and 
IRAK4 via a death domain present in both molecules (Li et al 2002). Upon LPS 
stimulation, TIRAP also associates with TLR4 via a TIR-TIR interaction, and is 
essential for MyD88-dependent signaling (Fitzgerald et al 2001).
The MyD88-independent signaling pathway was identified in studies using MyD88 
deficient mice. Activation of NF-kB and MAP kinases was observed in these LPS- 
stimulated MyD88-deficient cells with the delayed kinetics (Kawai et al 1999; Kawai 
et al 2001). These results suggested the existence of a MyD88-independent pathway 
downstream of ligand engagement of the TLR4 receptor. To account fora MyD88- 
independent pathway of NF-kB activation, a novel MyD88 homologue termed 
MyD88 adaptor-like (Mai) protein (Fitzgerald et al 2001) or TIR domain-containing 
adaptor protein (TIRAP) (Homg et al 2001) was described. This was shown to act as 
an adaptor protein specifically involved in TLR4 but not other TLRs or IL-1R- 
induced NF-kB activation. As Mal/TIRAP does not contain the death domain (DD) 
found in MyD88, this was proposed to induce an alternative signalling pathway that 
also involves RNA-dependent protein kinase (PKR) and leads to the induction of 
IFN6 and interferon-inducible protein-10 (IP-10) (Fitzgerald et al 2001; Homg et al 
2001 ) .
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In this study inhibition of MyD88 in monocytes was achieved using a cell permeable 
inhibitor peptide, which was added before cells were stimulated with test LPS, this 
inhibitor mimics the MyD88 BB loop heptapeptide and has been found to very 
effective (Rosenberg 2007). A significant reduction in TNF-a output was seen from 
cells stimulated with control E.coli LPS and with B.cenocepacia ET12 LPS however 
the reduction was not significant when our B.multivorans LPS was tested.
MyD88 deficient cells from mice fail to produce inflammatory cytokines in response 
to LPS although these cells do show activation of NF-kB and MAP kinases in 
response to LPS (Kawai et al 1999), however a study by Hoebe et al (2003) showed 
that MyD88'A murine macrophages do produce TNFa in response to LPS at lower 
levels and a recent study has demonstrated that LPS can indeed induce a cytokine 
response through the MyD88-independent pathway in human macrophages 
(Andreakos et al 2004).
The results here may suggest that LPS from B.cenocepacia activates these cells 
through MyD88 dependant pathways while LPS isolated from B.multivorans can 
activate cells through MyD88-dependent and through MyD88-independent pathways. 
In this regard, LPS from Bcc organisms may be similar to lipooligosaccharide from 
Neisseria meningitidis which has been found to activate both MyD88-dependant and 
MyD88-independent pathways in monocytes (Zughaier et al 2005). Such differential 
activation of cells might explain the differences in clinical outcomes observed in 
patients infected with B.multivorans or B.cenocepacia (LiPuma et al 2001). However 
the relevance of MyD88-independent signalling in human cells has yet to be 
established. This is of key importance given the major role of LPS in the pathology of
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sepsis. Further work would have to be done here to firmly establish whether this 
BcLPS sample does indeed signal through the MyD88-independent pathway, this 
could be done using a MyD88 knockout mouse or another suggested way of doing 
this would be using RNA interference (RNAi), this technique inhibits gene expression 
at the stage of translation or can hinder the transcription of specific genes. Small 
interfering RNA strands (siRNA) could be used to inhibit gene expression of MyD88, 
this would allow testing of BcLPS in cells of human origin and give a clearer result as 
to whether the MyD88 independent pathway is being triggered. The disadvantage to 
this technique would be time taken to optimise and cost of the procedure.
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4.7. Activation of MAPK pathways and NF-kB activation
Members of the mitogen activated protein kinase (MAPK) family are critically 
involved in intracellular signal transduction, mediating cell responses to a variety of 
different infectious and inflammatory stimuli, including LPS. In vitro, typical LPS 
from E.coli has been shown to activate p38 MAPK, c-jun N-terminal kinase (JNK and 
p42/44 MAPK (Hambleton et al 1996; Huh et al 2007; Lim et al 2002). One study 
found that LPS from E.coli activated p38 MAPK and p42/44 MAPK but not JNK in 
peripheral blood mononuclear cells (PBMCs) (van den Blink et al 2001).
Activation of MAPKs was initially investigated using Western blotting to ascertain 
whether specific MAPKs were being phosphorylated when cells were stimulated with 
LPS samples, the results from this indicated that P38 and P44/42 were being activated 
by all the BcLPS samples tested. However this technique just indicated whether 
activation was occurring and comparison of amount of activation could not be 
ascertained without densitometry. Also finding an effective antibody was difficult 
with all three MAPK families and expensive. Therefore signalling pathways involved 
in cell activation were investigated by analysing the roles played by these three MAP 
kinases that are known to be activated by stimulation with LPS by using specific 
inhibitors of MAP kinases. These compounds have been extensively tested and used 
in the last few years as research tool to elucidate intracellular signalling pathways and 
have been found to be effective and specific (Davies et al 2000; Ropert 2005). MAPK 
inhibitors are now even used in a clinical setting as a treatment for Crohn’s disease 
(van denBlink 2002).
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The IC50 (median inhibition concentration) for all the MAPK inhibitors used here 
ranged between 40nM and 1 pM and so they are very efficient.
Inhibition of these MAP kinases using selective MAPK inhibitors individually was 
found to reduce but not completely inhibit TNF-a production from LPS stimulated 
monocytes. This was true for E.coli LPS and BcLPS. Inhibition using two out of three 
of the combinations of MAPK inhibitors reduced the TNF-a production from E.coli 
and Bcc LPS stimulated cells to zero. This suggests that Bcc LPS activates these 
MAP kinases in monocytes and that co-ordinate activation of MAPK pathways is 
required for TNF-a production. These findings are consistent with a report by Reddi 
et al (2003) which showed that whole bacterial cells of a clinical isolate of 
B.cenocepacia induced IL-8 secretion in alveolar epithelial cells through CD 14 and 
MAPK signalling.
Inhibition using p42/44 and JNK inhibitors did not reduce TNF-a output from 
stimulated cells to zero as with the other combinations tested, which could be 
indicative of a compensation mechanism within the MAPK signalling cascade. 
Various investigators have observed an enhancement of p42/44 phosphorylation when 
specific p38 inhibitors have been used (Feng et al 1999; Ropert et al 2001) along with 
an increase of JNK activation. These finding may indicate a certain level of cross-talk 
and a compensation mechanism between the MAPKs. The results from our MAPK 
inhibition would suggest that there is also compensation by p38 when p42/44 MAPK 
and JNK are blocked. In future work the activation of various MAPKs could be 
ascertained by ELISA using antibodies that are specific to the phosphorylated forms 
of the MAPK, this may allow a quantitative result to be produced.
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In order to gain a more complete view of the signalling series triggered by BcLPS, the 
activation of NF-kB was studied. The transcription factor, NF-kB is generally present 
in an inactive, cytoplasmic form bound to the inhibitory protein IkB. Cell stimulation 
causes dissociation of this protein and allows translocation of NF-kB to the nucleus 
(May & Ghosh 1998). NF-kB mediates production of numerous pro-inflammatory 
genes, including TNF-a.
Investigation through Western blotting showed that the BcLPS isolates tested 
including B.cenocepacia and B.multivorans, activated IkB. This strongly suggested 
that NF-kB was also being activated, to confirm this EMSA analysis was performed 
on the BcLPS stimulated cell samples. Results confirmed that NF-kB was being 
translocated to the nucleus when the cells were stimulated with BcLPS and the 
strength of the bands increased over the times tested. NF-kB activation was seen for 
the LPS from B.cenocepacia and for LPS from the B.multivorans isolate.
This study demonstrates that LPS isolated from strains of Be complex bacteria and 
then highly purified, provokes a high production the inflammatory cytokines TNF-a 
and IL-6 from a monocytic cell line and IL-8 from an epithelial cell line, and that 
these levels are in some cases much greater than those stimulated by P. aeruginosa 
and comparable to the prototypical, highly inflammatory E.coli LPS. Conclusions and 
comparisons drawn from the work here are based on a small panel of bacterial 
samples and this is due to the lengthy, and often failure prone, process of purification 
to ensure that minimal contaminants are present. This is a process that is often 
missing from studies on bacterial products. It can be seen that the samples tested are
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highly inflammatory and that there is variation in this activity between the Cardiff 
isolates tested and between isolates from various UK CF centres.
The work done was conducted in non-CF cells of monocytic and epithelial origin and 
it may be of benefit in future studies to conduct work in CF cell lines or from primary 
cells of CF and non-CF origin, although it may be difficult to obtain these cells.
The cell signalling work conducted in this study indicates that BcLPS signals through 
TLR4 and not TLR2 and that the intracellular signalling cascade is similar to that of 
E.coli. As mentioned previously, further studies would have to be conducted to back 
up the evidence presented here, ideally utilizing a knockout or RNAi system and these 
methods may indicate more definitively the pathway being triggered, and may shed 
more light as to whether there are any BcLPS samples that utilize the MyD88- 
independent pathway.
The development of novel therapies for sepsis depends on the understanding of the 
basic mechanisms of the disease including elucidating any signalling cascades that the 
causative agent, LPS, activates. The results from this study indicate that the LPS from 
all Bcc species studied activate monocytes by conventional LPS signalling pathways 
and there is no difference that would explain the enhanced inflammatory activity of 
BcLPS. However LPS from Bcc species is much more inflammatory than LPS 
isolated from P.aeruginosa. A study by Ernst et al (1999) found structural differences 
in the lipid A component of LPS, the key determinant of pro-inflammatory activity, 
from P. aeruginosa isolated from the airways of CF patients compared with LPS from 
isolates from other patients and sites Human monocytes respond to very low levels of
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hexa-acylated lipid A but require much higher concentrations of penta-acylated lipid 
A (Hajjar et al 2002). The same may be true of Bcc lipid A and this may need further 
investigation. A recent study (DeSoyza et al 2004) found different acylation patterns 
between B.cenocepacia and B.multivorans which they used to explain the differences 
in inflammatory activities between the whole cell lysates of these species, however 
only one lipid A was analysed from each strain. It is possible that the differences in 
inflammatory activity from different purified BcLPS samples may be down to 
structural differences in the molecule and further study would be aimed at elucidating 
the relationship between lipid A structure and inflammatory activity in Bcc 
organisms. This would involve purifying many more strains of Bcc LPS sourced 
from different centres around the UK, then detailed mass spectrometry of the BcLPS 
samples would have to be compared to the inflammatory activity of the sample, this 
may allow a way of predicting which strains are likely to be the most inflammatory 
and therefore the most damaging in the host.
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Conclusion
LPS extracted for various clinical and environmental Bcc isolates confirmed that LPS 
elicits a massive inflammatory response from monocytes and epithelial cells. The use 
of highly purified LPS confirmed that the effect seen was not due to contaminants 
present in the LPS preparation such as flagellin or bacterial DNA.
BcLPS stimulated the release of greater amounts of cytokine on a weight for weight 
basis than LPS from P.aeruginosa, BcLPS from certain isolates were seen to be as 
inflammatory as E.coli LPS.
Variability in pro-inflammatory potential of LPS from different Bcc species and even 
within clonal strains was seen and this difference was not due to prolonged culturing 
in the laboratory. It is possible that modifications made by the bacteria, particularly 
structurally to the lipid A region, are responsible for the differences seen. Polymyxin 
B was seen to inhibit the inflammatory effect of BcLPS which strongly suggests that 
PMB is binding to BcLPS, therefore the PMB resistance that is seen in Bcc species 
may not be due to the lack of PMB binding the unusual structure of BcLPS.
Bcc species LPS was found to have a higher priming activity in monocytes for the 
respiratory burst response in comparison to LPS from P.aeruginosa. It was found that 
the ability to prime for respiratory burst was not related to the direct pro-inflammatory 
activity of LPS and in some cases was opposite. This may be due to the respiratory 
burst being a direct killing mechanism by the host and would be considered 
disadvantageous to bacterial colonisation.
181
The results from this study indicate that LPS from all species studied activate 
monocytes by conventional LPS signalling pathways, utilizing CD 14 and TLR4, by 
activating all three families of MAP kinases and prompting the translocation of NF- 
k B  to the nucleus. It was found that the B.multivorans LPS tested, may activate 
monocytes via a MyD88-independent pathway whereas the B.cenocepacia LPS 
tested, activated through a MyD88-dependant pathway.
The results of this investigation support the argument that BcLPS is an important 
virulence factor in CF lung disease. It provokes a large inflammatory response from 
human monocytes and epithelial cells and there is great variability in this response 
between species and even within different clonal strains. This may suggest that there 
are structural differences in the lipid A region such as differences in acylation status 
and other factors or pathways involved in the response to BcLPS (Trent 2004) which 
are responsible for the inflammatory effect. Therefore future studies should be aimed 
at elucidating the structure of BcLPS and relating this to the inflammatory activity of 
the molecule.
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Appendix 1
Bcc LPS preparation for analysis
Lysis buffer
Sodium dodecyl sulphate 200 mg
2-mercaptoethanol 400 pi
Bromophenol blue 10 mg
Stacking gel buffer 3 ml
Glycerol 1 ml
Water 6 ml
The SDS, glycerol and stacking gel buffer were added to 6 ml of sterile pyrogen free 
water. 400 pi of mercaptoethanol was added and the solution mixed thoroughly, 
finally 10 mg of bromophenol blue was added. The mixing was done entirely in a 
fume cupboard and the solution filtered through a 0.2 pm Millipore filter, the solution 
was then aliquoted into 1 ml amounts and stored at -20°C.
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Electrophoresis of LPS on 14% SDS PAGE
Stacking gel buffer: 0.5 M Tris-HCl (pH 6.81
6 g of Tris was dissolved in 40 ml water, titrated with 2 M HC1 to pH 6.8 and the 
volume was made up to 100 ml with water.
Resolving gel buffer: 3.0 M Tris-HCl (pH 8.8)
Tris 36.2 g
HC1 (2 M) 24 ml
Water up to 100 ml
Stock reservoir buffer: 0.25 M Tris. 1.92 M Glycine, 1% SDS (pH 8.3)
Tris 30.3 g
Glycine 144 g
SDS 10 g
Distilled water up to 1000 ml
This buffer was diluted 1:10 before use
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Stock acrvlamide bis solution
Acrylamide 30 g
Bisacrylamide 0.8 g
Dowex AG1 resin 1 g
This solution was stored in a dark bottle at 4°C and the resin was filtered off prior to 
use.
Ammonium persulphate solution: 1.5%
150 mg of ammonium persulphate was dissolved in 10 ml of distilled water freshly 
prior to use.
Sodium dodecvl sulphate (SDS) solution: 10%
1 g of SDS was dissolved in 10 ml distilled water and kept at RT.
Resolving gel (30 ml), 14% polyacrylamide
Acrylamide/Bis solution 14 ml
Rsolving gel buffer 3.75 ml
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1 0 %  S D S  0.3 m l
Ammonium persulphate 1.5 ml
Distilled water 10.4 ml
TEMED 30 pi
Stacking gel (20 mil. 2.5% polycrvlamide
Acrylamide/Bis solution 2.5 ml
Stacking gel buffer 5 ml
10% SDS 0.2 ml
Ammonium persulphate 1 ml
Distilled water 11.3 ml
TEMED 15 pi
Silver staining of LPS
Fixing reagent
Isopropanol 50 ml
Acetic acid 14 ml
W a te r 186 m l
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O x id is in g  reag en t
P e rio d ic  ac id  1.05 g
Isopropanol 2 ml
Acetic acid 200 pi
Water 150 ml
This reagent was made up freshly, just prior to use.
Silver nitrate solution
Silver nitrate 2 g
Water 10 ml
This reagent was stored in the dark.
Alkaline reagent
Sodium hydroxide (0.1 % solution) 28 ml
Ammonium hydroxide (35%) 1 ml
Water 115 ml
This reagent was made up freshly prior to use.
2 2 9
S ta in in g  so lu tio n
To the total alkaline solution, approximately 4 ml of Silver nitrate solution was added 
drop-wise with continual shaking until a permanent silver precipitate was just visible. 
Excess precipitation was reversed by adding ammonium hydroxide drop-wise. This 
solution was made up just prior to use.
Developing solution
Citric acid 12.5 mg
Citric acid was first dissolved in water and the formaldehyde was added to the 
solution just prior to use.
Stopping solution
Formaldehyde (37%) 125 j l i I
Water 250 ml
Acetic acid 1 ml
W a te r 2 5 0  m l
2 3 0
ELISA:
G en era l re ag en ts
TMB microwell peroxidase substrate KPL, UK
Horse-radish peroxidase streptavidin Zymed
Coating buffer 
Blocking buffer
Wash buffer 
Diluent solution
Stop solution
DPBS 
1% BSA
5% sucrose in PBS
0.05% Tween 20 in PBS (pH 7.4)
0.1% BSA
0.05% Tween 20 in Tris bufferes saline (pH 7.3) 
0.5 M H2S04
Specific TNF-q Reagents
Monoclonal mouse anti-human TNF-a antibody R&D Systems, UK
Biotinylated goat anti-human TNF-a antibody R&D Systems, UK
Recombinant human TNF-a standard R&D Systems, UK
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S p ec ific  IL -6  R eag en ts
Monoclonal mouse anti-human IL-6 antibody R&D Systems, UK
Biotinylated goat anti-human IL-6 antibody R&D Systems, UK
Recombinant human IL-6 standard R&D Systems, UK
Specific IL-8 Reagents
Monoclonal mouse anti-human IL-8 antibody 
Biotinyated goat anti-human IL-8 antibody 
Recombinant human IL-8 standard
R&D Systems, UK 
R&D Systems, UK 
R&D Systems, UK
Respiratory Burst measurement by enhanced chemiluminescence
Reagents
Opsonised Zymosan: stock 2.5 mg/ml, diluted 1:5 (500 pg/ml) in standard buffer for 
experimental use.
20 mM Luminol (5-amino-2,3-dihydro- 1,4-phthalozinedione): stock solution was 
prepared at 3.5 mg/ml in DMSO and stored in the dark at 4°C for no more than 1 
week. For experimental use it was diluted to 3.5 mM with distilled water prior to use.
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Standard buffer
For 100 ml (made up in water)
KH2PO4 4.58 mM
Na2HP04 8.03 mM
NaCl 0.76%
KC1 0.033%
Glucose 0.1%
Endotoxin free albumin 0.1%
MgCl2 0.5mM
CaCl2 0.45mM
This buffer was adjusted to pH 7.3 and aliquoted into 20 ml aliquots, it was then 
stored a -20°C until use.
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Western blotting of MAPK proteinsP44/42 (ERK1/2)
Cell fractionation
Reagents
RIPA buffer base
To 100 ml water add:
NaCl 150 mM
Tris-HCl 10 mM
EDTA 1 mM
EGTA 1 mM
RIPA buffer working solution
To 20 ml RIPA buffer base add:
1 Protease inhibitor cocktail tablet (Sigma) 
Na3V 04 200 mM
2 3 4
Protein estimation- Coomassie Blue G binding
Stock dye solution
Coomassie Blue G 330 mg
Phosphoric Acid/Ethanol
(2:1 v/v) 100 ml
Working dye solution
Stock dye reagent 3 ml
Phosphoric acid 8 ml
Ethanol 3.75 ml
Water to 100 ml. This solution was made up freshly on the day of use.
Electrophoresis using Novex system and NuPAGE gels
NuPAGE running buffer
50 ml NuPAGE stock running buffer added to 950 ml ultrapure water.
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R ed u c in g  b u ffe r
500 pi NuPAGE antioxidant added to 200 ml NuPAGE running buffer.
Transfer to nitrocellulose membrane
NuPAGE transfer buffer
Ultrapure water 750 ml
2 Ox NuPAGE transfer 
stock buffer 50 ml
NuPAGE antioxidant 1 ml
Methanol 200 ml
2 3 6
Electrophoretic Mobility Shift Assay (EMSA)
Preparation of subcellular fractions
Buffer A
Hepes
MgCl2
KC1
Water
Added just before use:
PMSF
DTT
Buffer C
Hepes
NaCl
MgCl2
EDTA
Glycerol (25%)
Water
Added just prior to use: 
PMSF
lOmM (pH 7.9)
1.5 mM 
10 mM 
10 ml
100 mM 
1M
20 mM (pH 7.9) 
420 mM
1.5 mM 
0.2 mM
2.5 ml 
10 ml
05 m M
2 3 7
Buffer D
H ep es  10 m M  (p H  7 .9)
KC1 25 mM
EDTA 0.1 mM
Glycerol (10%) 1 ml
Water 10 ml
Added just prior to use:
PMSF 0.5 mM
DTT 0.5 mM
Detection of NF-kB
1 OX Binding reaction buffer
Glycerol (40%) 20 pi
EDTA 10 mM
DTT 50 mM
Tris (pH 7.5) 100 mM
NaCl 1 M
Nuclease free BSA 1 mg/ml
B an d  sh ift gel
40% acrylamide mix 5 ml
10XTBE 5 ml
Water 40 ml
Ammonium persulphate 0.1 g
TEMED 2 pi
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Highly purified lipopolysaccharides from Burkholderia 
cepacia complex clinical isolates induce inflammatory 
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Summary
In cystic fibrosis (CF), bacteria of the Burkholderia 
cepacia complex (Bcc) can induce a fulminant inflam­
mation with pneumonitis and sepsis. Lipopolysac- 
charide (LPS) may be an important virulence factor 
associated with this decline but little is known about 
the molecular pathogenesis of Bcc LPS. In this study 
we have investigated the inflammatory response to 
highly purified LPS from different Bcc clinical isolates 
and the cellular signalling pathways employed. The 
inflammatory response (TNFa, IL-6) was m easured in 
human MonoMac 6 m onocytes and inhibition experi­
m ents were used to investigate the Toil-like receptors 
and associated  adaptor m olecules and pathways 
utilized. LPS from all clinical Bcc isolates induced 
significant pro-inflammatory cytokines and utilized 
TLR4 and CD14 to mediate activation of mitogen- 
activated protein kinase pathways, IkB-cc degradation 
and NFkB activation. However, LPS from different 
clinical isolates of the sam e clonal strain of Burkhold­
eria cenocepacia were found to induce a varied 
inflammatory response. LPS from clinical isolates of 
Burkholderia multivorans was found to activate the 
inflammatory response via MyD88-independent 
pathways. This study sugg ests  that LPS alone from 
clinical isolates of Bcc is an important virulence 
factor in CF and utilizes TLR4-mediated signalling 
pathways to induce a significant inflammatory 
response.
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Introduction
A feature of cystic fibrosis (CF) is the unusual respiratory 
inflammation that results from the interaction between 
bacterial pathogens and host cells. Despite intense 
research efforts, the detailed pathogenic mechanisms 
underlying these CF infections remain poorly understood. 
Members of the Burkholderia cepacia complex (Bcc) 
cause nosocomial infections in immunocompromised 
hosts and are particularly feared among CF patients as 
they can induce a rapid decline in lung function, with 
pneumonitis and sepsis (‘cepacia syndrome’) (Isles etal., 
1984; Vinion-Dubiel and Goldberg, 2003). In addition, 
many strains of Bcc are highly transmissible and once 
acquired are impossible to eradicate from the lungs due to 
antibiotic resistance.
A distinguishing feature of infections with Bcc compared 
with other major CF pathogens, such as Pseudomonas 
aeruginosa, is an increase in morbidity and mortality in 
patients with only mild or moderate lung disease (Muhdi 
et al., 1996). The pathogenic mechanisms involved in 
severe Bcc infections are poorly understood; however, it 
has been shown that lipopolysaccharide (LPS) from Bcc 
elicits a much stronger inflammatory response from leu­
cocytes compared with that of P. aeruginosa (Shaw et al., 
1995; Zughaier et al. 1999a).
Clinically, Burkholderia cenocepacia (formerly genomo- 
var III) is often associated with a rapid decline in lung 
function and the ET12 clonal strain has been responsible 
for multiple transmission and infections in North America 
and the United Kingdom (Govan et al., 1996). In a recent 
study, De Soyza and colleagues demonstrated that whole 
cell lysates from B. cenocepacia induced more TNFa and 
IL-1 compared with other Bcc genomovars (De Soyza 
et al., 2004). This activity was assumed to be due to the 
LPS from these isolates. In many European CF centres, 
however, Burkholderia multivorans (formerly genomovar 
II) is the most common species isolated. Furthermore, 
although LPS is an important inflammatory stimulus in 
Gram-negative organisms, Bcc strains exhibit many 
potential virulence factors that could contribute to clinical 
outcome. Indeed, it has been suggested that LPS- 
associated proteins may be responsible for the
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inflammatory responses (Shimomura et al., 2001) and 
that signalling mechanisms to Bcc LPS may be different 
from that for LPS from enteric species (Shimomura etal.,
2003). Although details of the signal transduction path­
ways elicited by LPS in innate immune cells are emerging 
(Karin and Ben-Neriah, 2000; Rao, 2001), there have 
been no studies on the signalling mechanisms by which 
Bcc LPS activates inflammatory responses in these cells. 
Moreover, some reports suggest that LPS from certain 
non-enteric organisms may signal through TLR2 (Werts 
et al., 2001; Erridge et al., 2004).
Due to the importance of Bcc in CF and the potential for 
LPS to induce the severe inflammatory decline associated 
with these infections, more information on the molecular 
mechanisms by which Bcc LPS can elicit inflammatory 
responses is required. Identification of the receptors and 
signalling pathways utilized by Bcc LPS will potentially 
allow new therapeutic approaches to the treatment of 
these important CF infections. Therefore, we undertook 
the current study to identify the pro-inflammatory signal­
ling pathways activated by LPS purified from a number of 
clinical isolates of different Bcc strains from CF patients.
Results
Cytokine production by phenol-chloroform-petroleum 
ether-purified and enzyme-treated LPS
An initial objective of this work was to compare the inflam­
matory potential of LPS derived from isolates of different 
clinical Bcc strains with LPS from a non-clinical source 
and from an unrelated enteric organism (Escherichia coif). 
We also sought to compare differences in these 
responses from LPS prepared from clinical isolates from 
the same Bcc strain. Additionally, we wished to confirm 
that the inflammatory activity associated with the purified 
LPS was not due to contaminating protein or nucleic 
acids. Thus we prepared LPS from three B. cenocepacia 
strains, all belonging to the ET12 epidemic strain, from a 
clinical isolate of B. multivorans and from an environmen­
tal B. cepacia strain. Each LPS preparation (Bcc LPS-1) 
was further treated with protease and DNAase to give a 
purified LPS preparation (Bcc LPS-2).
Treatment of the human monocyte cell line MonoMac 6 
(MM6) with LPS preparations from representative Bcc 
isolates induced the production of TNFa and IL-6 inflam­
matory cytokines as shown in Fig. 1. As a control, LPS 
purified by the same method from an E. coli strain was 
used to induce TNFa. The TNF-inducing activity of the 
purified extracted E. coli LPS and E. coli LPS from a com­
mercial source gave similar results and the commercial 
preparation was routinely used (data not shown). 
Figure 1A and B show that there was no difference in 
cytokine induction between the phenol-chloroform-
petroleum ether (PCP)-extracted LPS (Bcc LPS1) and the 
further purified LPS (Bcc LPS2) indicating that it is the 
LPS that is stimulating the cytokine responses and not 
other contaminants. We were particularly keen to investi­
gate differences in inflammatory potential of purified LPS 
extracted from different Bcc strains and from within the 
same clonal strain. Figure 1C shows the TNFa-inducing 
ability of highly purified LPS preparations from a larger 
number of clinical Bcc isolates, including ET12 epidemic 
strains of B. cenocepacia derived both from patients in 
Cardiff and from other UK centres. Figure 1C shows that 
LPS from environmental B. cepacia strains are much 
weaker TNFa inducers than LPS from Bcc clinical 
isolates. Furthermore, LPS from B. multivorans strains 
induced similar levels of TNFa to the B. cenocepacia 
strains and there was considerable variation in TNFa- 
inducing ability between LPS purified from isolates of the 
same B. cenocepacia clonal strain. Moreover, the TNFa- 
inducing ability of LPS from many clinical Bcc isolates was 
comparable with LPS purified from the enteric E. coli.
Antibody blocking of TLR4, TLR2 and CD 14 cell surface 
receptors
Having described the inflammatory cytokine responses 
induced by the LPS from different clinical strains of Bcc, 
we wished to investigate the receptors and signalling 
mechanisms by which the monocytes were responding to 
the LPS. In particular, are there differences in LPS recog­
nition and signalling that might explain the differences in 
cytokine responses seen both between Bcc strains and 
within the same epidemic Bcc strain. There are reports in 
the literature that LPS derived from some non-enteric 
pathogens might be recognized and signal via receptors 
other than TLR4 (Werts et al., 2001; Erridge et al., 2004). 
Thus, we first used antibodies to TLR4 to block this LPS 
receptor and monitored the TNFa responses as in the 
previous experiments.
In order to ascertain the receptor(s) utilized by Bcc LPS, 
specific antibodies were used to block a receptor in MM6 
cells, the cells were then stimulated with LPS from repre­
sentative strains of Bcc. The reduction in the level of 
TNFa after receptor blocking, compared with a non­
blocked control, indicates the level of signalling through 
that receptor. Isotype control antibody did not significantly 
inhibit LPS-induced responses and confirmed the speci­
ficity for blocking TLR4 (data not shown).
Anti-human TLR4 monoclonal antibody was incubated 
with MM6 cells for 1 h before stimulation with LPS. TNFa 
levels were then measured by enzyme-linked immunosor­
bent assay (ELISA) after 6 h. In E. coli and in the 
B. cenocepacia LPS samples an almost total reduction in 
TNFa production was seen. The B. multivorans samples 
also showed a large reduction (60%) in TNFa production
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Bcc isolate LPS
Fig. 1. ELISA experiments showing 
inflammatory cytokine induction in MM6 cells 
by Bcc LPS.
A. TNFa production after 6 h of stimulation 
with Bcc LPS from different sources.
B. IL-6 production after 6 h of stimulation with 
Bcc LPS from different sources. BcLPS-1 is 
the PCP-extracted LPS and BcLPS-2 is the 
more highly purified enzyme-treated 
preparation.
C. ELISA showing TNFa production from LPS 
purified from clinical epidemic and 
non-epidemic strains of Bcc, with LPS from 
environmental Bcc strains and from E. coli 
shown for comparison. Values are
means ±  SD of three independent 
experiments. For Bcc strain details see 
Table 1 and the text. *P <  0.01 compared with 
the average TNFa value for the Bcc clinical 
isolates.
when TLR4 was blocked, although not as much as for 
B. cenocepacia (Fig. 2A).
MM6 cells were also incubated with anti-CD14 antibody 
as above and similar results were seen with TNFa 
production. B. multivorans and B. cenocepacia- 
stimulated cells’ TNFa production was reduced to almost 
zero and production by E. coli LPS was reduced by 79%. 
(Fig. 2B). In order to ascertain whether the LPS signal 
was being transmitted through TLR2 as well as TLR4, 
cells were also treated with anti-TLR2 and then stimulated 
with the same LPS samples. There was minimal or no 
reduction in TNFa being produced for all three samples 
(Fig. 2C). The anti-TLR2 antibody inhibited TNFa produc­
tion from MM6 cells stimulated with the TLR2 ligand pep- 
tidoglycan (data not shown).
Mitogen-activated protein kinase inhibition in MM6 ceils 
stimulated with LPS
Various mitogen-activated protein kinase (MAPK) group 
members are activated by LPS, specific MAPK inhibitors 
prevent signal transduction and indicate the level to which 
that particular MAPK is involved in the signalling.
Specific MAPK inhibitors PD98059 (P42/44 inhibitor), 
SB03580 (P38 inhibitor) and SP600125 (JNK inhibitor) 
were incubated singly and in combination at a concentra-
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Fig. 2. ELISA experiments showing TNFa 
production from human MM6 cells treated 
with Bcc LPS in the presence of blocking 
antibody to LPS receptors.
A. Anti-TLR4.
B. Anti-CD14.
C. Anti-TLR2.
ELISA results shown are mean values ± SD 
from three independent experiments for LPS 
from B. cenocepacia (strains WP01101G3a, 
WP0103G3a) and B. multivorans (strains 
WA0103G2, WA0301G2).
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tion of 10 pM for 1 h before stimulation with LPS samples. 
Control samples using the inhibitors alone were included 
and the inhibitors were found to cause no reaction or 
significant reduction in viability (data not shown).
The most dramatic reduction in TNFa production from a 
single MAPK inhibitor came from the JNK inhibitor, this 
was the case with all the LPS samples. The JNK inhibitor 
reduced TNFa production by an average of 63%. P42/44 
inhibitor reduced TNFa production by an average of 47% 
and the least effective was the P38 inhibitor, which 
reduced production by an average of 37%. (Fig. 3). 
However, combinations of the inhibitors completely abol­
ished TNFa production from the monocytes (Fig. 3).
Activation of MyD88-independent pathways
Recent reports demonstrate that LPS can activate cells via 
TLR4 and the recruitment of the adapter protein
MyD88, or via MyD88-independent pathways via activa­
tion of the adaptors TRIF and TRAM (Palsson-McDermott 
and O’Neill, 2004; Jiang et al., 2005). We were keen to 
investigate if LPS from different Bcc isolates required 
MyD88 for cellular activation. Monocytes were therefore 
stimulated with LPS in the presence of either a specific 
MyD88 inhibitor peptide or a control peptide with no effects 
on cell signalling pathways and the production of TNFa 
measured. The results (Fig. 4) show that LPS from E. coli 
and from strains of B. cenocepacia predominantly utilize 
MyD88 for cell activation (Fig. 4A and B). However, TNFa 
production in cells stimulated with LPS from strains of 
B. multivorans was not significantly reduced by MyD88 
inhibition even when the concentration of inhibitory 
peptide was increased to 300 pM (Fig. 4C). This surprising 
result suggests that LPS from B. multivorans can activate 
cells by the MyD88-independent pathway that could yield 
different cellular responses and affect clinical outcome.
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Fig. 3. ELISA experiments showing TNFa 
production from human MM6 cells treated 
with LPS with and without the MAPK 
inhibitors PD98059 (P42/44 inhibitor) 
SB203580 (P38 inhibitor) or SP600125 (JNK 
inhibitor).
A. LPS from E. coli.
B. LPS from B. cenocepacia.
C. LPS from B. multivorans.
Cells were incubated with one or more 
inhibitors for 1 h before stimulation with LPS 
for 6 h. Results are mean values ± SD from 
three independent experiments for LPS from 
representative Bcc strains [B. cenocepacia 
(strains WP01101G3a, WP0103G3a) and
B. multivorans (strains WA0103G2, 
WA0301G2)].
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Dissociation of IkB-cc and activation of NFkB as 
measured by electrophoretic mobility shift assay
Lipopolysaccharide signalling causes the translocation of 
the transcription factor NFkB into the nucleus. In order to 
test whether Bcc LPS activated NFkB, dissociation of its 
inhibitor protein IkB was tested for after LPS stimulation. 
Then NFkB translocation was seen using an electro­
phoretic mobility shift assay (EMSA).
MM6 (1 x 106) cells were treated with LPS from E. coli 
and B. cenocepacia (strain WP01101G3a) for 1 h then 
washed and lysed. The lysates were then separated by 
electrophoresis and incubated with IkB-oc polyclonal 
antibody followed by detection by a chemiluminescent 
detection kit (see above). Stimulation with LPS from 
E. coli and B. cenocepacia caused IkB-cx to dissociate 
and degrade, this can be seen as narrower less intense
bands compared with an unstimulated sample (Fig. 5A). 
Measurement of NFkB activation was done by 
EMSA and a gradual but steady increase in transloca­
tion to the nucleus was seen over a 120 min period 
(Fig. 5B).
Discussion
Pathogens belonging to the Bcc are a particular problem 
in patients with CF due to their antibiotic resistance, their 
patient-to-patient spread and their ability to cause severe 
inflammation and fatal invasive disease (‘cepacia 
syndrome’). However, the identity of the bacterial mol­
ecules associated with this poor outcome in CF patients 
has remained elusive. We and others have been investi­
gating the role of Bcc LPS in stimulating the inflammatory
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Fig. 4. LPS stimulation of the 
MyD88-dependent and -independent 
pathways of cellular activation. ELISA data of 
TNFa production from MM6 cells in the 
presence and absence of a MyD88 inhibitor 
peptide.
A. Cells stimulated with LPS from E. coli.
B. Cells stimulated with LPS from
B. cenocepacia (strains WP01101G3a, 
WP0103G3a).
C. Cells stimulated with LPS from
B. multivorans (strains WA0103G2, 
WA0301G2).
Representative data are shown for each LPS 
type (mean ± SD) from three independent 
experiments. *P< 0.001 versus cells treated 
with control peptide and LPS.
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response in monocytes and macrophages (Shaw et al., 
1995; Hughes et al., 1997; Zughaier et al., 1999a,b).
In this study, we report that LPS purified from clinical 
strains of Bcc induce greater inflammatory cytokine 
responses compared with an environmental strain. There 
was variation in cytokine-inducing capacity of LPS from 
the different Bcc strains used, with LPS from some strains 
eliciting as much cytokine as LPS from an enteric E. coli 
strain. Furthermore, we show that the cytokine induction 
by all the purified Bcc LPS utilizes CD14 and TLR4 to 
stimulate MAPK and activate NFkB. Moreover, our use of 
highly purified LPS indicates that this activity is not due to 
contaminating protein or nucleic acids. Thus, we have 
demonstrated that Bcc LPS have significant pro- 
inflammatory cytokine-inducing capacity and that they 
stimulate gene expression via common TLR4-mediated 
LPS signalling pathways.
Considerable evidence is now emerging that LPS is 
an important virulence factor that stimulates the inflam­
matory response in Bcc infections (Hughes et al., 1997; 
Zughaier et al., 1999a,b; Ryley, 2004; Mahenthiralingam 
et al., 2005). Such evidence comes from studies 
showing that Bcc bacteria or the LPS derived from them 
can induce significant pro-inflammatory cytokine produc­
tion (Zughaier et al., 1999a; Shimomura et al., 2001; 
Reddi et al., 2003). Some studies have shown that Bcc 
bacteria or their LPS can elicit up to 10 times more 
TNFa from these cells as equivalent treatments with 
LPS from other lung pathogens including P. aeruginosa 
(Shaw et al., 1995; Hughes et al., 1997; Zughaier et al., 
1999a). However, it has been argued that the high levels 
of cytokine production observed in such studies may 
be due to protein contamination of the LPS and that a 
conventional phenol-water extraction may not remove
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Fig. 5. Activation of NFkB.
A. Representative Western Blot showing dissociation of I k B  from 
cells treated with LPS from E. coli (left panel), B. cenocepacia 
(strain WP01101G3a) (right panel) or untreated (centre panel).
B. Measurement of NFkB activation in nuclear fractions from MM6 
cells treated with Bcc LPS as measured by EMSA. Samples were 
taken at 0, 15, 30, 60 and 120 min.
protein contaminants (Shimomura et al., 2001). In the 
current study therefore, each LPS was prepared by both 
the conventional phenol-water extraction and a further 
round of proteinase, DNase and RNase treatment fol­
lowed by deoxycholate-phenol-water extraction. This 
latter treatment was developed for the removal of trace 
protein from LPS preparations and was previously 
reported to be effective in eliminating ‘non-LPS’ activity 
from purified LPS (Shimomura et al., 2001). We found 
no significant difference between either of the LPS 
preparations in their ability to induce pro-inflammatory 
cytokines in MM6 cells and conclude that, at least for 
the Bcc strains and cells used here, the conventional 
phenol-water extraction is sufficient. These conclusions 
were further endorsed by the fact that blocking the LPS 
receptors CD14 and TLR4 completely inhibited the LPS- 
induced pro-inflammatory responses.
Our study has shown that there is great variability in 
the inflammatory activity of LPS purified from different 
Bcc isolates. LPS derived from clinical isolates of Bcc 
(B. cenocepacia and B. multivorans) induced more TNFa 
and IL-6 production than the environmental strain [B. ce­
pacia (genomovar I)] and as much as was induced by 
LPS purified from the enteric E. coli strain. Although 
B. cenocepacia is seen as the most virulent strain and is
more frequently associated with ‘cepacia syndrome’ than 
other strains, we found B. multivorans was also a potent 
cytokine stimulator, which is interesting as, typically, sur­
vival rates for patients infected with B. cenocepacia are 
lower than patients infected with B. multivorans (LiPuma 
et al., 2001). These results are in contrast to a recent 
report by De Soyza and coworkers (De Soyza et al.,
2004) who found that whole cell lysates of B. cenocepa­
cia were more potent than lysates of B. multivorans in 
inducing cytokines from U937 monocytes. Although pre­
transplant infection with B. cenocepacia is reported to 
have a worse outcome than B. multivorans in patients 
undergoing pulmonary transplants (De Soyza et al., 
2001), growing evidence shows that B.multivorans is 
also associated with poor clinical prognoses in patients 
with CF not undergoing pulmonary transplant (Ryley and 
Doull, 2003). Furthermore, whole cell lysates, as used in 
De Soyza’s study, may stimulate cytokine release in 
monocytes by multiple non-LPS factors, some of which 
have been shown to bind to CD14 (Ryley, 2004; Urban 
et al., 2004).
Surprisingly, we found that there was also variability in 
cytokine induction capability between the LPS isolated 
from within the B. cenocepacia strains. The B. cenoce­
pacia strains used in our study belong to the ET12 
lineage -  a virulent strain that has been associated with 
transmission of Bcc infections between patients in differ­
ent CF clinics and a poor clinical outcome (Ledson 
et al., 1998; Ryley and Doull, 2003). All ET12 samples 
produced high levels of both TNFa and IL-6 (data not 
shown) with the exception of WP0101G3a which is also 
an ET12 clone but was a much less effective cytokine 
producer. This isolate was the index case from which 
ET 12 spread to nine other patients over a 10 year 
period. The patient acquired it following a stay in a 
summer camp in Ontario in 1987. Molecular typing has 
confirmed that there are no genetic differences between 
these isolates from different patients and the original 
environmental strain from which they have arisen 
(Mahenthiralingam et al., 2005). The variation in the pro- 
inflammatory activity of the LPS from this strain and the 
variable clinical outcome in different patients carrying 
this strain, suggests that there are other patient- or 
centre-derived factors and/or subtle patient-specific 
phenotypic changes in the LPS that mediate these 
clinical and inflammatory differences. Our results also 
suggest that it is not possible to conclude that all ET12 
clones will behave the same way in experimental 
models.
Due to the inherent variation in inflammatory response 
produced by LPS from the different Bcc strains used in 
our study, it was important to analyse the molecular 
mechanisms utilized by the different LPS in stimulating 
these responses. In contrast to the well-documented sig-
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nailing pathways utilized by LPS from enteric organisms, 
little is known about the molecular pathways underlying 
cell stimulation by LPS from Bcc strains.
Initial studies showed that blocking membrane CD14 
completely inhibited monocyte TNF production in 
response to stimulation with LPS from either 
B. multivorans or B. cenocepacia, suggesting LPS signal­
ling pathways similar to those of enteric organisms. 
However, as CD14 has been shown to also bind non-LPS 
ligands (Kurt-Jones etal., 2000; Esen and Kielian, 2005) 
we investigated the LPS signalling pathways further. 
TLR4 has been demonstrated to be almost exclusively 
used by LPS in innate immune responses (Beutler, 2000; 
Hajjar et al., 2002). However, some LPS has been sug­
gested to activate cells via binding to TLR2 (Kirschning 
et al., 1998; DaSilva Correia et al., 2001; Werts et al., 
2001; Erridge et al., 2004). We found that, at least for the 
Bcc strains used in our study, LPS from Bcc utilizes TLR4 
to induce cell responses and not TLR2. We investigated 
the signalling pathways involved in cell activation by anal­
ysing three MAPK pathways that are known to be acti­
vated by LPS stimulation; p42/p44 MAPK (Erk1/2), 
transcription factor c-Jun and p38 MAPK (Nick et al., 
1999; Guha and Mackman, 2001; Palsson-McDermott 
and O’Neill, 2004). Inhibition of each of these MAPK indi­
vidually was found to reduce but not completely inhibit 
TNFa expression in response to either E. coli or Bcc LPS. 
However, inhibition of more than one MAPK was seen to 
completely inhibit TNFa expression. This suggests that 
Bcc LPS activates these MAPK in monocytes and that 
co-ordinate activation of MAPK pathways are required for 
TNFa production. These findings are consistent with a 
recent report by Reddi et al. (2003), showing that whole 
bacterial cells of a clinical isolate of B. cenocepacia 
induced IL-8 secretion in alveolar epithelial cells through 
CD14 and MAPK signalling. Bcc LPS used in our study 
also activated NFkB via dissociation of the IkB complex, 
in a similar manner to E. coli LPS. NFkB mediates pro­
duction of numerous pro-inflammatory genes, including 
TNFa, highlighting that Bcc LPS from all the species 
studied activates monocytes by conventional LPS 
pathways. Furthermore, a recent study showed that 
P. aeruginosa LPS is extracted by the CFTR in epithelial 
cells and activates NFkB (Schroeder et al., 2002). 
However, Bcc LPS can induce a much greater inflamma­
tory response than P. aeruginosa LPS (Shaw et al., 1995; 
Zughaier et al., 1999a), suggesting that structural differ­
ences in the lipid A and other factors or pathways are also 
involved in the inflammatory response to LPS (Branden­
burg and Wiese, 2004; Trent, 2004).
Interestingly, our results with the inhibition of MyD88 
suggest that LPS from B. cenocepacia activates cells 
through MyD88-dependent pathways while LPS from 
B. multivorans can activate cells through MyD88-
independent pathways. In this regard, LPS from Bcc 
organisms might be similar to lipooligosaccharide from 
Neisseria meningitidis which was found to activate both 
MyD88-dependent and -independent pathways in mono­
cytes (Zughaier et al., 2005). Activation of the MyD88- 
independent pathway is associated with expression of 
interferon-p, and activation of STAT 1 and production of 
type 1 interferon-a/p, interferon-a-inducible protein 10, 
monocyte chemoattractant protein 5, nitric oxide and late 
activation of NFkB (Kawai etal., 2001; Rhee etal., 2003). 
Such differential activation of cells might explain the dif­
ferences in clinical outcomes observed in patients infected 
with B. multivorans or B. cenocepacia, particularly when 
acquired before lung transplantation (LiPuma etal., 2001).
A recent study has found structural differences in the 
lipid A component of LPS from P. aeruginosa isolated from 
the airways of CF patients compared with LPS from iso­
lates from other patients and sites (Ernst et al., 1999). 
Interestingly, the study by De Soyza and coworkers (De 
Soyza et al., 2004) found different acylation patterns 
between B. cenocepacia and B. multivorans which they 
used to explain differences in inflammatory activities 
between whole cell lysates of these species. However, 
they only analysed one lipid A from each strain and it may 
be premature to draw conclusions from that. Indeed, 
caution should be exercised when trying to apply results 
obtained in one cell type to another as it is expected that 
there will be host cell-specific variations in response to 
LPS. For example, recent studies have shown that murine 
cells show differences in Toll-like receptor expression and 
responses compared with human cells (Rehli, 2002). 
Poorly differentiated cell lines may also not be represen­
tative of host responses in vivo. In this study, we utilized 
the well-characterized human monocyte cell line MM6, 
previously shown to be a good model for human blood 
monocytes (Ziegler-Heitbrock, 1994; Zughaier et al., 
1999a). Preliminary results with our purified Bcc LPS 
using several epithelial cell lines also show similar results 
(data not shown) indicating the variation in inflammatory 
response we see is real.
Other studies have found no correlation between Bcc 
species and lipid A fatty acid profile and no apparent 
correlation between lipid A composition and O-antigen 
(Vinion-Dubiel and Goldberg, 2003). Distinguishing fea­
tures of Bcc LPS include the 4-amino-4-deoxy arabinose 
bound to phosphate in the lipid A (Vinion-Dubiel and Gold­
berg, 2003) that probably mediates the intrinsic resistance 
to antimicrobial peptides displayed by this species 
(LiPuma, 1998). Our results suggest that 4-amino-4- 
deoxyarabinose does not alter the binding or cellular acti­
vation pathways of LPS from Bcc. There is no complete 
information available on the chemical structure of Bcc lipid
A. However, a recent report by Silipo and coworkers 
(Silipo et al., 2005) showed that lipid A purified from a
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Table 1. Burkholderia cepacia complex strains used in the study.
Designation Bcc strain
NCTC 10743 B. cepacia
NCTC 10661 B. cepacia
WA0103G2 B. multivorans
WA0201G2 B. multivorans
WP0301G2 B. multivorans
WP0103G3a B. cenocepacia (ET12)
WP0104G3a B. cenocepacia (ET12)
WP0107G3a B. cenocepacia (ET12)
WP01101G3a B. cenocepacia (ET12)
WP0101G3a B. cenocepacia (ET12)
WP0501G3b B. cenocepacia Type b
LiverpoolG3a B. cenocepacia (ET12)
EdinburghG3a B. cenocepacia (ET12)
ManchesterG3a B. cenocepacia (ET12)
LondonG3a B. cenocepacia (ET12)
B. cepacia (genomovar I) clinical isolate had a penta- 
acylated tetrasaccharide backbone containing two 
phosphoryl-arabinosamine residues in addition to the 
archetypal glucosamine disaccharide. It remains to be 
seen if these features are common to all Bcc clinical 
isolates or only for B. cepacia (genomovar I). In addition, 
it would be interesting to analyse the chemical structures 
of lipid A from the clinical and environmental Bcc strains to 
see if there are clear structural differences that might 
explain the variation in pro-inflammatory activity observed 
between these strains.
In summary, we have found that purified LPS from Bcc 
clinical isolates can induce a strong inflammatory 
response and this is mediated by binding to TLR4 and 
activation of MAPK and NFkB. LPS from B. cenocepacia 
and B. multivorans were equally effective in inducing an 
inflammatory response although LPS from B. multivorans 
may activate cells via the MyD88-independent pathway 
and this could be linked to clinical outcome in some 
patients. There was variation in the inflammatory response 
elicited by LPS from different clinical isolates of a single 
clonal epidemic strain of B. cenocepacia. This suggests 
that patient-specific or centre-specific factors might modu­
late the LPS and detailed structural analyses of lipid A and 
LPS from these strains would be important. We are cur­
rently investigating these structures and other pathways 
that might be activated by Bcc LPS. Further understanding 
of the molecular mechanisms and pathways activated by 
Bcc LPS coupled with detailed structural analyses will 
allow a greater understanding of the mechanisms that 
contribute to ‘cepacia’ syndrome and potentially the devel­
opment of novel therapeutic strategies.
Experimental procedures
Bacteria isolates
The clinical Bcc isolates used in this work were obtained from the 
sputum of patients with CF attending either the Paediatric CF
Clinic, University Hospital of Wales, Cardiff or the Adult CF Clinic, 
Llandough Hospital, Penarth. The species of the isolates within 
the Bcc was determined using restricted endonuclease digestion 
of the PCR products from amplification of the RecA gene as 
described by Mahenthiralingam eta l. (2000) with confirmation by 
the restriction endonuclease digestion of the 16SrRNA PCR  
product. All isolates were genotyped by PCR of 16S-23S rRNA 
intergenic zone followed by Taq1 digestion of the PCR products 
(Ryley et al., 1995). The presence of clonal strains that were 
identified by the above method was confirmed by another geno- 
typing method, Randomly Amplified Polymorphic DNA (RAPD) 
PCR (Mahenthiralingam et al., 1996). The ET12 clonal strain 
found in our patients was the strain described previously as the 
Cardiff Paediatric Epidemic Strain (Ryley eta l., 1995). It had an 
identical genotype to the type strain, NCTC13008, as well as 
ET12 isolates from other UK centres (kindly supplied by Mrs 
Fiona Clode, Health Protection Agency, Laboratory of Health 
Care Associated Diseases, Colindale, UK)
Cell culture
The human monocytic cell line MonoMac 6 [obtained from the 
German Collection of Microorganisms and Cell Cultures (DSM  
ACC 124; Braunschweig, Germany)] was used. W e have previ­
ously validated this cell line as a useful model for human periph­
eral blood monocytes (Zughaier et al., 1999a). For culture, MM6 
cells were maintained in RPMI 1640, supplemented with 10%  
heat-inactivated fetal bovine serum (FBS; Labtech International, 
Ringmer, East Sussex, UK), 1% 2 mM L-glutamine, 1% nones­
sential amino acids, 1% penicillin (50 IU m l'1)/streptomycin 
(100 pg m l'1), and 1% sodium pyruvate. Cells were cultured in a 
humidified incubator at 37°C  with 5%  C 0 2.
Lipopolysaccharide preparations
The Bcc strains from which LPS was isolated in this study 
together with their previous genomovar designations are outlined 
in Table 1.
Bacterial cells were obtained by culture in tryptone soya broth 
(Oxoid, Basingstoke, UK) at 37°C for 48 h. LPS was extracted by 
conventional PCP extraction (Govan et al., 1996). This first 
preparation was referred to as BcLPS-1. For further purification,
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BcLPS-1 was treated with 1 pg of DNase ml"1 (from bovine pan­
creas; Sigma-Aldrich, Poole, UK) plus 1 pg RNase ml-1 (from 
bovine pancreas; BDH, Poole, UK) at 30°C  for 90 min at pH 7.5, 
followed by the addition of 1 pg ml-1 of trypsin (from bovine pan­
creas, Sigma-Aldrich, Poole, UK) and incubation at 30°C  for 
90 min. Finally 1 pg of proteinase K ml-1 (from fungi; Sigma- 
Aldrich, Poole, UK) was added and incubated at 30°C  for 90 min.
Following these enzymatic treatments the solution was dialy- 
sed against distilled water overnight and lyophilized. This prepa­
ration was then treated with 45%  phenol containing triethylamine 
and sodium deoxycholate and the LPS, extracted in the aqueous 
phase, was precipitated with ethanol by the deoxycholate- 
phenol-water extraction method to obtain a second LPS prepa­
ration, BcLPS-2. The extracted BcLPS-2 preparations were 
found to be essentially free from protein and DNA contamination. 
Lyophilized LPS preparations were stored at -8 0 °C  in depyroge- 
nated glass vials. For use, LPS was weighed and reconstituted in 
pyrogen-free ultra-pure water and diluted to the desired concen­
tration in pyrogen-free PBS. The LPS preparations were exam­
ined for induction of inflammatory cytokines in human cells. As a 
control enterobacterial LPS, E. coli 0111 :B4 LPS was purified by 
the methods outlined above and was also obtained commercially 
(Sigma-Aldrich, Poole, UK).
MM6 stimulation and cytokine assay
For experimental use, MM6 cells were suspended at 106 ml"1 in 
media in 24 well plates and stimulated with purified LPS for 6  h 
(TNFa) or 14 -1 6  h (IL-6). Supernatants were collected after cen­
trifugation at 2000 rpm for 3 min and were stored in aliquots at 
-8 0 °C  until assay. Our previous studies (Zughaier et al., 1999a) 
and dose-response experiments (data not shown) showed that 
100 ng ml"1 LPS gave optimal cytokine expression in MM6 cells 
and this concentration was routinely used. In some experiments, 
such as NFkB activation, higher doses of LPS (1 pg ml-1) gave 
more significant results.
TN F a and IL-6 levels were assessed by a specific ELISA using 
mouse anti-TNFa/anti-IL-6 capture antibodies and a biotin- 
conjugated goat polyclonal secondary antibody, and were 
detected with a streptavidin-peroxidase-o-phenylenediamine 
substrate. Cytokine levels were determined by using duplicates 
for each supernatant sample and compared with a standard 
curve for human recombinant T N F a  or IL-6.
Blocking TLR4, TLR2 and CD 14
MM6 cells were suspended at 10® ml-1 in media and dispensed in 
250 pi aliquots into 96 well plates. The cells were then pre­
incubated with 5 pl/250 pi of anti-human TLR4 monoclonal anti­
body (HTA125) or lgG2 isotype control antibody (Insight 
Biotechnology, Wembley, UK) for 1 h at 37°C. Our previous 
studies had demonstrated that this dilution of antibody and incu­
bation time gave optimal blocking activity. LPS was then added at 
a concentration of 10 0n g m l"1 to pre-incubated wells and to 
control wells, then incubated overnight at 37°C, 5% C 0 2 in a 
humidified incubator. Supernatants were collected after centrifu­
gation for 3 min at 2000 rpm and assayed for T N F a  by ELISA. 
The same procedure was carried out using anti-human TLR2  
(TL2.1) (AbCAM, Cambridge, UK) and using anti-human CD 14 
(R and D Systems, Abingdon, UK) monoclonal antibodies.
MAPK inhibition
MM6 cells were suspended at 10® ml-1 in media and dispensed in 
1 ml aliquots into 24 well plates. The cells were then pre- 
incubated with 10 pM of either PD98059 (P42/44 inhibitor), 
SB203580 (P38 inhibitor) or SP600125 (JNK inhibitor) (all from 
Sigma-Aldrich, Poole, UK) or combinations of the inhibitors, for 
1 h at 37°C. LPS was then added at a concentration of 
lO O ngm l"1 to pre-incubated wells and to control wells, then 
incubated overnight at 37°C, 5%  C 0 2 in a humidified incubator. 
Supernatants were collected after centrifugation for 3 min at 
2000 rpm and assayed for T N F a  by ELISA.
MyD88 pathway activation
MM6 cells (1 x 10® cells m l'1) were dispensed in 250 pi aliquots 
into 96 well culture plates and pre-incubated with 100 pM MyD88 
homodimerization inhibitory peptide or a control peptide 
(Imgenex, USA) for 24 h. Test LPS was then added to each well 
at a concentration of lO O ngm l"1. All experiments were con­
ducted in duplicate, and a control with LPS alone and an unstimu­
lated control were included. The cells were incubated at 37°C, 
5% C 0 2 for 6 h and then harvested, centrifuged at 2500 rpm for 
5 min and the supernatants collected. The supernatants were 
then either stored at -8 0 °C  until use or tested immediately for 
TN Fa concentration by ELISA.
IkB activation
MM6 cells (1.5 x 10® m l'1) were stimulated with LPS (as 
described above) for 1 h, stimulation was then terminated by 
centrifuging each sample at 2500 rpm and adding 10 ml ice cold 
PBS. The cells were then washed twice more in ice cold PBS, 
then they were resuspended in 300 pi ice cold RIPA buffer 
working solution [150 mM NaCl, 10 mM Tris-HCI, 1 mM EDTA, 
1 mM EGTA, 1 protease cocktail tablet (Roche, Welwyn, UK), 
200 mM Na3V 0 4, 1% Triton 100] and left on ice for 30 min. Cells 
were then sonicated and centrifuged at 2500 rpm for 5 min at 
4°C. Cell lysates were either assayed straight away or stored at 
-80°C .
Cell lysates were examined for equal amounts of protein by the 
Bradford method using bovine serum albumin (BSA) as a stan­
dard (Bradford, 1976). Samples of equal protein content were 
loaded onto 10% NuPAGE Tris-Bis precast gels (Invitrogen, 
Paisley, UK) and electrophoresed at 200 V for 1 h. Proteins were 
then transferred to a nitrocellulose membrane and detection 
was carried out using IxB-a antibody (1:1000) (kind gift from 
Dr P. Brennan, School of Medicine, Cardiff University) in con­
junction with an anti-rabbit Western Breeze chemiluminescent 
immunodetection kit according to the manufacturer’s instruc­
tions (Invitrogen, Paisley, UK).
Preparation of subcellular fractions
MM6 cells (1 x 1 0 6 ml"1) were treated with 1 pg ml"1 LPS at 
different time intervals (15, 30, 60, 120 min). Stimulation was 
terminated by adding 5 ml ice-cold PBS. Each sample was cen­
trifuged at 2500 rpm and then resuspended in 1 ml buffer A 
(10 mM Hepes, pH 7.9, 1.5 mM MgCI2, 10 mM KCI, 10 mM 
PMSF) and centrifuged at 13 000 rpm for 1 min at 4°C. Cells
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were then lysed by addition to 20 pi of buffer A containing 0.1% 
Nonident P40 and left on ice for 10 min, after which time they 
were centrifuged at 13 000 rpm for 5 min. The nuclear extract 
was prepared by adding 15 pi buffer C (20 mM Hepes, pH 7.9, 
420 mM NaCl, 1.5 mM MgCI2, 25% glycerol, 0.5 mM PMSF) to 
the supernatant. The mixture was left on ice for 15 min. It was 
then centrifuged at 13 000 rpm at 4°C for 5 min and the super­
natant was added to 75 pi buffer D (10 mM Hepes, pH 7.9, 
50 mM KCI, 0.2 mM EDTA, 20% glycerol, 0.5 mM PMSF). The 
protein in these extracts was measured using the Bradford 
method (Bradford, 1976). The extracts were stored at -80°C until 
NFkB assay.
Nuclear extracts and assessment of NFkB activation by 
EMSA
Samples of 1 pg protein were incubated with 10 000cpm of a 
^P-labelled oligonucleotide containing the consensus sequence 
for NFkB in binding buffer (40% glycerol, 1 mM EDTA, 10 mM 
TRIS, pH 7.5, 100 mM NaCl, 0.1 mg ml-' nuclease free BSA, 
50 mM dithiothreitol) and 2 pg of poly-(dl-dC) at room tempera­
ture for 30 min (Brennan and O’Neill, 1995). The samples were 
then subjected to electrophoresis on a 5% polyacrylamide gel 
that was then dried and autoradiographed overnight at -80°C.
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